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ABSTRACT
Small cell lung cancer (SCLC) comprises 18% of all lung cancer cases and is an
aggressive disease with a five-year survival rate of less than 5%, mainly due to the
advanced nature of the disease at the time of diagnosis. Despite the need to better
understand this disease, the genetic lesions that contribute to SCLC remain poorly
characterized. To investigate the genetic aberrations that occur in SCLC, we analyzed
the copy number alterations in tumors and metastases arising in a mouse model of
SCLC (mSCLC), driven by conditional inactivation alleles of two tumor suppressor
genes, Trp53 and Rbl. We identified frequent, high-level amplification of a novel, proto-
oncogenic transcription factor Nuclear Factor I/B (Nfib in mouse, NFIB in human), which
frequently occurred coincident with amplification of a previously characterized
oncogene, L-myc (Mycl). Functional studies revealed cooperation between Nfib and L-
myc in cellular transformation. Comparative genomics identified NFIB amplifications in
human SCLC and uncovered a role for NFIB in regulating cell viability and proliferation.
We also examined the effect of lung injury on SCLC initiation and progression
utilizing naphthalene, a chemical that ablates the cells that line the bronchioles of the
lung. The pulmonary neuroendocrine cells, the putative cell of origin of SCLC, are
refractory to naphthalene-mediated injury. We demonstrated that naphthalene-mediated
injury prior to tumor initiation in the mouse model of SCLC induced more advanced
mSCLC lesions and decreased tumor latency.
Throughout the course of this thesis work, we successfully utilized a mouse
model of SCLC to interrogate the initiation of SCLC as well as to define the genetic
alterations that occur in SCLC tumors and metastases. This work has led to the
identification of candidate genes that promote tumor progression and to a better
understanding of the process of tumor initiation. We anticipate that these findings will
not only enhance our understanding of SCLC, but may lead to the development of
therapeutics used to treat this aggressive disease.
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CHAPTER 1:
Introduction
I. LUNG CANCER
Lung cancer is the leading cause of cancer deaths worldwide each year (ACS
2010). In the United States alone, more than 220,000 people will be diagnosed this year
and nearly 160,000 people will succumb to the disease (ACS 2010). Non-small cell lung
cancer (NSCLC), which includes three major subtypes: adenocarcinoma, squamous
cell, and large cell carcinomas, accounts for 85% of lung cancer cases (Travis 2002;
Meuwissen and Berns 2005). The remaining 15% of lung cancer cases are small cell
lung cancer (SCLC), which is characterized by neuroendocrine features (Wistuba et al.
2001).
II. SMALL CELL LUNG CANCER
A. Characteristics of SCLC
Small cell lung cancer is an aggressive disease that has frequently metastasized
by the time of diagnosis (Worden and Kalemkerian 2000). Fewer than 6% of patients
present with one localized tumor, and the five year survival rate is dismal at less than
5% (Worden and Kalemkerian 2000; Cooper and Spiro 2006). While a range of SCLC
morphologic variations have been recognized, all have a very poor prognosis
(Meuwissen and Berns 2005). In addition, nearly 100% of SCLC patients are heavy
smokers, having smoked decades of pack years, which refer to the number of packs of
cigarettes smoked per day over the course of a year, by the time of diagnosis (Doll and
Peto 1981; Shopland 1995; Wistuba et al. 2001; Minna et al. 2002). The prolonged
exposure to tobacco smoke likely induces mutation and allelic loss of two tumor
suppressor genes, Trp53 (p53) and Rbl (Rb), and other genes in the entire bronchial
epithelium (Wistuba et al. 2000). Unlike NSCLC in which there are four stages of
disease, SCLC has two stages of disease: "limited" and "extensive" (Simon and Wagner
2003). Limited disease indicates that the disease is limited to the ipsilateral thoracic
cavity, although the disease may have spread to the contralateral lymph nodes (Simon
and Wagner 2003). Patients with extensive disease have disease spread throughout the
body to distant sites including the brain, bone, liver, adrenal glands, and lymph nodes
(Simon and Wagner 2003).
B. Histopathological Features of SCLC
Small cell lung carcinoma is characterized by a malignant grouping of small cells
with nuclear molding and very little cytoplasm (Junker et al. 2000). In addition, the
tumors are marked by high proliferation, visible by a high mitotic index (Junker et al.
2000) and they usually arise in central bronchi of the lung (Junker et al. 2000).
One of the primary features of SCLC is the expression of neuroendocrine
markers, such as neural cell adhesion molecule-1 (NCAM), calcitonin gene-related
peptide (CGRP), and achaete-schute homolog-1 (ASH-1) (Ball et al. 1993; Borges et al.
1997; Cavallaro et al. 2001; Shibayama et al. 2001). Based on the expression of
neuroendocrine markers in the tumors, SCLC is believed to arise from a neuroendocrine
cell, but this has not yet been directly examined (Wistuba et al. 2001). In addition, SCLC
is associated with paraneoplastic syndromes, such as the inappropriate secretion of
anti-diuretic hormone, Cushing's syndrome, and Eaton Lambert syndrome (Nicholson et
al. 2002).
C. Treatment for SCLC
Due to the fact that fewer than 6% of SCLC patients present with one localized
tumor, surgery is generally not considered to be a relevant treatment option (Cooper
and Spiro 2006). Instead, combination chemotherapy is routine, particularly platinum-
based treatments in combination with etoposide, which is a topoisomerase 11 inhibitor
(Simon and Wagner 2003). Platinum-based treatments induce DNA damage by forming
platinum-DNA adducts (Wang and Lippard 2005). Cisplatin is the preferred platinum-
based drug, but carboplatin is used in patients where toxicity is a concern (Simon and
Wagner 2003). Unfortunately, despite the fact that 20-30% of patients will respond
initially, nearly all patients suffer relapse (Simon and Wagner 2003). On average,
patients with extensive disease have progression-free survival for four months, while
those with limited disease are progression-free for twelve months (Simon and Wagner
2003). The near complete response observed in a subset of patients offers promise that
SCLC is curable (Minna et al. 2002) and a greater understanding of the mechanisms of
resistance is crucial to treatment of this disease.
Ill. MUTATIONS IN SCLC
Chromosomal banding techniques have identified several recurrent chromosomal
aberrations present in SCLC. The most frequent alteration is loss of heterozygosity
(LOH) of chromosome 3p in approximately 90% of SCLC (Whang-Peng et al. 1982). In
addition, frequent losses are present on chromosomes 13 (Rb1) (Harbour et al. 1988;
Yokota et al. 1988; Hensel et al. 1990) and 17 (Trp53) (Takahashi et al. 1989) and
amplification of C-MYC on chromosome 8 (Little et al. 1983). (Table 1)
A. 3p Tumor Suppressor Region
A region on the short arm of chromosome 3 (3p) is lost in approximately 90% of
human SCLC cases (Whang-Peng et al. 1982; Wistuba et al. 2001; Wistuba and
Gazdar 2003). Based on the fact that 3p loss is the most common alteration in SCLC, it
has been hypothesized that at least one tumor suppressor is contained in this region
(Wistuba et al. 2001; Wistuba and Gazdar 2003) and many studies have focused on
determining which genes are the relevant tumor suppressor genes in this region. The
expression of one candidate tumor suppressor gene, fragile histidine triad (EHIT),
located at 3p14.2 is altered in approximately 80% of small cell lung tumors (Sozzi et al.
1996). Another candidate gene is ras association domain family member 1 (RASSF1),
which is located at 3p21.3 (Dammann et al. 2000; Burbee et al. 2001). RASSF1
expression is not detected in SCLC cell lines due to promoter hypermethylation
(Dammann et al. 2000; Burbee et al. 2001). In addition, exogenous expression of
RASSF1 in A549 and NCI-H2199 cells, both human NSCLC cell lines, reduces their
ability to form colonies in soft agar and tumors upon transplantation into immune-
compromised mice (Dammann et al. 2000; Burbee et al. 2001). While several candidate
Table 1. Genetic mutations commonly observed in SCLC and NSCLC. a: Tumors, b:
Cell lines, c: Coincident amplification of more than one MYC family member is never
observed in a single tumor.
(Figure adapted and reprinted with permission from Meuwissen, R. and Berns, A.
(2005). Genes Dev. 19(6): 643-664.)
Gene Mutation Type SCLC NSCLC
(%) (%)
MYC family amplification 2 0 a-3 5 b 5a-20b
MYCL1 or MYCAC amplification 20 a-20 b <3a-Ob
RAS mutation <1 15-20
EGFR mutation -- 20
RB1 LOH 70 30
mutation 90 15-30
TP53 LOH 75-100 60
mutation 75 50
INK4a LOH 50 70
p 161NK4a mutation <5 20-50
3p chromosomal region LOH 90-100 70-80
tumor suppressor genes exist, the relevant genes have not yet been conclusively
determined.
B. Retinoblastoma Tumor Suppressor Gene
Discovery of RB1
The rare, childhood eye cancer, retinoblastoma, has both hereditary and non-
hereditary forms. Analysis of the hereditary form of this disease, which transmits
retinoblastoma with 90% penetrance in an autosomal dominant fashion, has led to the
identification of the retinoblastoma susceptibility tumor suppressor gene, RB1 (Knudson
1975). Early chromosomal banding experiments discovered that retinoblastoma tumors
lack a region on chromosome 13, band q14 (Lele et al. 1963; Knudson et al. 1976). In
addition, while this region is often heterozygous in somatic samples, both copies are lost
in tumors (Cavenee et al. 1983), suggesting that the responsible gene is acting in a
recessive manner (Knudson 1971). The identification of the chromosomal region that
confers susceptibility to retinoblastoma led to the cloning of the gene (Friend et al. 1986;
Lee et al. 1987; Fong et al. 1988). Later studies demonstrated that re-introduction of the
wild-type RB gene into tumor cells lacking RB results in an untransformed state (Huang
et al. 1988; Bookstein et al. 1990b). In addition, RB forms complexes with, and is
inactivated by, proteins from the tumor viruses, specifically papillomavirus protein E7,
SV40 large T antigen, and adenovirus Ela (DeCaprio et al. 1988; Whyte et al. 1988;
MOnger et al. 1989), which can also lead to cellular transformation.
RB Function
RB is a critical negative regulator of cell cycle progression, in particular the
transition between the G1 and S phases of the cell cycle (Burkhart and Sage 2008).
While RB is expressed at constant levels throughout the cell cycle, RB is
phosphorylated in a cell-cycle-dependent manner at the G1/S transition (Buchkovich et
al. 1989; DeCaprio et al. 1989) by cyclin/cdk complexes (Burkhart and Sage 2008). RB
regulates the cell cycle along with two other family members, termed pocket proteins,
p107 and p130 (Mulligan and Jacks 1998), and each of the pocket proteins binds E2F
family members (Trimarchi and Lees 2002). While RB preferentially binds the activating
E2Fs: E2F1, 2, and 3a along with E2F3b, a repressive E2F, p107 and p130 bind the
repressive E2Fs: E2F4, and 5 (Trimarchi and Lees 2002). Following phosphorylation of
RB, E2F is released and can regulate genes involved in cell-cycle control, such as
cyclin A, cyclin E and Cdc2, DNA replication, such as Cdc6, and enzymes involved in
nucleotide synthesis, such as thymidine kinase (Trimarchi and Lees 2002) (Figure 1).
RB is regulated upstream by CDKN2A, which encodes two tumor suppressor
proteins, p16 1nk4a and p14ARF (p1 9 ARF in mice) (Sherr 2006). p1 6 Ink4a acts by inhibiting
CDK4 and CDK6, which are then unable to phosphorylate RB, and thus inhibits the cell
cycle (Serrano et al. 1993; Sherr 2006) (Figure 1).
RB During Development
In order to assess the function of the Rbl gene in the mouse, a knockout mouse
(RIY) has been constructed (Jacks et al. 1992; Lee et al. 1992). RIJ' mice are
Figure 1. The p53 and Rb pathways. (a) Diagram of the p53 and Rb tumor suppressor
pathways with the relevant mediators of cell-cycle control and apoptosis shown. Green
arrows depict positive interactions, red block arrows depict repressive interactions.
(Figure adapted and reprinted with permission from Levine, A.J. (1997). Cell 88: 323-
331.)
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characterized by embryonic lethality by El 5.5 and suffer from severe anemia due to
defects in erythropoiesis (Jacks et al. 1992; Lee et al. 1992). It was of particular interest
whether mutation of the Rbl gene in mice would also induce retinoblastoma in Rb'4
mice, similar to humans who inherit one mutant Rb allele. Although none of the Rb*'
mice develop retinoblastoma, pituitary and thyroid tumors are observed (Jacks et al.
1992; Hu et al. 1994), indicating that loss of heterozygosity (LOH) of the wild-type allele
can induce transformation in the mouse.
RB and Cancer
Although RB1 mutations were first identified in retinoblastoma, they were later
discovered in multiple other tumor types. A notable example is osteosarcomas, which
arise frequently in retinoblastoma patients. Although initially thought to occur as a
consequence of the radiation treatment used (Friend et al. 1987; Eng et al. 1993), it was
later found that RB1 mutations can also occur in independently arising osteosarcomas
(Friend et al. 1987). To date, RB1 alterations have been identified in several tumor
types, such as SCLC (Harbour et al. 1988; Yokota et al. 1988; Hensel et al. 1990),
prostate carcinoma (Bookstein et al. 1990a), bladder carcinoma (Horowitz et al. 1989;
Horowitz et al. 1990), and breast cancer (Lee et al. 1988; T'Ang et al. 1988; Varley et al.
1989). Mutations of genes in the RB pathway are also frequently encountered in tumor
types that appear to retain wild-type RB. For example, CDKN2A is located in a region
on chromosome 9 that is frequently lost in certain types of cancer (Meuwissen and
Berns 2005), such as NSCLC, where RB itself is unaltered (Sherr 2006; Burkhart and
Sage 2008). Not only is RB1 critical for development of retinoblastoma, but the RB
pathway also regulates tumorigenesis of multiple tissues.
RB and SCLC
Mutations in the retinoblastoma gene are observed in approximately 90% of
SCLC (Wistuba et al. 2001). Mutations in the RB1 gene were first identified in SCLC
using chromosomal banding techniques, which identified a loss of human chromosome
13, band q14 in SCLC (Harbour et al. 1988; Yokota et al. 1988; Hensel et al. 1990).
RB1 is rarely expressed in SCLC; RB1 transcripts are undetectable in approximately
75% of SCLC cell lines (Hensel et al. 1990). Other RB family members, p107 and p130,
have also been analyzed in SCLC, and p130 mutations have been detected only rarely
in SCLC (Helin et al. 1997). In addition, upstream regulators of RB, notably pl61NK4a,
are rarely mutated in SCLC (Wistuba et al. 2001). The frequent mutation of RB1 in
SCLC signifies its importance in SCLC.
C. Trp53 Tumor Suppressor Gene
Identification of Trp53
Similar to RB1, Trp53 (p53) was first discovered for its role in binding DNA virus
oncoproteins, such as adenovirus El b, SV40 large T antigen, and papillomavirus E6
(Linzer and Levine 1979; Sarnow et al. 1982; Werness et al. 1990). Early experiments
indicated that p53 may be an oncogene, and it was not until later that the true nature of
p53 as a tumor suppressor was revealed. Over-expression of p53 resulted in
transformation in transgenic mouse models (Lavigueur et al. 1989). Additionally, co-
expression of p53 and ras transformed cells in in vitro experiments (Eliyahu et al. 1984;
Jenkins et al. 1984; Parada et al. 1984; Jenkins et al. 1985). However, later they
realized that mutant p53 cDNA had been expressed in these earlier experiments.
Expression of wild-type p53, in addition to mutant p53 and ras, abolishes the
transformation phenotype (Eliyahu et al. 1989; Finlay et al. 1989; Hinds et al. 1990).
Furthermore, wild-type p53 is often found to be mutated or lost in the majority of human
cancers, indicating that loss of p53 is critical for transformation and that p53 is actually a
tumor suppressor (Baker et al. 1989).
p53 Function
p53 is a transcription factor that regulates the cellular response to various
detrimental inputs, such as oncogene stress, hypoxia, chemotherapeutic agents,
ionizing radiation, and limited nucleotide precursors (Levine 1997). p53 in its active state
is a tetramer, actually a dimer of a dimer (Jeffrey et al. 1995). Mdm2 negatively
regulates p53 function (Momand et al. 1992; Oliner et al. 1993; Wu et al. 1993), and a
negative feedback loop between p53 and Mdm2 has also been described (Barak et al.
1993; Wu et al. 1993). In response to DNA damage, p53 up-regulates expression of its
downstream pathway member, p21 (el-Deiry et al. 1993; Harper et al. 1993). p21 can
then inhibit various cyclin and Cdk complexes to temporarily stall cell-cycle progression
while repair takes place, or initiate a permanent cell-cycle arrest, called senescence, if
the damage cannot be repaired (Levine 1997; Helton and Chen 2007) (Figure 1).
Notably, cells that are deficient for p53 and p21 are unable to trigger senescence
(Chang et al. 1999).
Another function of p53 is to regulate the induction of apoptosis in response to
cellular stresses. Cells expressing the adenovirus Ela protein and wild-type p53
undergo apoptosis (Debbas and White 1993; Lowe et al. 1994). Additionally, p53'
thymocytes are unable to induce apoptosis in response to DNA damage (Clarke et al.
1993; Lowe et al. 1993b). p53 also induces apoptosis in response to oncogene
expression or in the absence of tumor suppressors (Lowe et al. 1994). In addition, p53
can induce apoptosis in response to chemotherapeutic agents and other DNA damage-
inducing agents (Lee and Bernstein 1993; Lowe et al. 1993a; Lowe et al. 1993b). Thus,
p53 has a myriad of roles that affect many aspects of the cell cycle.
p53 and Cancer
p53 is one of the most frequently mutated genes in cancer (Olivier et al. 2002).
p53 aberrations are observed in many cancer types, including lung cancer - both
NSCLC and SCLC, breast cancer, and colon carcinoma (Baker et al. 1989; Nigro et al.
1989; Takahashi et al. 1989; Chiba et al. 1990; Mitsudomi et al. 1992). In addition,
patients with Li-Fraumeni syndrome inherit a mutant p53 allele. This syndrome was first
described in 1969 by Li and Fraumeni, who characterized a family with a dominant
inheritance pattern of cancers, including sarcoma and breast carcinomas (Li and
Fraumeni 1969). Later, mutations in p53 were attributed to the familial inheritance of this
syndrome (Malkin et al. 1990; Srivastava et al. 1990).
Mouse Models of p53 in Development and Transformation
Investigation of p53 knockout mice (p53~1) aided in the development of
knowledge about the role of p53 during mammalian development and tumorigenesis.
p53 knockout mice are viable and fertile, demonstrating that p53 is not required for
normal development (Donehower et al. 1992; Jacks et al. 1994). p53-- mice commonly
develop lymphomas and sarcomas, in contrast to p53' mice, which develop a much
wider tumor spectrum, to sites including the lung (adenocarcinoma) and bone
(osteosarcoma) (Donehower et al. 1992; Jacks et al. 1994).
While p53-deficient mice develop tumors, other mouse models with p53
mutations have been developed to account for the fact that mutation, rather than
deletion, of p53 is most often observed in human cancer (Olivier et al. 2002; Toyooka et
al. 2003). The p53 mutations are missense and are clustered in six different "hotspots"
in the DNA binding domain of p53 (Olivier et al. 2002). In order to model missense
mutations in the mouse, several groups have constructed transgenic mice over-
expressing mutant p53 alleles, including p53R172H (Li et al. 1998; Wang et al. 1998) and
p5 3A13 5 V (Lavigueur et al. 1989; Harvey et al. 1995). These transgenic mice develop a
wider array of tumor types compared to p53*' mice, but at the expense of expressing
p53 at a much higher level compared to endogenous levels. In order to examine the
effects of point mutant p53 expressed at endogenous levels, the Jacks laboratory has
engineered point mutations into the endogenous locus of p53 (Olive et al. 2004). One of
the point mutations, p5 3R27H, models a contact mutation in p53, and directly affects the
binding of p53 to DNA (Olive et al. 2004). The other mutation, p53R172H, represents a
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structural p53 mutant, which affects the overall structure of the p53 DNA-binding domain
(Olive et al. 2004). The point-mutant mice exhibit a different tumor spectrum compared
to p53*1 mice (Olive et al. 2004). In p 5 3 R2 70H/+ mice, which closely recapitulates the
syndromes of Li-Fraumeni patients, there is an increased incidence of carcinomas, in
particular lung adenocarcinomas, squamous cell carcinomas, and hepatocellular
carcinomas (Olive et al. 2004). In contrast, the p5 3 R72H/+ mice develop primarily
osteosarcomas (Olive et al. 2004). Most interestingly, the p 5 3R270H/+ point-mutant mice,
when crossed with a mouse model expressing oncogenic K-ras from its endogenous
locus, exhibit elevated incidence of lung adenocarcinomas, indicative of a dominant-
negative phenotype (Jackson et al. 2005).
p53 Mutations and SCLC
p53 alterations are observed in more than 75% of SCLC cases (Wistuba et al.
2001; Meuwissen and Berns 2005). Alterations on chromosome 17 are frequently
observed in SCLC, and are attributed to loss of p53 (Takahashi et al. 1989). In addition,
missense mutations, specifically G-T transversions, are common in the p53 gene in
SCLC, and are a hallmark of smoking (Toyooka et al. 2003; Lewis and Parry 2004).
Furthermore, in an analysis of the bronchial epithelium in patients with SCLC, allelic
losses are observed more frequently than in other lung tumor types, such as squamous
cell carcinoma and adenocarcinoma (Wistuba et al. 2000). Thus, p53 aberrations are
one of the primary characteristics of SCLC.
D. MYC Proto-oncogene
Identification of MYC Family Members
C-MYC (MYC) was first identified as one of the transforming oncogenes in avian
sarcoma virus (Sheiness and Bishop 1979; Parker et al. 1981; Vennstrom et al. 1982).
N-MYC (MYCN) was originally identified in neuroblastoma (Schwab et al. 1983) and
another MYC family member, L-MYC (MYCL1), was originally identified in a SCLC cell
line (Nau et al. 1985). L-MYC's sequence homology to C-MYC and N-MYC, coupled
with sequence differences and a location on chromosome 1, were indicative of a new
MYC family member (Nau et al. 1985).
MYC Function
All MYC family members are localized to the nucleus and are involved in
controlling cell proliferation, differentiation, and apoptosis. In addition, all family
members have a conserved basic helix-loop-helix structure, indicating their role in
controlling transcription (Murre et al. 1989). MYC proteins can also heterodimerize with
MAX, which is critical for their function as transcription factors (Blackwood and
Eisenman 1991; Prendergast et al. 1991). Based on expression studies and chromatin
immunoprecipitation (ChIP) assays, MYC has been found to regulate proliferation and
apoptosis targets (Grandori and Eisenman 1997; Patel et al. 2004). Furthermore, while
low levels of MYC expression can induce proliferation, over-expression of MYC can
stimulate the p53 pathway and apoptosis (Murphy et al. 2008). As a result, the level of
MYC expression is critical in controlling transformation. Additionally, gene expression
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studies have examined genes that are up- or down-regulated in tumors with MYC family
member amplification: 375 genes exhibited altered expression that correlated or anti-
correlated with C-MYC amplification, 250 correlated with N-MYC and 49 with L-MYC. In
addition, the altered sets of genes in cells with C-MYC and N-MYC amplifications
overlapped, but those altered in cells with L-MYC amplifications had limited overlap
(Kim et al. 2006b). Additionally, a gene set enrichment analysis (GSEA) confirmed that
very few gene sets were up- or down-regulated by L-MYC, and of those, very few
overlap with the gene sets enriched with C- or N-MYC. Thus, these studies highlight the
differences in the transcriptional targets and function of the MYC family members.
MYC Family Members During Development
L-MYC has a more restricted expression in mouse development compared to the
other MYC family members (Hatton et al. 1996). C-MYC is expressed ubiquitously
during development and adulthood (Zimmerman et al. 1986). N-MYC is highly
expressed in the developing brain, kidney, intestine, lung and heart (Zimmerman et al.
1986; Charron et al. 1992). L-MYC is highly expressed in the developing lungs, kidney,
and brain, but its expression becomes more limited to the lung in adult mice
(Zimmerman et al. 1986). The roles of all three family members during murine
development have been analyzed in knockout mice. In contrast to the inviability of mice
lacking C- or N-MYC (Charron et al. 1992; Davis et al. 1993), L-MYC-deficient mice are
viable (Hatton et al. 1996), further highlighting the difference between the MYC family
members.
MYC and Cancer
Amplification of MYC family members has been observed in many tumor types,
including neuroblastoma, SCLC, and lymphomas (Dalla-Favera et al. 1982; Neel et al.
1982; Taub et al. 1982; Schwab et al. 1983; Nau et al. 1985). C-MYC was identified for
its involvement in translocations with the immunoglobulin heavy chain locus frequently
observed in Burkitt's lymphoma (Dalla-Favera et al. 1982; Neel et al. 1982; Taub et al.
1982). C-MYC expression alone in rat embryonic fibroblasts is not sufficient to induce
transformation (Land et al. 1983; Lee et al. 1985), although C-MYC expression in
combination with H-ras expression is sufficient (Land et al. 1983; Lee et al. 1985).
Similar experiments involving N- and L-MYC identified the same phenomenon
(Yancopoulos et al. 1985; DePinho et al. 1987). Finally, C-MYC over-expression driven
from the immunoglobulin enhancer (Ep) promoter induces lymphomas in mice (Adams
et al. 1985).
MYC and SCLC
MYC family members are frequently amplified in SCLC (Richardson and Johnson
1993; Wistuba et al. 2001; Meuwissen and Berns 2005). Cytogenetic banding and
fluorescence in situ hybridization (FISH) experiments suggest a frequency of MYC
mutations in approximately 20-30% of SCLC cases (Wistuba et al. 2001; Meuwissen
and Berns 2005). On the other hand, whole genomic profiling techniques to assay copy
number changes in tumors have indicated that MYC family members are mutated in
61% of SCLC cell lines and 82% of SCLC primary tumors (Beroukhim et al. 2010;
Voortman et al. 2010). Thus, these platforms appear to be more sensitive to smaller
increases in copy number compared to techniques such as FISH. While amplifications
of all MYC family members are detected in SCLC, they are mutually exclusive
(Meuwissen and Berns 2005). Interestingly, C-MYC amplifications are observed in both
SCLC and NSCLC, but L- and N-MYC amplifications are limited to SCLC (Wistuba et al.
2001; Meuwissen and Berns 2005). The selection for differential amplification of MYC
family members suggests non-overlapping functions within different lung cell types.
IV. WHOLE GENOMIC PROFILING ASSAYS
While initial efforts to characterize mutations observed in SCLC relied heavily on
karyotyping to detect large chromosomal aberrations, new techniques have evolved to
detect gene expression changes, epigenetic regulation and copy number analysis
(CNA) in cancer and SCLC. Despite these new techniques, SCLC remains a complex
disease that is poorly understood.
Gene expression arrays have been utilized to detect genes that are significantly
up- or down-regulated in various cancer types and examine gene expression changes in
SCLC. One study analyzed gene expression in five primary small cell lung tumors, and
as expected, found that the tumors expressed neuroendocrine markers, such as
achaete-schute homolog 1 (ASCL-1) (Garber et al. 2001). Interestingly, these tumors
also highly expressed L-MYC (Garber et al. 2001). Another study examining expression
alterations in six primary SCLC samples also identified the up-regulation of
neuroendocrine markers, as well as up-regulation of p 18 /NK4c (Bhattacharjee et al.
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2001). While a third study corroborated the up-regulation of neuroendocrine markers,
up-regulation of many genes involved in proliferation was also identified (Rohrbeck et al.
2008). The question of the appropriate control to utilize in gene expression studies is a
critical one, especially because the cell of origin of SCLC is not known. While these
studies compared the SCLC samples to other lung tumors types and normal lung
(Bhattacharjee et al. 2001; Garber et al. 2001; Rohrbeck et al. 2008), comparison to
normal neuroendocrine cells in the lung may provide more informative results.
Techniques such as array comparative genomic hybridization (array CGH),
single-nucleotide polymorphism (SNP) arrays, and representational oligonucleotide
microarray analysis (ROMA) have been utilized to determine copy number profiles and
relevant cancer genes within chromosomal aberrations (Tonon et al. 2005; Kim et al.
2006a; George et al. 2007; C.G.A.R.N. 2008). Copy number alterations in human SCLC
have been examined utilizing array CGH on fourteen SCLC cell lines (Coe et al. 2006b).
Several copy number alterations, including amplification of a region on chromosome 7
that includes MAD1L1 were detected (Coe et al. 2006a; Coe et al. 2006b). Integration of
the copy number analysis with gene expression arrays also identified several genes
differentially expressed in SCLC, such as up-regulation of MRP5, a gene known for its
role in chemotherapeutic resistance (Weaver et al. 2005) and WNT inhibitors (Coe et al.
2006b).
Recently, new sequencing-based platforms have been utilized to generate whole-
genome tumor profiles. These massively parallel DNA sequencing methods no longer
require hybridization of probes to arrays, provide unbiased profiling, obtain single
nucleotide resolution, and detect amplification breakpoints (Chin and Gray 2008;
Meyerson et al. 2010). In addition, the decreasing cost has enabled these platforms to
be used for a wider array of techniques, such as the identification of point mutations
(Ley et al. 2008; Mardis et al. 2009), insertions and deletions (indels) (Ley et al. 2008;
Mardis et al. 2009), copy number alterations (Campbell et al. 2008b), and genomic
rearrangements (Campbell et al. 2008b).
Although whole genome profiling techniques have greatly increased our
knowledge of the mutations and aberrations that occur in cancer, the plethora of
information produced by such techniques can prove cumbersome. One human SCLC
cell line in particular has been examined for signs of tobacco exposure (Pleasance et al.
2010). Interestingly, the spectrum of point mutations was skewed toward G-T
transversions, which is a signature of exposure to carcinogens in tobacco smoke
(Toyooka et al. 2003; Lewis and Parry 2004; Pleasance et al. 2010). However, the study
identified more than 22,000 somatic mutations in this SCLC cell line (Pleasance et al.
2010), a close examination of which yielded only a couple hundred mutations that occur
within promoter or coding regions and are also non-synonymous alterations (Pleasance
et al. 2010). The wide array of mutations brings up the question of how to differentiate
"driver" and "passenger" mutations (Greenman et al. 2007; Stratton et al. 2009). Driver
mutations have a positive effect on proliferation and expansion of the cancer cells, while
passenger mutations do not confer a selective advantage to the cancer cell (Greenman
et al. 2007; Stratton et al. 2009) (Figure 2). Functional validation of changes that occur
is critical to understanding their role in tumor progression (Chin and Gray 2008).
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Figure 2. Accumulation of passenger and driver mutations. (a) Schematic of the
accumulation of mutations in cancer cells. Some of the mutations are passenger
mutations (circles), while others are driver mutations (stars). In addition, chemotherapy
resistance mutations (triangles) can arise in response to the treatment or exist prior to
chemotherapy.
(Figure adapted and reprinted with permission from Stratton, M.R. et al. (2009). Nature
458(7239): 719-724.)
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Chromosomal rearrangements, such as duplications and deletions, have been
identified using massively parallel sequencing technology. Sequencing of two SCLC cell
lines, NCI-H209 and NCI-H2171, led to the identification of CHD7 rearrangements,
which is located very close to C-MYC on chromosome 8 (Campbell et al. 2008b;
Pleasance et al. 2010). Translocations have recently been identified in epithelial
cancers, such as those involving the EML4 and ALK genes in NSCLC (Soda et al. 2007)
and the TMPRSS2 and ETS genes in prostate cancer (Tomlins et al. 2005).
Additionally, translocations can be identified using paired end sequencing. Translocation
involving genes on chromosomes 2 and 12 were identified in a SCLC cell line, NCI-
H2171 (Campbell et al. 2008b). Thus, new sequencing-based technologies can identify
chromosomal aberrations such as duplications and translocations, but they need to be
functionally validated to assess their role in tumorigenesis.
Genetically engineered mouse models with defined genetic mutations frequently
observed in human cancers can be utilized to narrow the list of relevant candidate
genes in transformation. A few such comparative oncogenomics studies have been
performed and have aided in the identification of mutations common to both human and
mouse cancers. Genomic profiling of tumors arising in mouse models can narrow down
regions of amplification, for example, and additionally provide a means to perform
functional tests. Studies on metastatic melanoma implicated a new oncogene, NEDD9,
in metastatic progression (Kim et al. 2006a). Using another approach, candidates
identified in human hepatocellular carcinoma were examined using in vivo RNAi studies.
These have identified a role for cooperating oncogenes YAP! and clAP1, as well as a
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tumor suppressor, XPO-4, in hepatocellular carcinoma (Zender et al. 2006; Zender et al.
2008).
While whole-genome analyses have been performed on SCLC samples, the
majority has examined cell lines. Unfortunately, this is due to the fact that primary
human SCLC samples are in short supply because tumors are rarely surgically resected
(Cooper and Spiro 2006). The copy-number and gene-expression analyses have
yielded a wealth of information, but have also left the question of what alterations arise
in primary tumors unanswered. Many of the cell lines were derived following
chemotherapy treatment and it would be informative to determine alterations that arise
in tumors compared to metastases in primary tissue samples (Phelps et al. 1996).
More recently, copy number profiling has been performed on primary tumors.
One study profiled seventeen primary tumors and twenty-three cell lines (Beroukhim et
al. 2010), while another profiled a collection of thirty-three SCLC primary tumors and
thirteen SCLC cell lines (Voortman et al. 2010). The latter study observed frequent
amplification of MYC family members (Voortman et al. 2010). In fact, twenty-seven out
of thirty-three tumors and eight out of thirteen cell lines had amplification of one of the
MYC family members (Voortman et al. 2010). This frequency far exceeds the 20-30%
frequency that was previously determined using cytobanding and FISH techniques
(Meuwissen and Berns 2005; Voortman et al. 2010).
V. MOUSE MODELS OF SCLC
The first mouse model of SCLC indicates cooperation between Trp53 and Rbl in
inducing SCLC (Williams et al. 1994). The mouse model combines germline knockout
alleles of Trp53 and Rbl (Williams et al. 1994). 38% of p53 null and Rb heterozygous
animals (Rb-;p53~) mice develop hyperplasias of the neuroendocrine cells in the lung,
which resemble early SCLC lesions (Williams et al. 1994). These mice succumb to
lymphomas, pancreatic islet cell carcinomas and pinealblastomas, among other tumor
types, by six months of age, and the early lesions resembling neuroendocrine tumors
are unable to advance to SCLC (Williams et al. 1994). In another early transgenic
mouse model of SCLC, human achaete-schute homolog 1 (ASCL-1) is constitutively
expressed from the Clara cell promoter (CC10) (Linnoila et al. 2000; Wang et al. 2007).
ASCL-1 is a marker of neuroendocrine cells, is expressed in human SCLC, and is
integral to proper neuroendocrine differentiation in mouse (Borges et al. 1997).
Combining this transgenic mouse model with another transgenic mouse driving
expression of SV40 large T antigen from the CC10 promoter (CC1 0-SV40 Tag) leads to
neuroendocrine dysplasias and aggressive lung adenocarcinomas (Linnoila et al. 2000).
Based on the role of SV40 large T antigen in inactivating the tumor suppressors p53
and Rbl, these findings suggest that expression of hASH-1 can cooperate with SV40 in
the development of SCLC. Furthermore, the fact that these mice were able to develop
neuroendocrine lesions from the Clara cell promoter indicates that another cell type,
other than the neuroendocrine cells, can initiate SCLC lesions. In contrast, this could
Rbflox!!!ox/f t OW
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Figure 3. Genetically engineered mouse model of SCLC. (a) Schematic of the alleles
used in mSCLC. Exon 19 and exons 2-10 are flanked by loxP sites (floxed) in the Rb1
(Rb) and Trp53 (p53) genes (p53""fO;RbOxf"Ox), respectively. Following Cre
recombinase-mediated recombination, the exons are deleted.
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indicate that 0010 is in fact expressed in neuroendocrine cells due to leaky expression
of the transgene.
The next generation of SCLC mouse modeling was developed by the Berns
laboratory by combining conditional inactivation alleles of p53 and Rb (Meuwissen et al.
2003). Following lung delivery of an adenovirus containing Cre recombinase, the exons
between the loxP sites are excised, and null alleles of both p53 and Rb are created
(Jonkers et al. 2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 2003). In
p53, the loxP sites flank exons 2 through 10 (flox) (Jonkers et al. 2001), and loxP sites
flank either exon 3 (Vooijs et al. 2002) or 19 (Sage et al. 2003) in the Rb allele (Figure
3). Following Cre-mediated recombination, the mice develop tumors that resemble
SCLC with nearly complete penetrance and a median latency of 210 days (Meuwissen
et al. 2003). During the first several months following tumor initiation, the
p53 4""";Rb"""" mice develop hyperproliferations of the pulmonary neuroendocrine
cells, which reside in the epithelial lining of the bronchioles (Figure 4) (Meuwissen et al.
2003). Eight months after Adeno-Cre, tumors are visible invading out of the bronchiole
into the surrounding lung epithelium (Figure 4) (Meuwissen et al. 2003). Invasive,
disseminated tumors are apparent eight to twelve months post tumor initiation (Figure 4)
(Meuwissen et al. 2003). The murine SCLC (mSCLC) metastasize locally to the lymph
nodes, and to distant sites, such as the liver, brain, bone, adrenal gland, and ovaries,
closely recapitulating the human disease (Figure 4) (Meuwissen et al. 2003). The
mSCLC tumors resemble human SCLC histopathologically: the cells are very small
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Figure 4. Tumor progression and metastasis in a mouse model of SCLC. (a) An in situ
small cell lung lesion eight months after infection. (b) High magnification of an invasive
tumor. At later stages, tumors disseminate within the lung to the (c) blood vessels and
(d) lymphatic vessels, and metastasize locally to the (e) lymph nodes, and distantly to
the (f) liver, (g) adrenal glands and (h) bone. (a-h): Hematoxylin and eosin stain.
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with scant cytoplasm, have a high number of mitotic figures, and express
neuroendocrine markers (Meuwissen et al. 2003). The development of this mouse
model enabled the investigation of the processes that occur during tumor progression
and metastasis.
The development of the mSCLC model allowed investigation into the
requirements for loss of p53 and Rb in SCLC. Interestingly, complete recombination of
the Rb allele is required for SCLC development (Meuwissen et al. 2003). Mice
heterozygous for either the Rb or p53 floxed alleles developed SCLC, but with an
increased latency (Meuwissen et al. 2003). Analysis for recombination indicated that the
wild-type allele must be lost by LOH in order to transform the cell of origin (Meuwissen
et al. 2003). In addition, analysis of recombination of the alleles in p53"ox"f""x;Rb""*f""x
mice demonstrated that recombination of all four alleles occurred in tumors (Meuwissen
et al. 2003). Interestingly, the requirement for complete loss of Rb in SCLC was not
required in adenomas arising in this model (Meuwissen et al. 2003). Although
adenomas lost both copies of p53 in p5344ox/f";Rbf"* mice, they did not lose both copies
of Rb (Meuwissen et al. 2003). While inactivation of p53 was required for adenoma
formation, inactivation of both p53 and Rb was required for SCLC, indicating a striking
difference in the requirement for loss of Rb in transformation and development of SCLC
(Meuwissen et al. 2003). These data also highlight the role of Rb in neuroendocrine
cells. Rb is frequently lost in neuroendocrine tumors, such as neuroblastomas, pituitary
carcinomas, and retinoblastoma (Cavenee et al. 1983; Vooijs et al. 1998; Marino et al.
2000; Wechsler-Reya and Scott 2003).
More recently, this mouse model has been combined with conditional inactivation
alleles of another Rb pocket protein, p130. The p53 44o;Rbxflx;p13044""fIx mice
developed mSCLC with decreased latency (Schaffer et al. 2010). Six months following
tumor initiation, forty tumors were observed on average in lungs of triple compound
mutant mice, compared to just a few tumors in p534"x"fx;Rb"Y"f""x mice (Schaffer et al.
2010). In addition, the tumors resemble those that arise in the original mSCLC model
(Schaffer et al. 2010). Although p130 mutations have been detected in SCLC (Helin et
al. 1997), p130 alterations are rarely observed. The decreased latency and increased
tumor number suggest that p130 loss can cooperate with loss of p53 and Rb in mSCLC,
and provide a mouse model that is easier to work with.
VI. NUCLEAR FACTOR ONE
The work described in Chapter 2 describes the identification of a novel potential
proto-oncogene in small cell lung cancer. This gene, Nuclear Factor I/B (Nfib),
cooperates with L-myc (Myc/l) to enhance cellular transformation.
Nuclear factor I/B is a member of the nuclear factor one (NF-1) family of
transcription factors. This family of transcription factors was originally identified for its
role in regulating adenovirus replication (Nagata et al. 1983; Guggenheimer et al. 1984;
Rawlins et al. 1984). Nuclear factor I family members, also known as CCAAT box
transcription factors or CTF, bind to the origin of replication of adenoviruses (Nagata et
al. 1983; Santoro et al. 1988). NF-1 family members regulate gene expression by
forming stable hetero- and homo-dimers at their binding sites (Kruse and Sippel 1994).
Four family members have been identified: NFIA, NFIB, NFIC, and NFIX (Rupp et
al. 1990; Kruse et al. 1991). The family members are highly conserved with other
nuclear factor I family members in organisms such as chicken, worms and humans
(Gronostajski 2000). In addition, the family members recognize the conserved,
consensus-binding site TTGGC(N5)GCCAA (Gronostajski 2000).
All four NF-1 family members are expressed during murine development, albeit to
varying extents (Chaudhry et al. 1997). In the adult mouse, all family members are
highly expressed in the lung, liver, brain, and heart (GrOnder et al. 2002). To examine
the role for each NF-1 family member during development, knockout mice of each of the
individual family members have been constructed and phenotypes have been
characterized (das Neves et al. 1999; Grinder et al. 2002; Shu et al. 2003; Steele-
Perkins et al. 2003; Steele-Perkins et al. 2005; Driller et al. 2007; Campbell et al.
2008a).
Nfia' mice have severe brain defects, namely a failure to develop the corpus
callosum, and dilation of the lateral and third ventricles (das Neves et al. 1999; Shu et
al. 2003). Interestingly, the defects present in these mice appear to be maternally
regulated. Furthermore, there is a postnatal lethality that is almost 100% penetrant (das
Neves et al. 1999). Nfic' mice do not display an overt phenotype other than a tooth root
defect despite the expression of Nfic throughout development and in the adult (Steele-
Perkins et al. 2003). Nfix-/- mice have been constructed by two different groups, and
despite differences in their findings, both groups determined that the mice exhibit a
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failure to properly develop the corpus callosum and possess skeletal defects (Driller et
al. 2007; Campbell et al. 2008a).
A. Nuclear Factor VB
The brain defects in the Nfib-/- mice resemble those in the Nfia-' mice, but are
more severe (Steele-Perkins et al. 2005). In addition, Nfib- exhibit severe lung
hypoplasia and differentiation defects, and as a result, die from respiratory failure shortly
after birth (Grander et al. 2002). In order to understand the lung defects in more detail,
the authors examined the lungs at various stages during development (Gronder et al.
2002). While the lungs of Nfib- and Nfib'** mice appear similar at embryonic day sixteen
(E16), defects in branching were observed by E18 (GrCinder et al. 2002). Furthermore,
differentiation defects were noted, specifically a decrease in both alveolar type I and Il
cells (GrOnder et al. 2002). Interestingly, lung defects were also observed in Nfib*'- mice,
indicating haploinsufficiency (GrOnder et al. 2002).
The severe lung defects in the Nfib-/- mice are indicative of a role for Nfib in
regulating lung development. The genes that Nfib regulates during development and
adulthood are of prime interest. A candidate gene approach has been utilized to identify
a short list of genes and have identified that Nfib-/- mice have reduced expression of
lung differentiation genes compared to Nfib*' mice. One of the genes that Nfib regulates
is surfactant protein C, which is specifically expressed in lung alveolar type II cells
(Bachurski et al. 1997; Bachurski et al. 2003). In addition, a chromatin
immunoprecipitation followed by microarray (ChIP-chip) analysis was performed in C.
elegans, which identified that NFI-1, the C. elegans ortholog, binding sites are enriched
100-fold in the C. elegans genome compared to the expected frequency (Whittle et al.
2009). Furthermore, NFl-1 binds genes that are integral for viability, egg-laying and
movement (Whittle et al. 2009).
Interestingly, Nfib expression is restricted to the bronchial epithelium and alveolar
type Il cells in the normal adult lung (Chaudhry et al. 1997; Steele-Perkins et al. 2005).
However, the exact cell type in which Nfib is expressed in the bronchial epithelium has
not been examined and it remains an open question as to whether Nfib is expressed in
normal neuroendocrine and/or Clara cells residing in the bronchial epithelium.
B. Nuclear Factor VB and Cancer
Initial in vitro experiments demonstrated that NF-1 may actually suppress
transformation (Schuur et al. 1995). In chicken embryonic fibroblasts, avian NF-I
suppressed foci formation by jun, fos, junB, myc and qin oncogenes (Schuur et al.
1995). More recently, amplifications of nuclear factor I/B have been identified in human
cancers, such as a subtype of breast cancer lacking expression of estrogen,
progesterone and HER2 receptors (Han et al. 2008). In addition, NFIB is contained
within an amplicon commonly found in squamous cell carcinoma (Yang et al. 2001).
While the gene of interest has often been thought to be GASC1, gene amplified in
squamous cell carcinoma 1, the actual gene of interest could be NFIB (Yang et al.
2001). NFIB is also a frequent translocation site in cancers (Geurts et al. 1998). MYB-
NFIB translocations are frequently observed in adenoid cystic carcinomas of the breast
and head and neck (Persson et al. 2009) and HMGA2-NFIB translocations are observed
in lipomas (Pierron et al. 2009).
In addition to the evidence for the role of NFIB in cellular transformation, Nfib has
been identified as a relevant amplified gene in mouse models of cancer. In a mouse
model of hepatocellular carcinoma involving transposon mutagenesis, Nfib was a
recurrent Sleeping Beauty transposon insertion site (Keng et al. 2009). Notably, Nfib
was amplified in tumors arising in a prostate cancer model using a prostate-specific Cre
recombinase and conditional inactivation alleles of p53 and Rb1 (Zhou et al. 2006). In
addition, concurrent amplification of Nfib and L-myc was identified in the tumors. These
data signify the potential importance of Nfib in human and mouse cancer development.
VIl. LUNG INJURY
The work described in Chapter 3 describes the analysis of the role of lung injury
in the initiation of SCLC.
A. Structure of the Lung
The murine adult lung contains many specialized regions, or niches, which
harbor distinct cell types (Figure 5). The trachea and proximal bronchi of the lungs are
cartilaginous and have a distinct proportion of cell types. While they are lined with
ciliated cells, goblet cells, and non-ciliated, columnar cells termed Clara cells, they also
contain pockets of submucosal glands that contain both ciliated and basal cells (Rawlins
and Hogan 2006). The bronchi narrow to the bronchioles in the more distal lung and
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Figure 5. Schematic of the lung structure. (a) The epithelium in large bronchi is lined
with Clara (pink), goblet (red), and ciliated (yellow) cells and contains pockets of
submucosal glands. The bronchioles in the distal lung are lined by Clara (pink) and
ciliated (yellow) cells, and contain the rare neuroendocrine cell (not pictured). The
alveolar epithelium consists of the cuboidal alveolar type II (ATII) cells and the
elongated alveolar type I (ATI) cells. Supporting cells include smooth muscle, fibroblasts
and vasculature cells. (Figure adapted and reprinted with permission from Neuringer,
I.P. and Randell, S.H. (2004). Respiratory Research 5: 6.)
.... ............................
.. ............... ...... ....
Clara cells comprise the majority of the cells lining the bronchioles. The rest of the
bronchiolar lining consists of ciliated cells and pockets of neuroendocrine cells (Rawlins
and Hogan 2006). Neuroendocrine cells exist alone or in small clusters, termed
neuroendocrine bodies (NEBs) (Van Lommel et al. 1999). In the non-cartilaginous
bronchioles, there are more Clara cells, very few ciliated cells, and more
neuroendocrine cells compared to their cartilaginous counterparts (Rawlins and Hogan
2006).
As the bronchioles narrow, the ends of the bronchioles, termed terminal
bronchioles, meet the alveolar space at a region called the bronchio-alveolar duct
junction (BADJ) (Kim et al. 2005; Rawlins and Hogan 2006). It is here that a stem cell
population, termed the bronchio-alveolar stem cells (BASCs), resides (Kim et al. 2005).
The BASCs, which represent a stem or progenitor population have the ability to
regenerate both alveolar and Clara cells as well as harbor marks of both differentiated
cell populations (Kim et al. 2005).
Gas exchange, the primary function of the lung, occurs in the alveolar space. The
alveolar sacs are comprised of two cell types, the alveolar type I (ATI) and alveolar type
II (ATII) pneumocytes (Rawlins and Hogan 2006). ATI cells are elongated cells and are
responsible for the C02-02 gas exchange in the lungs (Rawlins and Hogan 2006). ATII
cells are cuboidal in shape and they produce and secrete surfactant, which coats the
surface of the alveolar epithelium and enhances the environment for the gas exchange
(Uhal 1997; Rawlins and Hogan 2006). While equal numbers of the two cell types are
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present, the AT1 cells comprise 95% of the surface area of the alveolar sacs (Uhal
1997).
B. Lung Cell Type Markers
Existing cell markers have been determined by relying on knowledge of the
function of each of the lung cell types. One of the main surfactants secreted by ATII
cells is surfactant protein C (SP-C). A marker for ATI cells is aquaporin-5 (Nielsen et al.
1997). Aquaporins are essential to maintaining the correct fluid balance in the lung
epithelium (King and Agre 1996). Neuroendocrine cells have endocrine secretory
functions and are innervated by nerves (Van Lommel et al. 1999). Several markers are
specific to the neuroendocrine cells in the lung, such as calcitonin gene related peptide
(CGRP), synaptophysin, and neural cell adhesion molecule (NCAM) (Meuwissen et al.
2003). Clara cells secrete secretoglobulins, and Scbglal, which is also known as
CCSP, CC10 and CCA, is frequently used as a Clara cell marker (Rawlins and Hogan
2006). Acetylated tubulin serves as a marker for ciliated cells (Rawlins and Hogan
2006). The only cell type with known cell surface markers, which can be utilized in
fluorescence-activated cell sorting (FACS) assays, is the BASC. While the BASCs are
double positive for both Clara cell (CC10) and ATII cell (SP-C) cytoplasmic markers,
they also express the cell surface stem cell marker, Sca-1 (Kim et al. 2005). While
sorting for Sca-1+ and CD34* cells further enriched for the BASCs, the addition of CD34
limits the number of cells that can be collected (Kim et al. 2005). The analysis of specific
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cell-type markers clearly demonstrates a lack of cell-surface markers that can be utilized
to isolate and analyze various lung cell types in in vitro experiments.
C. Lung Injury Experiments
Injury studies have been performed to ablate specific lung cell populations in
hopes of identifying cell populations responsible for regeneration. ATII pneumocytes
have been shown to repair the lung following bleomycin injury, which specifically ablates
the ATI pneumocytes (Aso et al. 1976). A model for tracheal injury involves inhaling
sulfur dioxide, which elicits more widespread damage by ablating the epithelial cells
lining the trachea and leaving behind the submucosal glands that are resistant to
damage (Borthwick et al. 2001). Label-retaining experiments indicate that the
submucosal glands are capable of regenerating the entire tracheal epithelium
(Borthwick et al. 2001).
Naphthalene, a chemical that is the primary ingredient in mothballs, ablates the
Clara cells lining the bronchioles (Stevens et al. 1997). More specifically, naphthalene
ablates cells expressing cytochrome P450, which converts naphthalene into a toxic
product (Rawlins and Hogan 2006). Two populations in the lung are resistant to
naphthalene treatment (Reynolds et al. 2000a; Reynolds et al. 2000b; Hong et al. 2001;
Giangreco et al. 2002). One population resides at the terminal bronchioles and
represents the BASCs, while the other population is the neuroendocrine cells (Reynolds
et al. 2000a; Reynolds et al. 2000b; Hong et al. 2001; Giangreco et al. 2002; Kim et al.
2005). BASCs proliferate in response to naphthalene treatment and aid lung
regeneration (Kim et al. 2005). The first evidence of proliferating BASCs was identified
fifty-two hours following naphthalene treatment (Kim et al. 2005). Seventy-two hours
after treatment, 001M0SP-C cells were also BrdU*, indicating that the BASCs had most
likely given rise to these Clara cells (Kim et al. 2005). Further, in vitro evidence indicates
that BASCs give rise to Clara, ATI and ATII cells (Kim et al. 2005). However, in vivo
experiments tracing Clara cells indicate that BASCs give rise to Clara cells, but not ATII
cells (Rawlins et al. 2009). Thus, these data support the conclusion of previous injury
experiments that ATII cells give rise to ATI cells (Aso et al. 1976).
D. Lung Injury and Neuroendocrine Cells
The other cell population that is resistant to naphthalene injury in the distal lung is
the neuroendocrine cells. Naphthalene studies have indicated that not only did the
neuroendocrine cells proliferate in response to injury, but there was an increase in NEB
size as well (Stevens et al. 1997; Reynolds et al. 2000a; Reynolds et al. 2000b).
Additionally, lung-injury experiments have been performed utilizing genetic
ablation. Transgenic mice were engineered to express the herpes simplex virus
thymidine kinase (HSVtk) from the CC10 promoter (Reynolds et al. 2000b). Following
chronic ganciclovir treatment, cells expressing the CC10 promoter were ablated
(Reynolds et al. 2000b). This experiment corroborated naphthalene experiments by
confirming that the neuroendocrine cells proliferate in response to Clara cell injury
(Reynolds et al. 2000b). In addition, hyperplasia of the NEBs was also observed
(Reynolds et al. 2000b).
One of the primary functions of the neuroendocrine cells is to sense oxygen
levels in the lungs (Van Lommel et al. 1999). In experiments involving the chronic
treatment of hamsters with hyperoxia and diethylnitrosamine (DEN), the neuroendocrine
cells proliferated and became hyperplastic (Sunday and Willett 1992; Willett et al. 1999).
However, the neuroendocrine hyperplasia was temporary and spontaneously
disappeared following fourteen weeks of chronic treatment (Sunday and Willett 1992;
Willett et al. 1999). These data are indicative of the neuroendocrine cells' ability to
sense hyperoxic conditions.
E. Injury and Tumorigenesis
Chronic injury correlates with increased tumorigenesis. One prime example of
this is the increased incidence of lung cancer in smokers. Tobacco smoke contains
more than twenty known carcinogens and mutagens (Minna et al. 2002) and the lung of
a smoker is injured over the course of time. In fact, mutations are frequently observed in
the normal bronchioles of smokers with SCLC (Wistuba et al. 2000). Another example of
the effect of injury on tumorigenesis is that patients with chronic pancreatitis have an
increased risk of developing pancreatic cancer (Lowenfels et al. 1993; Malka et al.
2002). This has been supported utilizing mouse models where the adult pancreas is
mostly refractory to transformation (Guerra et al. 2007; Gidekel Friedlander et al. 2009).
In contrast, the adult pancreas chronically injured with caerulein was transformed and
pancreatic intraepithelial neoplasias progressed to pancreatic ductal adenocarcinomas
(Guerra et al. 2007; Gidekel Friedlander et al. 2009).
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Experiments involving the analysis of stem cell populations within the lung led to
the discovery of a potential cell of origin for NSCLC. In a mouse model utilizing
conditional activation of an oncogenic K-ras allele, an expansion of BASCs at the
terminal bronchiole was observed following tumor initiation (Kim et al. 2005). In addition,
naphthalene treatment prior to tumor initiation led to an increase in the number and area
of tumors six weeks following treatment (Kim et al. 2005). These data implicate BASCs
as the cell of origin of NSCLC due to their expansion following tumor initiation and an
increase in tumors following injury.
VIll. CONCLUSION
The work in this thesis describes the analysis of the initiation, progression, and
metastasis of small cell lung cancer. In Chapter 2, we identified tumor and metastasis
copy number alterations in a mouse model of SCLC, including a recurrent amplification
of a region on mouse chromosome 4 that contains a novel potential proto-oncogene,
Nuclear Factor I/B. We also identified Nuclear Factor I/B amplifications in human SCLC.
In further experiments, we demonstrated a role for the functional cooperation of Nuclear
Factor I/B with a known oncogene in SCLC, L-myc. In Chapter 3, we investigated the
initial stages of SCLC. Injury experiments utilizing naphthalene indicated that the
neuroendocrine cells, which are the putative cell of origin of SCLC, responded to injury
and aided the lung regeneration process. We extended these experiments to analyze
the role of injury in SCLC tumorigenesis and demonstrated that naphthalene injury prior
to tumor initiation in a mouse model of SCLC enhances SCLC progression and
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decreases latency. Through these studies, we have demonstrated the usefulness of the
mouse model of SCLC in probing the various stages of tumorigenesis to enhance our
understanding of this aggressive disease.
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ABSTRACT
Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin
that is often diagnosed only after it has metastasized to distant sites (Meuwissen and
Berns 2005; Cooper and Spiro 2006). Despite the need to better understand this
disease, SCLC remains poorly characterized at the molecular and genomic levels
(Forgacs et al. 2001; Pleasance et al. 2010). Using a genetically engineered mouse
model of SCLC driven by conditional deletion of Trp53 and Rbl in the lung (Jonkers et
al. 2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 2003), we identified
several frequent and high-magnitude focal DNA copy-number alterations in tumors and
metastases. We uncovered the coincident amplification of two proto-oncogenes: L-myc
(Mycl) and a novel proto-oncogenic transcription factor, Nuclear Factor I/B (Nfib).
Comparative genomics further identified NFIB as an important oncogene in human
small cell lung tumors. Functional studies indicated a role for NFIB in the regulation of
apoptosis and proliferation in human SCLC, as well as cooperation with L-myc in
cellular transformation.
INTRODUCTION
Small cell lung cancer (SCLC) is a highly lethal form of cancer that comprises
18% of all lung cancer cases (Wistuba et al. 2001; Meuwissen and Berns 2005).
Unfortunately, SCLC is frequently diagnosed after metastatic spread of the disease, and
the five-year survival rate is dismal at 5% (Worden and Kalemkerian 2000; Cooper and
Spiro 2006). Some insight has been gained as to the underlying mechanisms of this
aggressive disease, including the identification of loss-of-function mutations in Trp53
(Yokota et al. 1987; Takahashi et al. 1989; Takahashi et al. 1991) and the RB1 (Harbour
et al. 1988; Yokota et al. 1988) tumor suppressor genes, which are observed in 75%
and 90% of SCLC cases, respectively (Wistuba et al. 2001; Meuwissen and Berns
2005). In addition, MYC family members (C-MYC, L-MYC, and N-MYC) are frequently
amplified in SCLC (Nau et al. 1985; Meuwissen and Berns 2005). However, very little is
known about other functionally relevant alterations in SCLC, and a more complete
understanding of the disease is required to allow the development of new targeted
treatments.
Whole-genome profiling has been utilized to gain information about copy-number
alterations, point mutations, and translocations in tumors (Campbell et al. 2008; Ley et
al. 2008; Mardis et al. 2009). One recent examination of thirty-three primary SCLC
tumors and thirteen SCLC cell lines identified MYC family amplifications in 82% of
tumors and 62% of cell lines (Voortman et al. 2010). Another study identified 22,000
point mutations in a SCLC cell line, the majority of which were G-T transversions, a
hallmark of smoking (Toyooka et al. 2003; Lewis and Parry 2004; Pleasance et al.
2010). However, the identification of point mutations selected during tumorigenesis
proves to be a daunting task (Greenman et al. 2007; Stratton et al. 2009). Comparative
studies utilizing mouse models have aided in narrowing the list of candidate genes (Kim
et al. 2006b; Zender et al. 2006; Zender et al. 2008). One such study identified NEDD9
as a novel oncogene involved in metastatic melanoma (Kim et al. 2006a). Thus, mouse
models of cancer can aid in the identification of candidate oncogenes and tumor
suppressors in cancer.
A mouse model of SCLC (mSCLC) has previously been described that
inactivates two conditional ("floxed") alleles of two tumor suppressor genes, Trp53 and
Rbl (p53'/;Rb"/4), which are commonly mutated in human SCLC (Supplementary Figure
1a) (Jonkers et al. 2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 2003).
Inhalation of adenovirus containing Cre recombinase results in infection of lung
epithelial cells and deletion of p53 and Rb specifically in the lung (DuPage et al. 2009).
Over time, tumors and metastases develop, at sites such as the lymph nodes, liver,
adrenal gland and bone, that histopathologically resemble human SCLC (Meuwissen et
al. 2003). Thus, this genetically engineered mouse model provided an ideal setting to
identify genetic alterations that occur during tumor progression.
RESULTS
We first ensured that we could recapitulate the tumors and metastases described
in the original report by Meuwissen et al. (Meuwissen et al. 2003). Following inhalation
of adenovirus containing Cre recombinase, the mice first developed in situ tumors that
are limited to the bronchiolar lumen (Supplementary Figure 1). At later stages, the
tumors invaded the surrounding lung epithelium and disseminated throughout the lung
into the lymphatic and blood vessels (Supplementary Figure 1). Similarly to human
SCLC, the murine small cell lung tumors (mSCLC) metastasized to the thoracic lymph
nodes, liver, adrenal glands, and bone (Supplementary Figure 1). The mice have a
median survival time of 350 days, during which the tumors become malignant and
metastatic (Supplementary Figure 1). In addition, the tumors expressed neuroendocrine
markers, such as calcitonin-gene-related peptide (CGRP), synaptophysin, and neural
cell adhesion molecule (NCAM) (Supplementary Figure 2) (Meuwissen et al. 2003).
Further, the tumors were highly proliferative and exhibited apoptosis, both of which are
characteristics of human SCLC (Supplementary Figures 2, 3) (Meuwissen et al. 2003).
To determine the genetic alterations that occur in mSCLC tumors and
metastases, primary tumors and metastases were dissected and used for histology,
DNA and RNA isolation, as well as for the derivation of cell lines. Each tumor was
verified histopathologically to be SCLC and tumor purity was assessed by PCR for the
recombined Trp53 and Rbl alleles (Supplementary Figure 4). The analysis of DNA
copy-number alterations in murine tumor models has previously aided in the
identification of functionally important genes in several human tumor types (Kim et al.
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2006a; Zender et al. 2006). Thus, we analyzed mSCLC tumors and metastases using
sequencing-based DNA copy-number analysis (Chiang et al. 2009) and found that while
the majority of the genome was surprisingly unaltered, several high-level, focal
amplifications and deletions were observed (Figure 1 a, Supplementary Figures 5, 6). In
particular, we identified two recurrent focal amplifications centered around 82 Mb and
122 Mb on mouse chromosome 4 and a heterozygous deletion spanning from
approximately 148.5 Mb to the end of chromosome 4 (Figure 1 b). Although one of the
focal amplifications on chromosome 4 contained a known proto-oncogene involved in
SCLC, L-myc (Mycl) (Nau et al. 1985), the other focal amplification contained no genes
previously implicated in SCLC (Figure 1 c, Supplementary Figure 5). Interestingly, the
region between the two focal amplifications is near diploid and contains the tumor
suppressor gene, Cdkn2a. Despite the well-known role of Cdkn2a in regulating p53 and
Rb, which are already deleted in tumors, the fact that the copy-number of this gene is
kept low is consistent with this locus regulating other Rb family members (Schaffer et al.
2010). To identify the relevant targets within the amplified region centered around 82
Mb, the amplification breakpoints were mapped using statistical changepoint analysis of
the normalized copy-number ratios (Chiang et al. 2009). Nuclear Factor I/B (Nfib) was
the only gene within this region amplified in each of the samples (Figure 1 c).
Furthermore, Nfib is located at the apex of the amplified peak in tumors and tumor-
derived cell lines (Figure 1d, e). Thus, Nfib represents a newly identified amplified gene
in SCLC.
Nuclear Factor I/B (Nfib) is a CCAAT-box-binding transcription factor that
regulates the expression of lung differentiation genes (Santoro et al. 1988; Steele-
Perkins et al. 2005). Nfib knockout mice have lung hypoproliferation and differentiation
defects, in addition to brain defects, and die shortly after birth (GrOnder et al. 2002;
Steele-Perkins et al. 2005). The chromosomal region containing Nfib has been reported
to be frequently amplified in a mouse model of prostate cancer (Zhou et al. 2006) and in
human triple-negative breast cancer, which is negative for the estrogen, progesterone,
and human epidermal growth factor (HER2) receptors (Han et al. 2008). Based on the
identification of Nfib as an amplified gene in SCLC and its potential importance in other
prevalent tumor types, we chose to examine Nfib further.
The DNA copy-number of Nfib and the expression of Nfib mRNA were
determined using real-time PCR in a panel of twenty-eight mSCLC-derived cell lines
(Figure 2a, b). Out of twenty-eight cell lines, sixteen had Nfib and six had L-myc
amplifications (Figure 2a, Supplementary Figure 2b). Notably, four mSCLC cell lines had
amplified both Nfib and L-myc (Supplementary Figure 7). mSCLC cell lines with
increased Nfib copy-number also expressed high levels of Nfib (Figure 2b).
Interestingly, two cell lines with normal Nfib copy-number expressed high levels of Nfib
mRNA suggesting that mechanisms other than genomic alteration may increase Nfib
levels in SCLC (Figure 2b).
To confirm Nfib amplification in mouse tumors, we performed fluorescence in situ
hybridization (FISH). FISH confirmed the amplification of Nfib in the lymph node
metastasis analyzed in Figure 1 (Figure 2c, d). We also confirmed the expression of
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Nfib at the protein level in mSCLC tumors and metastases by performing
immunohistochemical (IHC) staining. Interestingly, in another primary tumor, Nfib
amplification correlated with a region with increased Nfib expression (Figure 2e, f). In
normal lung, Nfib protein was localized appropriately to the nucleus of alveolar type II
cells (Steele-Perkins et al. 2005). Nfib was also nuclear in primary SCLC, but was not
detected in lung adenomas that occasionally arise in this mouse model (Figure 2g, h, k
and data not shown). Further, we observed that both lymph node and liver metastases
very frequently expressed increased levels of Nfib (Figure 2i-k). These data confirmed
amplification and expression of Nfib in mSCLC tumors and metastases.
We next examined whether NFIB is amplified and expressed in human SCLC.
Copy-number analysis revealed a broad region of amplification on chromosome 9p23
encompassing 210 genes. GISTIC analysis (Beroukhim et al. 2007) identified
approximately a 200 kb minimal region of amplification containing only one gene, NFIB.
In total, sixteen of forty-six human SCLC cell lines had NFIB copy-number gains (Figure
3a). Interestingly, eleven of the cell lines with NFIB amplification also had L-MYC
amplification, and fifteen out of the sixteen cell lines with amplification of NFIB displayed
additional amplification of one of the MYC family members (Supplementary Figure 7).
Increased copy-number of NFIB was confirmed by real-time PCR (Figure 3b).
Additionally, NFIB amplification was detected by FISH in 15% of primary human tumor
samples (Figure 3c). In gene-expression studies, NFIB was more highly expressed in
SCLC than in other lung tumor types (Supplementary Figure 8) (Bhattacharjee et al.
2001). We next addressed whether NFIB protein was expressed in human SCLC tumor
78
samples by performing IHC on a tissue microarray containing sixty-eight distinct human
SCLC samples (Figure 3d). High level NFIB protein expression was noted in 16% of
samples and the protein was detectable in 65% of samples (Figure 3d). Collectively,
these data suggest a potentially oncogenic role for NFIB in SCLC.
To determine which cellular processes are regulated by NFIB, we used RNA
interference (RNAi) to inhibit NFIB in several human SCLC cell lines. In one adherent
cell line, NCI-H446, which has both high-level NFIB amplification and expresses very
high levels of NFIB, RNAi-mediated NFIB knockdown caused a dramatic increase in
apoptosis and a corresponding decrease in proliferation (Figure 4a-c). Decreased
proliferation after NFIB knockdown was confirmed in two other human cell lines
(Supplementary Figure 9). In another cell line lacking NFIB amplification, NCI-H196,
NFIB knockdown led to different outcomes depending on the shRNA used, with one
inducing apoptosis and the other cellular senescence (Figure 4d-g). These data suggest
that NFIB expression is integral to human SCLC cell line viability and/or continued
proliferation.
In some cases, we characterized the DNA copy-number profiles of mSCLC cell
lines and the tumors from which they were derived. The pattern of DNA copy-number
alteration was nearly identical between mouse tumors and their related cell lines,
supporting the latter's use for functional investigation of Nfib (Figure 1 c, Supplementary
Figures 5, 6 and data not shown).
We examined the effect of Nfib inhibition using RNAi in several mSCLC cell lines.
While proliferation and survival were not as dramatically affected as they were in the
human SCLC cell lines, we observed fewer cells infected with Nfib shRNAs, indicating
selection against cells infected with Nfib shRNAs in a lymph node metastasis cell line
that highly expresses Nfib (Supplementary Figure 10). In addition, we observed a
reduction in the ability of the same lymph node metastasis cell line (shown in
Supplementary Figure 10) with Nfib knockdown to grow in anchorage-independent
conditions (data not shown). While proliferation and survival were not as significantly
affected on tissue culture plastic as they were in the human SCLC cell lines, these data
indicate that Nfib is integral to mSCLC cell line viability as well.
We then examined whether concurrent amplification of Nfib and L-myc in murine
small cell lung tumors was indicative of functional cooperation in cellular transformation.
Importantly, mSCLC cell lines with high Nfib expression also expressed high levels of L-
myc (Supplementary Figure 5). For initial functional cooperation studies, we utilized
mSCLC cell lines that expressed low levels of endogenous Nfib and L-myc and we
stably expressed Nfib, L-myc, or both L-myc & Nfib (Figure 5a, Supplementary Figure
11). Ectopic expression of L-myc & Nfib in two independent mSCLC cell lines increased
the number and size of anchorage-independent colonies compared to either gene alone
(Figure 5b, c, Supplementary Figure 11). Furthermore, cells over-expressing both L-myc
& Nfib proliferated more quickly under standard culture conditions (Supplementary
Figure 12). We then determined whether L-myc and Nfib would function synergistically
in a heterologous setting by testing whether L-myc and Nfib could transform wild-type
mouse embryonic fibroblasts (MEFs). When cells were plated at high density to assay
for the ability to overcome contact inhibition of growth, significantly more three-
dimensional foci formed when MEFs expressed L-myc & Nfib (Figure 5d, e,
Supplementary Figure 13). A Bliss independence test indicated that L-myc and Nfib
were acting synergistically. Additionally, expressing either Nfib or L-myc & Nfib
significantly increased colony formation in a low-density colony formation assay
(Supplementary Figure 13). In this assay, L-myc and Nfib cooperation was variable.
To begin to explore the molecular pathways that underlie the cooperative effects
of L-myc and Nfib expression, we performed gene expression arrays on two mSCLC
cell lines stably expressing Nfib, L-myc or L-myc & Nfib (shown in Figure 5a and
Supplementary Figure 11). We identified significantly more down-regulated than up-
regulated genes upon Nfib and/or L-myc expression (Figure 5f, g, Supplementary
Tables 1-7). While more genes were down-regulated upon expression of both L-myc &
Nfib than with either L-myc or Nfib alone, we identified more significantly up-regulated
genes in cells expressing Nfib alone than with L-myc & Nfib (Figure 5f, g). These data
suggest that stable expression of L-myc & Nfib induces both cooperative and
antagonistic effects (Figure 5g). Notably, expression of either L-myc or Nfib led to the
up- and down-regulation of completely different sets of genes (Figure 5f, g). To assess
which pathways were affected by the over-expression of these transcription factors, we
performed a Gene Set Enrichment Analysis (GSEA) (Supplementary Figure 14). Within
curated gene sets, a cancer-related transcription factor gene set was up-regulated in
Nfib and in L-myc & Nfib expressing cells (Supplementary Figure 14,
BrentaniTxnFactors). Additionally, as expected L-myc is involved in proliferation and
DNA repair and we identified a role for Nfib in modulating the interferon specific immune
response and angiogenesis. Interestingly, we observed that cell adhesion gene sets are
anti-correlated with L-myc & Nfib expression. In addition, we performed a gene ontology
analysis (GeneGo) (Figure 5h, Supplementary Table 8). Similar to the GSEA, we also
identified cell adhesion, cancer, and angiogenesis pathways of interest in the Gene
Ontology terms (Figure 5h). We also identified that Nfib, alone or in the context of
simultaneous L-myc expression, regulates proliferation and extracellular matrix
remodeling pathways (Figure 5h, Supplementary Table 8). These data support our
hypothesis of cooperation of these proto-oncogenes at the molecular level (Figure 5h,
Supplementary Figure 14, Supplementary Tables 1-8).
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Figure 1. Nuclear Factor I/B is amplified in murine SCLC tumors. (a) Log2 ratio of tumor
to somatic DNA copy-number across the whole genome of a mSCLC lymph node
metastasis cell line. The X chromosome has a copy-number ratio of 2 due to the male
reference genome while the sample was derived from a female mouse. (b) DNA copy-
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number ratio of chromosome 4 of the same sample as in (a). (c) Integrated genome
viewer (IGV) plot of the DNA copy-number of position 79.5 to 84.5 Mb on chromosome
4. Scale bar indicates the log2 copy-number ratio of tumor to somatic reference sample.
Dotted line indicates the boundaries of the minimally conserved region. (d) Focally
amplified peak containing Nuclear Factor I/B is shown in two tumors. (e) Focally
amplified peak containing Nuclear Factor I/B is shown in two cell lines. (b, d, e) Copy-
number data is plotted as the copy-number ratio of tumor to somatic. T: primary lung
tumor, Liv: liver metastasis, LN: lymph node metastasis, gray labels: tumor samples,
black labels: cell lines.
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Figure 2. Nuclear Factor I/B is expressed in mSCLC. (a) NfO is amplified in tumor- and
metastasis-derived cell lines. A DNA copy-number ratio greater than 1.2 was considered
to be amplified, as determined by real-time PCR on genomic DNA. Mets: metastasis-
derived cell lines. (b) Cell lines with increased copy-number of the N locus also have
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increased expression of Nfib. (c) DNA FISH analysis on a lymph node metastasis
confirming known amplification of Nfib from copy-number analysis. Inset is of a cell with
amplified Nfib. (d) Matching Nfib IHC on the same lymph node metastasis as in (c),
which has high Nfib expression. (e) DNA FISH analysis of a lung tumor illustrating
amplification of Nfib in a subset of tumor cells. Left inset illustrates a cell with normal
Nfib copy-number, right inset is a cell with amplified Nfib. (f) Matching Nfib IHC on the
same lung tumor as in (e) demonstrating increased Nfib expression in the region with
Nfib amplification. (c-f: scale bar is 20 pM, red: Nfib probe, green: control chromosome
4qA1 probe, blue: DAPI.) (g) Nfib can be detected by IHC in an in situ SCLC lesion. (h)
Nfib is expressed in an invasive small cell lung tumor. (i) Nfib is expressed in a lymph
node metastasis. (j) Nfib is expressed in a liver metastasis. T: liver metastasis, Liv:
normal liver. (g, h: 20X objective, scale bar is 100 pM; i, j: 1OX objective, scale bar is
200 pM) (k) Percent of lesions positive (dark gray), weak (light gray), and negative
(white) for Nfib expression in lung tumors that are in situ, invasive (Inv.), disseminated
(Dis.) as well as lymph node (LN) and liver metastases.
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Figure 3. Nuclear Factor I/B is amplified and expressed in human small cell lung
cancer. (a) Integrated Genome Viewer (IGV) plot of forty-six human SCLC cell lines
from position 11.1 -17.2 Mb on human chromosome 9. Dotted line indicates the
boundaries of the minimally conserved region. Scale bar indicates the log2 copy-number
ratio of tumor to somatic reference sample. (b) NFIB amplifications were confirmed by
real-time PCR on genomic DNA. All cell lines are NCI cell lines, except where otherwise
noted. (c) NFIB was amplified in human tissue samples, as detected by DNA NFIB
FISH. Left panel is a representative sample with normal NFIB copy-number, right panel
is a representative sample with amplified NFIB. Red: NFIB probe, green: control
chromosome 9q12 probe, blue: DAPI. Scale bar is 10 pM. (d) NFIB was frequently
expressed in human SCLC tissue samples as detected by IHC for NFIB. NFIB protein
expression was graded on a scale of 0 (not expressed) to 3 (highly expressed). The
scale bar is 200 pM.
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Figure 4. NFIB knockdown induces death and reduces proliferation in human SCLC. (a)
Two hairpins knocked down NFIB in an adherent cell line, NCI-H446. (b) NFIB
knockdown increases cleaved caspase 3 (CC3) staining by FACS compared to control
infected cells. (c) Quantification of BrdU incorporation by FACS following NFIB
knockdown. (d) Western blot demonstrating NFIB knockdown in NCI-H196 using two
different hairpins. (e) NFIB shRNA #1 induces apoptosis, as observed with an increase
in CC3 staining by FACS. (f) Reduced BrdU incorporation as detected by FACS
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following NFIB knockdown. (g) Representative pictures of senescence-associated B-
galactosidase staining (SA-Bgal) in an adherent cell line, NCI-H196, following control
(left) or NFIB (right) knockdown with shRNA#2. Quantification of the SA-Bgal staining is
shown in the right panel. (* p value < 0.05 , ** p value < 0.005, *** p value < 0.0005).
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Figure 5. Synergy between Nfib and L-myc in murine SCLC. (a) Stable expression of
Nfib and L-myc in a mouse primary SCLC cell line with low endogenous expression of
both Nfib and L-myc. (b) Crystal violet staining of soft agar colonies in the uninfected
cell line or cell line stably expressing Nfib and/or L-myc. Images are representative of
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two separate experiments and visualized using crystal violet staining. (c) Quantification
of the number of soft agar colonies. The values represent the mean +/- standard
deviation of triplicate plates. (d) Western blot demonstrating stable expression of Nfib
and/or L-myc in wild-type mouse embryonic fibroblasts (MEFs). (e) Wild-type MEFs
either uninfected or infected with Nfib- and/or L-myc-expressing viruses were plated at a
high density and assayed for three-dimensional colony formation. Colonies were
visualized using crystal violet and quantified. Values represent the mean +/- standard
deviation of the total number of foci in triplicate plates of both experiments utilizing two
different MEF preparations. (*: p value < 0.05, **: p value < 0.005, ***: p value < 0.0005).
(f) Heat map representing all the differentially regulated genes following expression of L-
myc and/or Nfib in one of the cell lines. Each condition has two replicates. Scale bar
ranges from a z-score of -2 (green) to 2 (red). (g) Venn diagram indicating the
proportion of genes that are up- or down-regulated following expression of Nfib and/or
L-myc. The circle size is proportional to the number of genes up-regulated following
expression of both L-myc & Nfib. Red circles: up-regulated genes, green circles: down-
regulated genes. (f-g) The log2 fold change was greater than 1 or less than -1, in
addition to a p-value less than 0.05, to be significantly up- or down-regulated. (h) Gene
Ontology terms from the GeneGo Analysis highlights several pathways of importance in
cells expressing Nfib and/or L-myc. "Y" indicates that the gene set is significant, with a p
value less than 0.05.
DISCUSSION
The use of a genetically engineered mouse model of SCLC enabled us to
interrogate the genomic alterations that occur in SCLC. We identified several high-level
focal amplifications and deletions and, notably, uncovered amplification of a novel
potential proto-oncogene, Nuclear Factor I/B. This mouse model provides several
advantages over studying this cancer type in humans. First, the tumors are initiated by
defined genetic events and the disease progresses in the absence of smoking
carcinogen-induced passenger mutations and alterations. Second, a wealth of tumor
and metastasis samples can be collected and utilized for DNA, RNA, and protein
analyses as well as histology and cell line derivation. And third, tumors can be collected
at different stages, with our data indicating that Nfib is highly expressed in the most
advanced stages of mSCLC. Interestingly, the human SCLC cell lines in which we
demonstrated that NFIB is involved in tumor maintenance were also derived from
patient pleural effusions and a lymph node metastasis. Thus, advanced lesions still
appear to critically depend on NFIB for cell viability.
We identified several pathways that were specifically altered in response to the
co-expression of Nfib and L-myc, corroborating their functional interaction when
concurrently amplified in SCLC (Figure 5h, Supplementary Figure 14, Supplementary
Table 8). This analysis would be advanced by the identification of the direct targets of
Nfib, such as through chromatin immunoprecipitation followed by sequencing of the
targets (ChIP-seq). While we know that Nfib controls lung differentiation, the
identification of the direct targets would prove useful in understanding the role of Nfib
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amplification in SCLC (Steele-Perkins et al. 2005). The pathways identified may yield
new therapeutic targets for SCLC and aid in the discovery of targeted therapeutics to
treat this poorly understood disease.
In addition, this mouse model can be utilized to address the roles of Nfib and
future candidate genes in tumor initiation, maintenance, and progression. We have
recently demonstrated that lentiviruses can induce tumors in this mouse model, albeit
with a lower penetrance (Supplementary Figure 15). In contrast to adenoviruses,
lentiviruses provide a genetic tag based on their integration site in the genome, which
enables the identification of matched primary tumors and metastases. Thus, we can
determine whether Nfib amplifications, for example, only occur in primary tumors that
metastasized. The role of Nfib in tumor initiation can be determined by expressing Nfib
from the time of tumor initiation by infecting mice with lentiviruses expressing Cre
recombinase and the Nfib cDNA. In contrast, the role of Nfib during tumor progression
can be analyzed using either lentiviruses or genetically engineered mice expressing a
regulatable allele of Nfib, such as one regulated by doxycycline. Such studies will
enable the direct analysis of Nfib in mSCLC initiation and progression.
The copy-number profiling uncovered several loci that have yet to be analyzed.
Additional alterations, such as the loss at the end of chromosome 4, can be investigated
for candidate genes of interest in mSCLC progression. Additionally, given our success
of analyzing copy-number alterations in mSCLC, future efforts to catalogue point
mutations in mSCLC, followed by cross-species analyses, would likely prioritize the
daunting number of potentially meaningful mutations being identified in human SCLC
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(Pleasance et al. 2010). Thus, our study highlights the power of rationally designed
mouse models to uncover novel cancer-promoting alterations and documents the
cooperation between proto-oncogenic transcription factors in SCLC.
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Supplementary Figure 1. Tumor progression and metastasis in a mouse model of
small cell lung cancer. (a) Schematic of the mouse model. Exon 19 and exons 2-10 are
flanked by loxP sites (floxed) in the Rb1 and Trp53 genes (p53f"f';Rbf"''), respectively.
Following Cre recombinase-mediated recombination, the exons are deleted. (b) An in
situ small cell lung lesion eight months after infection. (c) High magnification of an
invasive tumor. At later stages, tumors disseminate within the lung to the (d) blood
vessels and (e) lymphatic vessels, and metastasize locally to the (f) lymph nodes, and
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distantly to the (g) liver, (h) adrenal glands and (i) bone. (j) Detection of a bone
metastasis using luciferase imaging of a p53 " ";Rb"f";Rosa2 6LSL-Luciferase/LSL-Luciferase
mouse. (k) Micro-computed tomography imaging of the bone metastasis. The bone
metastasis is osteolytic, consistent with metastatic human SCLC. (left panel: right knee
with bone metastasis, right panel: normal left knee.) (1) Kaplan-Meier survival curve of
mice infected with two different titers of adenovirus expressing Cre recombinase.
(squares: 2.5x10 7 PFU, median latency: 475 days; diamonds: 1x108 PFU, median
latency: 350 days). (b-i): Hematoxylin and eosin stain.
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Supplementary Figure 2. mSCLC tumors express neuroendocrine markers and are
highly proliferative. (a) Hematoxylin and eosin (H&E) stain of an early in situ mSCLC
lesion. (b) The early lesion shown in (a) expresses CGRP, a neuroendocrine marker, as
determined by IHC. (c) H&E of a mSCLC tumor. (d) The tumor shown in (c) is highly
proliferative, as determined by IHC for Ki-67, a marker of cycling cells. (e) H&E of an in
situ mSCLC lesion. (f) The early lesion shown in (e) expresses CGRP. (g) H&E of an in
situ mSCLC lesion. (h) The early lesion shown in (g) expresses Ki-67. a, b, e, f, g, h:
40X objective; c, d: 20X objective.
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Negative TUNEL
Supplementary Figure 3. mSCLC tumors contain apoptotic cells. (a) Negative control
for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in an in situ
mSCLC lesion. (b) The early lesion shown in (a) has apoptotic cells, as determined by
TUNEL staining. (c) Negative control for TUNEL staining in an in situ mSCLC lesion. (d)
The early lesion shown in (c) has apoptotic cells, as determined by TUNEL staining. (e)
Negative control for TUNEL staining in a mSCLC tumor. (f) The tumor shown in (e) has
apoptotic cells, as determined by TUNEL staining. green: TUNEL staining, blue: DAPI.
a-d: 40X objective; e, f: 20X objective.
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Supplementary Figure 4. p53 and Rb alleles are recombined in mSCLC cell lines. (a)
p53 and Rb pre fully recombined in five out of six cell lines assessed by PCR. The PCR
reactions for the recombined p53 and Rb alleles are marked by A. The H20 serves as a
negative control.
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Supplementary Figure 5. Amplification of L-myc in murine small cell lung tumors and
cell lines. (a) Amplification of L-myc (Mycl) in four cell lines analyzed using Illumina
sequencing-based DNA copy-number analysis. T: primary lung tumor, Liv: liver
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metastasis, LN: lymph node metastasis. (b) Real-time PCR on genomic DNA for
amplification of the L-myc locus indicates that L-myc is amplified in tumor- and
metastasis-derived cell lines. A DNA copy-number ratio greater than 1.2 was considered
an amplification, as determined by real-time PCR on genomic DNA. Mets: metastasis-
derived cell lines. (c) Real-time PCR indicates that cell lines that express high levels of
Nfib also express high levels of L-myc. (d) Integrated genome viewer (IGV) display of
copy-number from 120-8-124.8 Mb on chromosome 4. The samples are organized from
highest L-myc amplification to lowest. Scale bar indicates the log2 copy-number ratio of
tumor to somatic reference sample. The dotted line indicates the boundaries of the
minimally conserved region. T: primary lung tumor, Liv: liver metastasis, LN: lymph node
metastasis, gray labels: tumor samples, black labels: cell lines.
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Supplementary Figure 6. mSCLC samples contain focal amplifications and deletions.
(a) Integrated genome viewer (IGV) plot of DNA copy-number changes in all samples
across the genome. Samples are plotted as the 1092 ratio of tumor to somatic copy-
number. Scale bar indicates the 1092 copy-number ratio of tumor to somatic reference
sample. The dotted line indicates the boundaries of the minimally conserved region. T:
primary lung tumor, Liv: liver metastasis, LN: lymph node metastasis, gray labels: tumor
samples, black labels: cell lines.
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Supplementary Figure 7. Co-amplification of L-myc and Nfib in SCLC. (a) Number of
mSCLC cell lines with amplifications of Nfib, L-myc or both Nfib and L-myc. A DNA
copy-number ratio greater than 1.2 was considered amplified, as determined by real-
time PCR on genomic DNA. (b) Number of human SCLC cell lines with amplification of
NF/B and/or L-MYC. A DNA copy-number ratio greater than 1.2 was considered
amplified, as determined by the copy-number profiling. The probability of encountering
both NF/B and L-MYC amplifications trends toward being significant. (Fisher Exact
probability test, p value = 0.06).
104
amplified
0 E
CO
E
...... .... ....................... .  ....................... . ...........    ........ ... . ....
NFIB
6.5-
6.0
5.5
5.0
S4.5
E4.0
3.5
S3.0
S2.5
c 2.0
COE11 .5
E 1.0
'07 0.5
0.0-*
-0.5
-1.0
-1.5 Adenocarcinoma Carcinoid SCLC Squamous
Supplementary Figure 8. NFIB is expressed in human SCLC. (a) NFIB is more highly
expressed in SCLC compared to other lung cancer types, including adenocarcinoma,
carcinoid, and squamous cell carcinoma. The blue bar represents the data from the 25th
to 75th percentiles, the black horizontal line represents the median, the error bars
represent the data range from the 10 th to the 9 0 th percentile, and the black dots
represent the maximum and minimum values detected. Figure adapted from Oncomine
(www.oncomine.org) (Bhattacharjee et al. 2001).
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Supplementary Figure 9. NFIB knockdown in human SCLC cell lines. (a) NFIB
knockdown is detected by Western blotting in NCI-H889. (b) NFIB knockdown reduces
proliferation in NCI-H889, as assessed by BrdU incorporation by FACS. Values
represent the mean +/- standard deviation of duplicate wells of a representative
experiment. (c) NFIB knockdown is detected by Western blotting in NCI-H82. (d) NFIB
knockdown reduces proliferation in NCI-H82, as assessed by BrdU incorporation by
FACS. Values represent the mean +/- standard deviation of duplicate wells of a
representative experiment.
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Supplementary Figure 10. Nfib knockdown in mouse SCLC cell lines. (a) Western blot
demonstrating Nfib knockdown over time (days 2-5 following infection) in a mSCLC
lymph node metastasis cell line. Nfib has multiple isoforms, and not all isoforms are
knocked down efficiently. (b) Following infection with a virus expressing GFP and the
shRNA, the GFP* % was monitored for five days following infection by flow cytometry.
Cells infected with Nfib shRNA #1 select against cells expressing the Nfib shRNA
(GFP*) compared to cells infected with a control hairpin.
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Supplementary Figure 11. Synergy between Nfib and L-myc in mSCLC. (a) Stable
expression of Nfib and L-myc in a mouse primary SCLC cell line (3583T3) with low
endogenous expression of both Nfib and L-myc. Another primary SCLC cell line
(3151T4) is shown in Figure 5a-c. (b) Quantification of the number of soft agar colonies,
as visualized using crystal violet staining. The number of colonies in at least nine
camera views per plate using a 1OX objective was quantified. The values represent the
mean +/- standard deviation of triplicate plates. (**: p value s 0.005).
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Supplementary Figure 12. L-myc and Nfib cooperate to increase growth in mSCLC.
(a) Growth curve of a primary tumor cell line, 3151T4. (b) Growth curve of a primary
tumor cell line, 3583T3. (a, b) The slope decreases from day 3 to 4 because the cells
were reaching confluency after three days. Values represent the mean +/- standard
deviation of triplicate wells.
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Supplementary Figure 13. Synergy between Nfib and L-myc in SCLC. (a) Western blot
demonstrating stable expression of Nfib and/or L-myc in the second preparation of wild-
type MEFs. (The other MEF preparation is depicted in Figure 5d). (b) Wild-type MEFs
either uninfected or infected with Nfib and/or L-myc expressing viruses were plated at
low density. Colonies were visualized using crystal violet. (c) The total number of
colonies per plate was quantified and the y-axis represents the mean number of
colonies +/- standard deviation of triplicate plates using two different MEF preparations.
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Supplementary Figure 14. Significant curated gene sets from the Gene Set
Enrichment Analysis (GSEA). Curated gene sets of interest following expression of Nfib
and/or L-myc in mouse SCLC cell lines. A description of each of the gene sets is
included. The values in the table represent the normalized enrichment score (NES). An
NES greater than 1 (correlated) or less than -1 (anti-correlated) was required to be
significant, in addition to a false discovery rate (FDR) less than 0.25.
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1.95 - -- Genes downregulated by exogenous BRCA1 in
EcR-293 cells
1.82 - - Genes overexpressed in myeloma cells from
patients with low expression of TACI and clinical
parameters of poor prognosis
-- 2.06 - Genes that are associated with cell cycle quies-
cence and stemness are overexpressed in freshly
isolated CD31 vs. CD31+ cells
-- 1.96 - Genes upregulated in MEF cells from PARP
knockout mice
- - 1.78 Transcription factors involved in hematopoiesis
- - 1.71 Genes upregulated by E2F and downregulated by
pRB and p16
1.92 - 1.78 Polyclonal plasmablast genes overexpressed in
multiple myeloma patients with low expression of
TACI and poor prognosis
1.99 - 2.30 HOX genes related to hematopoiesis
- 1.73 1.95 Cancer related genes that are also transcription
factors
-- 1.92 1.86 Genes up-regulated in human myometrial micro-
vascular endothelial cells at 12hrs following VEGF
treatment
-2.42 - - Genes induced in RAW 264.7 macrophages after
3h of treatment with bacterial lypopolysaccharide
-2.23 - - Most increased transcripts in activated cultured
human and mouse mast cells (MCs)
-- -2.02 - Genes differentially expressed during plasma cell
development
-- -1.78 - Helper T-cell pathway
- - -1.98 Cancer-related genes involved in cell adhesion
and metalloproteinases
- - -1.95 The 50 most significantly down-regulated genes in
multiple myeloma vs. normal bone marrow plasma
cells
-2.51 - -2.01 Genes up-regulated in the pancreas of E2F1/E2F2
compound mutant mice
-2.31 - -2.00 Genes up-regulated in AML with nucleophosmin
(NPM1) mutation versus AML with wild type NPM1,
which have favorable prognostic value with regard
to survival
- -1.80 -1.93 Matrix metalloproteinase gene set contributed by
the Broad
- -1.79 -1.92 Members of the BCR signaling pathway
bSupplementary Figure 15. Lentiviruses can initiate mSCLC. (a) mSCLC primary lung
tumor induced by lentivirus expressing Cre recombinase. (b) Lentivirus induced primary
tumors metastasize to the lymph nodes. T: Lymph node metastasis, LN: normal lymph
node. (c) A liver metastasis in a mouse infected with lentivirus expressing Cre
recombinase. T: liver metastasis, Liv.: normal liver. (a-c) Hematoxylin and eosin stain
(H&E).
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METHODS
Mice. p53"";Rbf' and p 5 3 "fl;Rb"/f";Rosa2 6 LSL-Luciferase/LSL-Luciferase mice have been
described (Meuwissen et al. 2003) (Rosa2 6LSL-Luciferase/LSL-Luciferase mice are unpublished,
Erica Jackson, Tyler Jacks). They were infected intranasally or intratracheally with
2.5x1 07 or 108 PFU of adenovirus, as previously described (DuPage et al. 2009). Mouse
research was approved by the Committee for Animal Care, and conducted in
compliance with the Animal Welfare Act Regulations and other federal statutes relating
to animals and experiments involving animals, and adheres to the principles set forth in
the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996
(Institutional animal welfare assurance no. A-3125-01).
Mouse imaging. Bioluminescence imaging was performed according to manufacturer's
instructions (Xenogen). Micro-computed tomography (GE Healthcare) was performed on
fixed specimens as previously described (Meylan et al. 2009) with a 27 pM voxel size.
Isolation of Tumor DNA and Production of Cell Lines. Primary tumors from the
mouse model were snap frozen for DNA isolation and stored at -800C. In addition, part
of each tumor was kept for histology, cell line preparation, and snap frozen in RNALater
(Ambion). To isolate DNA, tumors were digested in 800 pg/mL Proteinase K overnight at
550C and phenol/chloroform extracted. To dissociate tumors for cell lines, minced
tumors were digested in HBSS (without calcium and magnesium), 1 mg/mL Collagenase
IV (Worthington Biochemicals), and 0.025% trypsin-EDTA (Gibco) at 370C for 30
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minutes. Following dissociation, samples were quenched in PBS with 10% FBS,
incubated in 25 pg/mL DNase I (Sigma), centrifuged, filtered, and plated in standard
tissue culture media (DME, 10% FBS, 1% L-glutamine and 50 units/mL Penicillin, 50
pg/mL Streptomycin).
Illumina sequencing and data analysis. Libraries for DNA copy-number analysis were
prepared from 5 pg of DNA using the Illumina Genomic DNA Sample Preparation Kit.
Single-end 35 nucleotide reads were generated using the Illumina Genome Analyzer Ilx.
Reads were aligned to the mm9 reference genome with MAQ and filtered for mapping
quality greater than 30. For each 100 kb genomic window, the number of reads aligning
to that window were normalized by the total number of aligned reads in the sample.
Copy-number ratios were calculated as the number of normalized reads from the tumor
sample, divided by the number of normalized reads from the parental 129/SVJ strain.
Chromosomal boundaries of copy-number changes were identified by changepoint
analysis (Chiang et al. 2009). DNA copy-number was visualized using the Broad
Institute's Integrated Genome Viewer (http://www.broadinstitute.orgqAv).
Human SCLC cell line copy-number profiling. Affymetrix SNP 6.0 data was obtained
from the Cancer Cell Line Encyclopedia (manuscript in preparation). DNA isolation and
hybridization arrays were performed as recommended by Affymetrix. Probe
normalization, segmentation, and copy-number profiles were determined as previously
described (C.G.A.R.N. 2008). Significantly recurrent regions of somatic copy-number
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alterations were identified using the latest GISTIC methodology as described
(Beroukhim et al. 2007; Beroukhim et al. 2010).
RNA purification, reverse transcription, and real-time PCR. RNA was isolated
following manufacturer's instructions for TRIzol (Invitrogen). 1.5 pg of RNA was reverse
transcribed following manufacturer's instructions for High-Capacity cDNA Reverse
Transcription (Applied Biosystems). cDNA was then diluted 1:10 for real-time PCR
reactions. All cDNA PCR data was normalized to external controls of wild-type MEFs
(mouse reactions) or normal human lung cDNA (human reactions). Real-time PCR
reactions on genomic DNA were performed using 100 ng (mouse cell lines) or 200 ng
(human cell lines) of DNA. All genomic PCR reactions were normalized to an external
control of DNA isolated from wild-type MEFs (mouse reactions) or normal human DNA
(human reactions). All real-time PCR reactions were performed using SYBR green
(Applied Biosystems). Reactions were performed in triplicate and normalized to the
levels of an internal control, external control (mentioned above), and analyzed using the
comparative Ct method.
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Genomic DNA primers:
Organism Name Sequence
Mouse Nfib F 5' ATTGCTTCACCCGGCGTTCTGTTT
Mouse Nfib R 5' AGGGTGCCAAGACAGGTGTGAAAT
Mouse L-myc F 5' AGACTCAGGCCTGCTC
Mouse L-myc R 5' GATTTCAAACAGCGGTAGATAG
Mouse Chromosome 5 control F 5' GAAGAAATTAGAGGGCATGCTTC
Mouse Chromosome 5 control R 5' CTTCTCCCAGTGACCTTATGTA
Human NFIB F 5' ATTGCTTCACCCGGCGTTCTGTTT
Human NFIB R 5' AGGGTGCCAAGACAGGTGTGAAAT
Human L-MYC F 5' ACTGCACTCCCAGCCTCGAA
Human L-MYC R 5' TGAGAAGAGCCAATGCCTGACCT
Human NUCLEOLIN F 5' AAACTTTTGCGACGCGTACG
Human NUCLEOLIN R 5' GGGACTCCGACTAGGGCC
cDNA primers:
Organism Name Sequence
Mouse Nfib F 5' GGGACTAAGCCCAAGAGACC
Mouse Nfib R 5' GTCCAGTCACAAATCCTCAGC
Mouse L-myc F 5' ACTCCTAGTCTGGAAGCCAGTAAC
Mouse L-myc R 5' ACGGTCACCACGTCAATCTCTTCA
Mouse Gapdh F 5' AGCTTGTCATCAACGGGAAG
Mouse Gapdh R 5' TTTGATGTTAGTGGGGTCTCG
Human NFIB F 5' GCCACAATGATCCTGCCAAGAA
Human NFIB R 5' GGTGGAGAAGACAGAGACCTCTGA
Human L-MYC F 5' ACTGCACTCCCAGCCTCGAA
Human L-MYC R 5' TGATGGTGACCGGCTTCCGAATAC
Human GAPDH F 5' AGCCACATCGCTCAGACAC
Human GAPDH R 5' GCCCAATACGACCAAATCC
Immunohistochemistry. IHC was performed using standard methods. Briefly, slides
were deparaffinized, boiled in 10mM sodium citrate buffer pH 6 in a pressure cooker,
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washed in H20, and incubated in 3% H202 for 10 minutes. Slides were loaded into the
Cadenza system, blocked for avidin and biotin (Vector Laboratories), blocked in 10%
goat serum in PBS with 0.05% Tween 20 for one hour, and incubated overnight at 40C
in 1:500 anti-NFIB antibody (Abcam) in PBS with 0.05% Tween 20 and 2% BSA. Slides
were washed, incubated in biotinylated secondary antibody, washed, incubated in ABC
reagent to form avidin-biotinylated HRP complexes (ABC kit, Vectastain), signal was
detected with a DAB peroxidase substrate kit (Vector Laboratories), and counterstained
with hematoxylin. Human tissue arrays (LC2001 and LC2082) were purchased from US
Biomax, Inc. CGRP (anti-CGRP, Sigma, 1:5000) IHC was performed as above, except
block and primary antibody steps were supplemented with 0.5% BSA. Ki-67 IHC was
performed as above, except slides were blocked in 10% horse serum in PBS with 0.2%
TritonX-1 00 and incubated in primary antibody (anti-Ki-67, BD Pharmingen, 1:50)
diluted in PBS with 0.2% TritonX-100 and 10% horse serum. TUNEL staining was
performed according to the manufacturer's suggestions (In Situ Cell Death Kit, Roche).
Fluorescence in situ hybridization (FISH). Human BAC clones RP1 1-355C15 and
RP1 1-1107G7 (spanning NFIB in 9p22-23), and mouse BAC clones RP23-386C23 and
RP23-132D24 (for Nfib in 4qC3), together with proximal MMU4 reference clone RP23-
458D19 were utilized in FISH analyses (BACPAC resources). BAC DNA was isolated by
standard alkaline lysis and labeled with Red dUTP (NFIB, Nfib) or Green dUTP
(reference probe) (Abbott Molecular, Inc., Des Plaines, IL) by nick translation. Human
cosmid clone cCMP9.27, containing chromosome-specific satellite 3 repeats in 9q12,
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was used as reference on the human tissue microarrays. Mouse reference BAC RP23-
59B17 was part of a 1 Mb clone set kindly proved by YJ Chung (Chung et al. 2004). The
samples were imaged with an Applied Precision deconvolution microscope, using a
60X, NA 1.3 oil objective, and Softworx software. The acquired z-stack images (5
microns thick sample, 0.2 micron/z section) were deconvolved, and a maximum
projection was generated for each z-stack (Koch Institute Microscopy Core Facility).
Immunoblotting. Anti-NFIB antibody (Active Motif, 1: 2000), anti-MYCL1 (Santa Cruz,
clone C-20, 1:200), anti-Hsp90 (BD Transduction Laboratories, 1:20000) were used for
western blotting following standard methods.
Transformation assays. The mouse embryonic fibroblast (MEF) experiments were
performed using wild-type MEFs from two different embryos, in triplicate, and before
passage 6. Following infection with L-myc and/or Nfib overexpression vectors, cells
were used in two different assays. The low-density plating experiments were performed
essentially as previously described (Sage et al. 2000), except colonies were allowed to
grow for three weeks and colonies were stained with 0.5% crystal violet in 25%
methanol. In the foci formation assay, 3.8x10 5 MEFs were plated in 6 cm plates and
were performed as previously described (Sage et al. 2000) except the foci were stained
using 0.5% crystal violet in 25% methanol after two weeks. All MEFs were grown in
DME, 10% FBS, 1 % L-glutamine and 50 units/mL Penicillin, 50 pg/mL Streptomycin, 1
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mM sodium pyruvate (Sigma), non-essential amino acids (Sigma), 0.1 mM B-
mercaptoethanol (Sigma). p values were determined using Student's T-tests.
Human SCLC cell line functional experiments. Human SCLC cell lines were
obtained from ATCC. Broad TRC clones were used for NFIB knockdown in human
SCLC cell lines (shRNA #1: TRCN000001 4680, shRNA #2: TRCN0000014681). All
human cell lines were maintained in RPMI supplemented with 10% FBS, 1% L-
glutamine and 50 units/mL Penicillin, 50 pg/mL Streptomycin. Cells were infected with
NFIB or control vectors, and after two days were selected using puromycin (Sigma).
After puromycin selection, cells were used for cell viability and cell cycle analyses.
Cleaved caspase 3 (CC3) staining was performed according to manufacturer's
instructions for flow cytometry staining (Cell Signaling). Goat anti-rabbit secondary
antibody (Invitrogen Molecular Probes, 1:200) directly conjugated to PE was utilized.
CC3 staining was analyzed on a flow cytometer (FACS Calibur, Becton Dickinson). For
cell cycle analysis, cells were incubated for one hour with BrdU prior to collection and
stained for cell cycle analysis according to manufacturer's instructions for the BrdU Flow
Kit (BD Pharmingen). p values were determined using Student's T-tests.
Senescence-associated B-galactosidase staining. SA-B-gal staining was performed
as previously described (Dimri et al. 1995; Itahana et al. 2007) with modifications. Cells
were washed twice in PBS, fixed in freshly prepared 3.7% formaldehyde in PBS for 3-5
min at RT, and then washed twice in PBS. Cells were incubated overnight at 370C in X-
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gal staining solution (1 mg/mL X-gal, 40mM citric acid/sodium phosphate buffer pH 5.5,
5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl, 2 mM
MgCl 2) and then the percent of SA-Bgal* cells was determined by counting the number
of SA-Bgal* in at least 500 cells. p values were determined using Student's T-tests.
Mouse SCLC cell line functional experiments. Nfib and L-myc were stably expressed
in mouse cell lines using MSCV-Nfib-PGK-Neo and MSCV-L-myc-PGK-Puro, and
selected with G418 (Invitrogen) or Puromycin (Sigma), respectively. The mouse Nfib
cDNA was FLAG tagged, and a Kozak sequence was added before the ATG in both the
L-myc and Nfib expression vectors.
Primers:
Mouse Nfib cDNA F: 5' CTAGAGTTAACATGATGGATTACAAAGACGATGACGATAAA
TATTCTCCCATCTGTCTC,
Mouse Nfib cDNA R: 5' TGACAAGATCTTCAGTTGCTTGTCTCCGCTT,
Mouse L-myc cDNA F: 5' ATGATCTCGAGCCACCATGGACTTCGACTCGTAT,
Mouse L-myc cDNA R: 5' TAGCACGGAATTCTTAGTAGCCACTGAGGTACGCGA
For soft agar colony formation assays, 1.5x1 04 cells were plated in 3 cm plates in 0.4%
agarose on top of a layer of 0.8% agarose (Seaplaque). Soft agar colony formation
assays were done in triplicate and performed at least twice. Cultures were fed weekly
and after two weeks, colonies were stained with 0.2% crystal violet and the number of
colonies in at least nine camera views per plate using a 1OX objective was quantified. p
values were determined using Student's T-tests. Nfib was knocked down in mSCLC cell
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lines using pSicoRev Puro vectors (Ventura et al. 2004). Hairpins were designed using
pSICOLIGOMAKER 1.5 (http://web.mit.edu/jacks-lab/protocols/pSico.html; created by
A. Ventura, Memorial Sloan-Kettering Cancer Center).
Growth Curves. Cell lines were infected and selected for stable expression of Nfib, L-
myc or L-myc & Nfib. 105 cells were plated in triplicate wells in 6-well plates and the
number of cells was counted each day for four days (Coulter Counter, Beckman).
Gene expression analysis.
Microarray analysis. RNA was isolated with TRIzol (Invitrogen), labeled and hybridized
to Affymetrix 430Av2 chips according to manufacturer's instructions. Affymetrix data
analysis was done using statistical tools provided by the r/Bioconductor projects
(http://cran.r-project.org/; http://www.bioconductor.org/). Data import and quality control
assessment was done using the packages Affy and AffyPLM and data was summarized
and normalized using gcRMA (Bolstad et al. 2005a; Bolstad et al. 2005b). Differential
expression analysis was carried out using limma (Smyth 2005). All the R commands (*.r
files), input data (*.CEL files) and environment-specific details (*.Rout files) required to
duplicate these analyses are located here:
(http://luria.mit.edu/caw web/Dooley Supplemental/). Normalized intensity values,
limma differential expression results and various annotations were combined in a single
file using Spotfire DecisionSite (Tibco Software Inc.). For differential expression testing,
biological replicates of the different treatments of the 3583T3 and 3151 T4 cell lines were
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averaged. Analysis of differential expression with respect to control was conducted for
each cell line using the limma differential expression results. The lists of differentially
expressed genes for each cell line were then cross referenced to each other to generate
a final list that represents the overlap between the two cell lines. A log2 fold change
value of greater than or equal to 1 and a BH adjusted p value less than or equal to 0.05
were used. Using Spotfire DecisionSite 9.1.1, expression values for genes that were
differentially up- or down-regulated in each of the treatment classes were row
normalized using z-scores. The resulting data was subjected to hierarchical clustering
(Ward's method) and a heatmap was generated. The Max Per Gene (MPG) annotation
was added using excel and consists of flags where a "Yes" indicates the probe set for
each gene that reports the maximum average expression across all samples.
Gene Set Enrichment Analysis (GSEA). GSEA (http://www.broad.mit.edu/gsea) was
used to examine the distribution of groups of manually curated gene sets
(http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=C2) within genes
rank-ordered based on differential expression between the treatment classes. All the
files required for these analyses and the results are available here
(http://luria.mit.edu/caw web/Dooley Supplemental/).
GeneGo Analysis. Groups of differentially expressed genes identified with limma (BH
adjusted p value of 0.05 and a log ratio of greater than 1 or less than -1) were examined
using GeneGO (http://www.genego.com/) pathway and network analysis tools.
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ABSTRACT
Lung injury studies have elucidated the presence of multiple stem cell
populations within the lung, each localized in specialized niches (Rawlins and Hogan
2006). Naphthalene, a chemical found in cigarette smoke, has been utilized to identify
two populations of bronchial epithelial cells resistant to injury (Reynolds et al. 2000a;
Reynolds et al. 2000b; Giangreco et al. 2002). One of these populations represents the
pulmonary neuroendocrine cells and is the putative cell of origin of small cell lung
cancer (SCLC), a particularly aggressive and deadly form of lung cancer (Reynolds et
al. 2000a; Reynolds et al. 2000b; Giangreco et al. 2002). We utilized a genetically
engineered mouse model of SCLC (mSCLC) in which two tumor suppressor genes,
Trp53 (p53) and Rbl (Rb) (p53f"f';Rb"f'), were conditionally inactivated in the lung
(Jonkers et al. 2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 2003). We
assessed the effect of naphthalene injury on SCLC initiation and progression by treating
mice at various timepoints in relation to tumor initiation. Naphthalene injury five weeks
prior to tumor initiation increased the number and size of NEBs in the lung and the
prevalence of advanced SCLC lesions. Furthermore, administration of two naphthalene
treatments, one week prior to and four weeks after tumor initiation, decreased survival.
130
INTRODUCTION
The lung contains many specialized areas that harbor distinct differentiated cell
types (Rawlins and Hogan 2006). In the proximal airways, the trachea and bronchi are
comprised of Clara, goblet, ciliated and basal cells while in the distal airways the
bronchioles are lined with columnar Clara cells, ciliated cells and pockets of
neuroendocrine cells (Van Lommel et al. 1999; Rawlins and Hogan 2006). The
neuroendocrine cells can exist in isolation or in small groupings, termed neuroendocrine
bodies (NEBs) (Van Lommel et al. 1999). The bronchioles narrow to meet the alveoli at
the bronchio-alveolar duct junction (BADJ) (Rawlins and Hogan 2006). The alveoli
consist of two cell types, the elongated alveolar type I (ATI) and cuboidal alveolar type II
(ATII) cells (Uhal 1997; Rawlins and Hogan 2006).
Each of these specialized niches in the lung is hypothesized to contain its own
stem cell population (Otto 2002). Following bleomycin ablation of ATI cells, ATII cells
can regenerate the ATI cells (Aso et al. 1976). In addition, injury studies utilizing sulfur
dioxide, which ablates the tracheal lining, identified cells in the submucosal glands
capable of repairing the damage (Borthwick et al. 2001). Naphthalene, one of the
chemicals found in cigarette smoke, specifically ablates Clara cells in the lung
(Giangreco et al. 2002; Rawlins and Hogan 2006). Previous naphthalene studies have
identified two bronchiolar populations that are resistant to injury, one of which
represents the neuroendocrine cells (Stevens et al. 1997; Giangreco et al. 2002). The
other population of resistant cells represents a stem cell population, termed the
bronchio-alveolar stem cells (BASCs), which resides at the BADJ (Kim et al. 2005). The
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BASCs, which express markers of the differentiated cell types, ATIl and Clara cells,
proliferate in response to injury and are capable of regenerating both ATII and Clara
cells in vitro (Kim et al. 2005). Injury studies focusing on the response of the
neuroendocrine cells have documented the proliferation of neuroendocrine cells in
response to Clara cell injury (Stevens et al. 1997; Reynolds et al. 2000a; Reynolds et al.
2000b; Hong et al. 2001; Giangreco et al. 2009).
Lung cancer is divided into two main subtypes, non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC) (Minna et al. 2002; Travis 2002; Meuwissen
and Berns 2005). Due to the typically advanced nature of the disease at the time of
diagnosis, very little is known about the initial stages of lung cancer (Worden and
Kalemkerian 2000; Cooper and Spiro 2006). One study indicates that the BASCs are
the cell of origin of NSCLC and more recent evidence suggests that BASCs represent
the tumor-propagating cells within tumors arising in a mouse model of NSCLC (Kim et
al. 2005; Curtis et al. 2010). The cell of origin for small cell lung cancer (SCLC), which
comprises 18% of lung cancer cases, has not yet been determined experimentally
(Wistuba et al. 2001). Nonetheless, based on expression of neuroendocrine markers,
such as neural cell adhesion molecule (NCAM), calcitonin-gene-related peptide (CGRP)
and achaete-schute homolog 1 (ASH-1), SCLC is believed to be of neuroendocrine
origin (Ball et al. 1993; Borges et al. 1997; Cavallaro et al. 2001; Shibayama et al.
2001).
A mouse model of SCLC (mSCLC) has previously been described, which utilizes
conditional deletion alleles of two tumor suppressor genes, Trp53 (p53) and Rbl (Rb)
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(p53";Rb""'), commonly mutated in human SCLC (Jonkers et al. 2001; Wistuba et al.
2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 2003; Meuwissen and
Berns 2005). Following infection of lung epithelial cells with an adenovirus expressing
Cre recombinase (AdCre), p53 and Rb are inactivated. Tumors and metastases
resembling human SCLC histopathologically develop with a median latency of 350 days
(Meuwissen et al. 2003). In addition, the mouse small cell lung tumors express
neuroendocrine markers, such as CGRP, synaptophysin, and NCAM, recapitulating the
human disease (Ball et al. 1993; Borges et al. 1997; Cavallaro et al. 2001; Shibayama
et al. 2001; Meuwissen et al. 2003). This mouse model of SCLC provides a relevant
platform on which to examine the initiation and progression of SCLC, a previously
unattainable feat.
Although the neuroendocrine cells are hypothesized to be the cell of origin of
SCLC, this has not been directly examined. The development of this mouse model of
SCLC allows careful documentation of the initial stages of SCLC, which is not possible
in human SCLC patients. Since the neuroendocrine cells are resistant to naphthalene
injury and are stimulated in response to naphthalene injury, we decided to examine the
effect of naphthalene injury on the neuroendocrine cells and tumor progression in
mSCLC.
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RESULTS
Neuroendocrine cells respond to Clara cell ablation induced by naphthalene
injury in the lung. Our first goal was to confirm that the neuroendocrine cells in the
normal adult murine lung respond to naphthalene injury as previously described.
Following naphthalene or control treatment of mice, we examined the size and number
of neuroendocrine bodies (NEBs) at short timepoints: twenty-four, forty-eight and
seventy-two hours, following injury. To monitor the long-term lung regeneration, the
NEBs were monitored weekly for one to six weeks following naphthalene treatment. As
expected, naphthalene ablated all of the Clara cells and two populations of bronchial
epithelial cells, the BASCs and neuroendocrine cells, were resistant to naphthalene
injury (data not shown) (Giangreco et al. 2002). The number of cells within each NEB
was determined by performing immunohistochemistry (IHC) for calcitonin-gene-related
peptide (CGRP), which is a marker of neuroendocrine cells (Figure 1) (Shibayama et al.
2001). We observed an increase in NEB size seventy-two hours after treatment (data
not shown) (Stevens et al. 1997; Reynolds et al. 2000a). Interestingly, the overall
number of NEBs was increased in naphthalene-treated compared to control-treated
mice (Figure 2a). One week after treatment, the number and size of naphthalene-
treated NEBs declined to control levels, and by four to six weeks following injury, the
lung epithelium was completely regenerated (Figure 2a).
Next, we determined whether the neuroendocrine cells proliferated in response to
naphthalene injury by monitoring the incorporation of bromodeoxyuridine (BrdU). We
examined the percent of NEBs that contained BrdU* cells (Figure 1). As expected, due
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to the very low rate of normal lung turnover (Uhal 1997), we did not observe any
proliferating cells within NEBs in control-treated mice (Figure 2b). In contrast, we did
observe proliferating cells within NEBs twenty-four and seventy-two hours following
naphthalene treatment (Figure 2b) (Stevens et al. 1997). Injury was maximal forty-eight
hours after treatment, and we did not observe any proliferating cells within the NEBs at
this timepoint. These proliferation data indicate that the NEBs expand and proliferate in
response to naphthalene treatment and that they do not represent a quiescent
population of differentiated cells in the lung.
We then sought to determine whether naphthalene injury affects tumor initiation
and progression in mSCLC. Kim et al. demonstrated that naphthalene injury induced the
BASCs to proliferate and increased both tumor size and number in a mouse model of
NSCLC (Kim et al. 2005). Based on previous evidence that naphthalene injury results in
an expansion of neuroendocrine cells, the potential cell of origin of SCLC, we
hypothesized that injury preceding tumor initiation would enhance tumor progression in
a mouse model of SCLC. Due to the fact that injury induced an increase in size, number
and proliferation of NEBs during the first week, we reasoned that infecting mice with
AdCre during this time would inactivate p53 and Rb in more putative tumor initiating
cells of SCLC. Due to toxicity concerns following naphthalene treatment, we waited until
one week after naphthalene treatment to initiate tumors. Mice were treated with
naphthalene or vehicle (corn oil) one, two or five weeks prior to tumor initiation and first
examined for the effect on NEBs three to four months following tumor initiation. Three
months after infection with AdCre, mice treated with naphthalene one or two weeks prior
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to tumor initiation had a similar size and number of NEBs compared to control-treated
mice (Figure 3a, b). Unexpectedly, we observed an increase in both the number and
size of NEBs in mice treated five weeks prior to tumor initiation (Figure 3c). These data
suggest that although the lung appears morphologically normal five weeks following
injury, the regenerated lung is not actually the same.
To determine the long-lasting effects of naphthalene treatment on the lung, we
also examined the NEBs of naphthalene- or control-treated mice eight months after
tumor initiation. While we did observe a slight increase in larger NEBs in mice treated
with naphthalene two and five weeks prior to tumor initiation compared to vehicle-
treated mice, the increase was not large enough to be statistically significant (Figure 3d,
e, Supplementary Figure 2). Interestingly, very large NEBs with more than twenty cells
were found only in mice treated two weeks prior to tumor initiation (Supplementary
Figure 2).
We next examined the effect of naphthalene injury on small cell lung tumor
initiation and progression. The observation of an in situ small cell lung tumor two months
after tumor initiation, much earlier than previously observed, served as an indication that
naphthalene injury enhanced tumor progression (Supplementary Figure 3a). We
examined the rest of the mice three to four months and eight months after tumor
initiation. When we examined the histology of the mice sacrificed three to four months
after tumor initiation, we did not observe any other mSCLC lesions in either
naphthalene- or control-treated mice. At eight months, however, we were able to assess
the effect of naphthalene injury on mSCLC. To categorize the type of lesions observed,
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we classified tumors by both the size and location of the lesion. NEBs with more than
twenty to thirty cells were classified as a hyperproliferation, while a tuft of
neuroendocrine cells extending into the bronchiole was classified as an in situ tumor.
We also quantified larger tumors extending into the bronchiole and surrounding lung
epithelium as well as invasive tumors growing near blood vessels and lymphatic
vessels. Surprisingly, we noted no differences in number or location of lesions in mice
treated with naphthalene one or two weeks prior to tumor initiation compared to control-
treated mice (Figure 4a, b). In contrast, we observed an increase in tumors and invasive
tumors in mice that had been treated with naphthalene five weeks prior to tumor
initiation (Figure 4c). In addition, we observed more mice with lesions of any size and an
increase in the average number of lesions per mouse in naphthalene-treated mice five
weeks prior to tumor initiation compared to the other injury groups (Supplementary
Figure 3b, c). This corroborates our earlier evidence of increased NEB size in mice
treated with naphthalene five weeks prior to tumor initiation (Figure 3c). These data
indicated that naphthalene injury five weeks before infection with AdCre increased the
number of tumors at the eight-month timepoint.
We next determined whether injury following tumor initiation would enhance
tumor progression and decrease tumor latency. Mice were treated with naphthalene
either one week prior to, the same day as, one week after, four weeks after, six weeks
after, or one week prior to and four weeks after infection with AdCre (Supplementary
Figure 4). The short-term effects on the NEBs were monitored sixteen weeks after
AdCre. While we did observe a significant increase in the total number of NEBs in mice
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treated with naphthalene one week prior to AdCre infection, we did not observe a
significant increase in any other treatment group compared to control-treated mice
(Figure 5a). In addition, the average size of NEBs in each of the treatment groups was
similar to that of control-treated mice (Figure 5b). Although mice treated with
naphthalene one week prior to AdCre infection did have an increase in the number of
NEBs, the average size was similar to control-treated mice (Figure 5a, b). In addition,
the difference in results between these mice and those in Figure 3 could be explained
by the infection of these mice with an increased titer of AdCre. There was no difference
in the percent of NEBs that contained proliferating cells at the sixteen-week timepoint
(Supplementary Figure 5).
We also determined whether naphthalene injury following AdCre infection would
positively affect the number of SCLC lesions. We examined the number of in situ lesions
and tumors sixteen weeks after infection and were able to identify lesions at this
timepoint due to the higher titer of AdCre utilized (Figure 6). There was no difference in
the number of in situ lesions or tumors in naphthalene-treated and control-treated mice
(Figure 6). Survival data were collected to monitor the long-term effect of the treatments
on mSCLC latency (Figure 7). Treating mice one week prior to tumor initiation slightly
increased survival as the median latency of this group of naphthalene-treated mice was
419 days compared to 350 days for control-treated mice (Figure 7). Thus, these survival
data corroborate our previous findings that naphthalene treatment one week prior to
tumor initiation does not enhance mSCLC development (Figures 4, 7). In contrast, mice
treated with naphthalene after AdCre infection exhibited no difference in or slightly
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decreased survival compared to control-treated mice, which suggests that naphthalene
injury following tumor initiation may enhance tumor progression (Figure 7). Conversely,
mice treated one week prior to and four weeks after AdCre infection had a significant
decline in survival (Figure 7). The median latency of naphthalene-treated mice in this
group was 298 days compared to 350 days for control-treated mice (Figure 7). Thus,
mice administered two naphthalene treatments exhibited decreased tumor latency,
perhaps by mimicking conditions of chronic injury.
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Figure 1. NEBs proliferate in response to naphthalene treatment. (a) CGRP IHO
seventy-two hours following naphthalene treatment. (b) CGRP IHO one week following
naphthalene treatment. (c) CGRP IHC seventy-two hours following treatment with
vehicle alone. (d) CGRP IHC one week following treatment with vehicle alone. (e) BrdU
IHC detected proliferating cells in the NEB seventy-two hours following naphthalene
treatment. (f) BrdU IHC detected proliferating cells in the NEB one week following
naphthalene treatment. (g) BrdU IHC did not detect proliferating cells in the NEB
seventy-two hours following treatment with vehicle alone. (h) None of the cells within the
NEB are proliferating as detected by BrdU IHC one week following treatment with
vehicle alone.
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Figure 2. NEBs expand and proliferate in response to naphthalene treatment. (a)
Quantification of the CGRP IHC indicating an expansion in number of NEBs per mouse
in naphthalene-treated mice compared to control-treated mice. (b) Quantification of
proliferating cells within NEBs indicates that proliferation is only observed in
naphthalene-treated mice.
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Figure 3. Effect of naphthalene treatment and tumor initiation on NEBs. (a) Number and
size of NEBs three months after tumor initiation as determined by CGRP IHC on mice
treated with naphthalene or control one week prior to tumor initiation. (b) Number and
size of NEBs four months after tumor initiation as determined by CGRP IHC on mice
treated with naphthalene or control two weeks prior to tumor initiation. (c) Number and
size of NEBs three months after tumor initiation as determined by CGRP IHC on mice
treated with naphthalene or control five weeks prior to tumor initiation. (d) Total number
of NEBs per mouse eight months after tumor initiation for each of the treatment groups.
Data represents mean +/- standard deviation. (e) Average size of each NEB eight
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months after tumor initiation for each of the treatment groups. Data represents mean +/-
standard deviation. (a-c) gray bars: naphthalene-treated mice, white bars: control-
treated mice. (d, e) The number of mice in each treatment group is noted in (d). (a-e)
The matched control mice for each treatment group have been combined. Number and
size of NEBs was quantified on one slide per mouse. *: p-value < 0.05.
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Figure 4. Naphthalene injury enhances tumorigenesis in mice treated five weeks prior
to tumor initiation. (a) Number of each tumor type in mice treated one week prior to
tumor initiation with naphthalene or control. (b) Number of each tumor type in mice
treated two weeks prior to tumor initiation with naphthalene or control. (c) Number of
each tumor type in mice treated five weeks prior to tumor initiation with naphthalene or
control. Quantification of each SCLC lesion type was performed on one slide for each
mouse. Tumors were classified as hyperproliferations of the NEB (Hyper.), in situ
lesions within the bronchioles, tumors, or invasive (Inv.) tumors. Circles: naphthalene-
treated mice, triangles: control-treated mice. Each data point represents the number of
lesions in that category for one mouse and the horizontal black line represents the
mean. The matched control mice for each treatment group have been combined.
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Figure 5. Naphthalene injury after tumor initiation does not affect the NEB number or
size. (a) Total number of NEBs per mouse in each treatment group compared to control-
treated mice. (b) Number of CGRP* cells per NEB for each treatment group compared
to control-treated mice. Data represents mean +/- standard deviation. The matched
control mice for each treatment group have been combined. Number and size of NEBs
was quantified on one slide per mouse. The number of mice in each treatment group is
marked in (b). **: p-value < 0.005.
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Figure 6. Effect of naphthalene injury after tumor initiation on SCLC lesions at the
sixteen-week timepoint. (a) Number of each type of lesion in mice treated on the same
day as tumor initiation with naphthalene or control. (b) Number of each type of lesion in
mice treated one week after tumor initiation with naphthalene or control. (c) Number of
each type of lesion in mice treated four weeks after tumor initiation with naphthalene or
control. (d) Number of each type of lesion in mice treated six weeks after tumor initiation
with naphthalene or control. Data represents mean +/- standard deviation. The matched
control mice for each treatment group have been combined. In situ tumors represent
those at are still contained within the lumen of the bronchiole. Number of SCLC lesions
was quantified on one slide per mouse.
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Figure 7. Kaplan-Meier survival curves of all the naphthalene treatment groups. (a)
Survival curves for each of the treatment groups compared to control-treated mice. The
only survival curve that is statistically different from control-treated mice is for mice
treated one week prior to & four weeks after AdCre infection (*: p-value < 0.05). The
median latencies (in days) are as follows: one week prior (419), same day (351.5), one
week after (317), four weeks after (306.5), one week prior to and four weeks after (298),
control (350). The matched control mice for each treatment group have been combined.
The number of mice is marked in the figure legend.
147
............. -  ................................. ..  ....................... .....
Normal lung epithelium Model 1: altered
neuroendocrine cell
c d
Model 2: generation of Model 3: altered
novel cell type environment
Figure 8. Models of lung injury repair. (a) Schematic of a portion of the normal distal
lung bronchiolar epithelium that contains a neuroendocrine body. (b) In the first model,
neuroendocrine cells are altered during the course of lung repair, as represented by
their orange color. (c) During lung repair, a novel cell type (purple) is generated that is
more susceptible to transformation. (d) The surrounding lung environment is altered
during lung repair, as demonstrated by the presence of cytokines (brown dots in lumen).
(b-d) Schematics of the lung epithelium are representative of five weeks after
naphthalene injury. (a-d) Clara cells (blue), neuroendocrine cells (red), ciliated cells
(green), basement membrane (gray box), cytokines (brown dots in lumen).
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DISCUSSION
This study demonstrated that naphthalene injury increased tumor initiation and
progression in a mouse model of SCLC. Our data documented that the stimulation of
neuroendocrine cells five weeks prior to infection with AdCre led to the development of
more advanced mSCLC lesions. Most interestingly, the lung appears histologically
normal five weeks following naphthalene injury. Several models can explain this
phenomenon (Figure 8). First, stimulation of the neuroendocrine cells during lung injury
and repair resulted in a cell that is more susceptible to transformation, either due to
increased infection by adenovirus or increased susceptibility to transformation following
inactivation of p53 and Rb. Second, a novel cell type is produced during the repair
process and is less refractory to transformation following p53 and Rb deletion. Third, the
lung environment surrounding the neuroendocrine cells is altered during injury and
repair, possibly with an increase in inflammation or changes to the underlying
extracellular matrix, and resulted in enhanced transformation. These models are not
mutually exclusive and more than one could explain our findings. Future studies to
address the causative model(s) will be informative.
Our data indicated that administration of two naphthalene treatments decreased
mSCLC survival, suggesting that chronic injury enhances tumor progression. Although
we did observe decreased survival in this treatment group, the administration of two
naphthalene treatments greatly increased toxicity compared to a single naphthalene
treatment. An increased number of doses with a lower naphthalene concentration would
need to be examined to determine whether mice exhibit reduced toxicity and increased
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mSCLC progression. In addition, mice injured with naphthalene after tumor initiation
exhibited a slight decrease in survival. In contrast, mice injured prior to AdCre infection
benefited with slightly extended survival, suggesting that injury one week prior to tumor
initiation may enhance tumor progression.
The combination of naphthalene injury and tumor initiation in this mouse model of
SCLC provides a new potential mouse model with decreased tumor latency. Although
the original mouse model closely recapitulates the human disease, the long tumor
latency hinders utilizing this mouse model for specific in vivo experiments. The
combination of Trp53 and Rbl conditional deletion alleles with conditional deletion
alleles of p130 (p 1304") increased the number of mSCLC lesions and metastases, as
well as decreased latency (Schaffer et al. 2010). While decreased latency was observed
in this updated model, p130 mutations are not commonly observed in human SCLC
(Helin et al. 1997). We have demonstrated that increased tumor progression can be
obtained by treating mice with naphthalene prior to tumor initiation. However, we still
need to confirm that naphthalene is not altering the type of copy number alterations or
gene expression changes that are frequently observed in mSCLC, just as was
performed on tumors arising in p534"f;Rb"f';p1304"f mice (Calbo et al. 2005; Schaffer et
al. 2010).
This study demonstrates not only that naphthalene stimulates the proliferation
and expansion of neuroendocrine cells in response to Clara cell ablation, but also
provides the first direct evidence that naphthalene injury increases mSCLC initiation and
progression. A better understanding of the initial stages of SCLC development would
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enhance our ability to treat this aggressive form of lung cancer and develop targeted
therapeutics.
151
2 g,
4
~,. .4 5 t
f
*4~
iV
' 'C"I
S
.~ ~
.4 4.
# of cells within each NEB
4-6 7-9
* c d
K' d
444
>10
* P
I
CGRP
Supplementary Figure 1. NEBs of different sizes exist in normal adult lung. (a) NEB
with one to three cells in a control-treated mouse. (b) NEB with four to six cells in a
control-treated mouse. (c) NEB with seven to nine cells in a control-treated mouse. (d)
NEB with more than ten cells in a control-treated mouse. (e) NEB with one to three cells
in a naphthalene-treated mouse. (f) NEB with four to six cells in a naphthalene-treated
mouse. (g) NEB with seven to nine cells in a naphthalene-treated mouse. (h) NEB with
more than ten cells in a naphthalene-treated mouse. NEBs were categorized according
to the number of cells within each NEB as detected using CGRP IHC.
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Supplementary Figure 2. Response of NEBs to naphthalene injury and tumor initiation
eight months after tumor initiation. (a) Number of each size of NEBs in mice treated with
naphthalene or control one week prior to tumor initiation. (b) Number of each size of
NEBs in mice treated with naphthalene or control two weeks prior to tumor initiation. (c)
Number of each size of NEBs in mice treated with naphthalene or control five weeks
prior to tumor initiation. Each data point represents one mouse analyzed. Circles:
naphthalene-treated mice, triangles: control-treated mice. The matched control mice for
each treatment group have been combined.
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Supplementary Figure 3. Naphthalene injury enhances tumorigenesis in mice treated
five weeks prior to tumor initiation. (a) Hematoxylin and eosin stain of an in situ tumor in
a mouse treated with naphthalene two weeks prior to tumor initiation two months after
infection. Picture was taken with a 40X objective. (b) Quantification of the percent of
mice with SCLC lesions of any size. (c) Average number of tumors per mouse. The data
represents the mean +/- standard deviation. The matched control mice for each
treatment group have been combined. The number of mice in each group is listed in (b).
p-value < 0.05.
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Supplementary Figure 4. Timeline of injury experiments. (a) Mice were treated with
naphthalene at a dose of 275 mg / kg one week prior to (gray arrow), the same day as
(blue arrow), one week after (yellow arrow), four weeks after (green arrow), six weeks
after (purple arrow), or one week prior to and four weeks after (asterisks) infection with
AdCre (red arrow). Mice were infected intra-tracheally using a titer of 1x1 08 PFU. Half of
the mice were sacrificed (black arrow) sixteen weeks following AdCre infection and the
remaining mice were utilized for survival studies.
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Supplementary Figure 5. Naphthalene injury following AdCre infection does not affect
proliferation at the sixteen-week timepoint. (a) Percent of NEBs with any proliferating
cells, as quantified with IHO for Ki-67. The values represent the mean +1- standard
deviation. The matched control mice for each treatment group have been combined.
The number of mice in each group is marked.
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METHODS
Mice. p534" ;Rbf"" mice have been previously described (Meuwissen et al. 2003). They
were infected intranasally or intratracheally with 2.5x1 07, 4x1 07, or 108 PFU of
adenovirus expressing Cre recombinase, as previously described (DuPage et al. 2009).
Mouse research was approved by the Committee for Animal Care, and conducted in
compliance with the Animal Welfare Act Regulations and other Federal statutes relating
to animals and experiments involving animals, and adheres to the principles set forth in
the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996
(Institutional animal welfare assurance no. A-3125-01).
Treatments. Naphthalene was freshly dissolved in corn oil prior to use. The stock
solution concentration was 30 mg / mL and was vortexed for one hour to enhance the
ability of naphthalene to go into solution. The mice were administered naphthalene intra-
peritoneally (l.P.) at a dose of 275 mg / kg in the morning. Control mice were injected
with 10 pL / g body weight of corn oil. Background-matched mice were utilized for
control injections. Naphthalene treatments or AdCre infections were started when the
mice were between six and twelve weeks of age.
BrdU Injections. Bromodeoxyuridine (BrdU) stock of 10 mg / mL in PBS was utilized.
BrdU was injected I.P. at 3 pL / gram body weight (final dose of 30 mg / kg) three hours
prior to euthanasia for proliferation studies.
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Immunohistochemistry for neuroendocrine markers. IHC was performed using
standard methods. Briefly, slides were deparaffinized, boiled in 10mM sodium citrate
buffer pH 6 in a pressure cooker, washed in H20, and incubated in 3% H202 for ten
minutes. Slides were loaded into the Cadenza system, washed, blocked in 10% goat
serum and 0.5% BSA in PBS with 0.2% TritonX-100 for one hour, and then incubated
overnight at 40C in primary antibody (anti-CGRP, Sigma, 1:5000) in 10% goat serum
and 0.5% BSA in PBS with 0.2% TritonX-1 00. Slides were washed, incubated in
biotinylated secondary antibody, washed, and incubated in ABC reagent to form avidin-
biotinylated HRP complexes (ABC kit, Vectastain). Signal was detected with a DAB
peroxidase substrate kit (Vector Laboratories) and counterstained with hematoxylin.
Immunohistochemistry for proliferation. IHC for proliferation, either using BrdU or Ki-
67 antibodies, was performed on serial sections with CGRP IHC. IHC was performed as
above, except for BrdU IHC, endogenous peroxidases were quenched in 0.3% H20 2
and slides were blocked in 10% horse serum in PBS with 0.2% TritonX-100. Ki-67 IHC
was performed as above, except slides were blocked in 10% horse serum in PBS with
0.2% TritonX-100 and incubated in primary antibody diluted in PBS with 0.2% TritonX-
100 and 10% horse serum. Antibodies: anti-BrdU (BD Biosciences, 1:200), anti-Ki-67
(BD Pharmingen, 1:50).
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CHAPTER 4:
Conclusions and Future Directions
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I. SMALL CELL LUNG CANCER PROGRESSION
Chapter 2 described the use of a mouse model of small cell lung cancer (SCLC)
to identify a novel oncogene, Nuclear Factor I/B (Nfib). Further, we identified concurrent
amplification of Nfib and an already known oncogene, L-myc (Mycl). Although both of
these amplifications are observed in human SCLC, the frequency of the concurrent
amplification in the mouse model is indicative of the cooperation of these proto-
oncogenes. Functional validation studies in mouse tumor cell lines and in mouse
embryonic fibroblasts highlighted the cooperation of Nfib and L-myc in promoting
growth. The mouse model of SCLC (mSCLC) can now be used as a launching point to
assess the roles of Nfib and L-myc in tumor progression and metastasis, as well as to
test novel therapeutics.
A. SCLC Progression
Although we detected copy number alterations other than amplifications of Nfib
and L-myc, we have not yet pursued them. The copy-number data can be probed for
additional genomic alterations of interest. As discussed in the Introduction, whole
genomic profiling techniques other than copy-number profiling exist. mSCLC tumor and
metastasis samples can be utilized for other techniques, such as paired-end sequencing
to detect translocations and sequencing to detect point mutations (Campbell et al. 2008;
Pleasance et al. 2010). One benefit to using a mouse model of SCLC (mSCLC) is the
availability of primary tumors and metastases, as well as tumor- and metastasis-derived
cell lines, for subsequent analyses. Due to the fact that the mouse model has defined
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initiating mutations, we will most likely observe fewer point mutations than in human
samples (Chin and Gray 2008), which would aid in distinguishing passenger and driver
mutations (Greenman et al. 2007; Stratton et al. 2009). Additionally, gene expression
studies can be performed on mSCLC samples to identify altered genes and pathways.
The identification of altered gene expression in primary tumors and metastases that
correlates with Nfib and/or L-myc amplification would be of particular interest.
The mouse model of SCLC can also be utilized to determine whether metastasis-
specific alterations occur. Although we would like to identify metastasis-specific
alterations, or even alterations that only occur in metastases to a particular tissue site,
we did not observe either of these situations. While metastasis-specific alterations have
been identified in other models (Kim et al. 2006), this is yet to be obtained in SCLC. The
additional profiling techniques mentioned above may aid in this matter. In addition,
obtaining information about which primary tumor gave rise to a particular metastasis
may be particularly informative. Initiating tumors with lentiviruses, which provide a
genetic tag by integrating into the genome, would allow for the identification of the
primary tumor from which a metastasis arose. For example, Nfib amplifications may
only occur in primary tumors that metastasized. All of the aberrations that occur in
mSCLC could be integrated and a timeline of mSCLC mutations formed.
Additionally, an analysis of the types of genetic alterations that occur during
tumor progression would be of interest. The p5 34f4""";Rb""f'' mice could be crossed to
a conditional fluorescent reporter mouse, such as Rosa2 6LSL-GFP. Although small cell
lung tumors contain very little stroma, the fluorescent reporter can be utilized by flow
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cytometry to sort purified tumor cells, either from the lung or from crudely dissected
tumors. After tumor cells are collected at various timepoints following tumor initiation,
they would be profiled for copy number alterations. These studies may identify the order
in which Nfib and L-myc amplifications occur. Further, these studies may identify
different alterations from those in advanced, end-stage tumors.
Altogether, additional genomic profiling techniques and the identification of
alterations that occur during tumor progression and metastasis, will aid in the production
of a timeline of frequently observed mSCLC mutations. Such a "Vogelgram" for SCLC
would most likely have loss of chromosome 3p first (Fearon and Vogelstein 1990).
Chromosome 3p loss occurs in nearly 100% of SCLC tumors and thus indicates that it
likely occurs first during the course of tumorigenesis (Whang-Peng et al. 1982; Wistuba
et al. 2001; Wistuba and Gazdar 2003). In addition, although p53 and Rb mutations are
frequently observed in SCLC (Wistuba et al. 2001), very little is known about the order
of other mutations, such as amplifications of Nfib and L-myc, in SCLC.
B. Nfib in SCLC Progression
Although Nuclear Factor I/B (Nfib) is known to regulate lung and brain
development, very little is known about the genes that it regulates. One study
highlighted the binding sites of the C. elegans ortholog, NFl-1, but this has yet to be
done in mammalian cells. Our gene expression studies indicated that Nfib may regulate
the inflammatory response and the extracellular matrix, but these studies do not
differentiate between the direct and indirect targets of Nfib. Chromatin
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immunoprecipitation followed by sequencing of the targets (ChIP-seq) would identify the
direct targets of Nfib and prove beneficial in our understanding of the role of Nfib in
tumor progression. In addition, the direct targets may provide new therapeutic
treatments for treating this aggressive disease.
The current studies need to be extended to examine the role of Nfib during tumor
initiation and progression. To address whether Nfib is required for tumor initiation,
conditional inactivation alleles of Nfib would first have to be generated. We would be
unable to use the already available Nfib-' mice because they are not viable after birth.
Mice containing floxed alleles of Nfib (Nfib"j/f") would be bred to p53 4o/4"*;Rb"""/"
mice. Following infection of lung epithelial cells with adenovirus containing Cre
recombinase, Nfib, p53 and Rb would be deleted and the ability of SCLC tumors to
develop would be assessed.
We would also like to determine whether Nfib is required for mSCLC
maintenance. Although we detected frequent high-level amplification of Nfib in
advanced tumors and metastases, we have yet to determine the point at which Nfib
amplification is integral to tumor progression. To begin to address this question, we
engineered lentiviruses to express Cre recombinase and Nfib or Cre recombinase and
L-myc. Due to the fact that lentiviruses integrate into the genome, Cre recombinase,
along with either Nfib or L-myc, is expressed from the time of tumor initiation. However,
due to the low titer of lentivirus obtained, we have had little success inducing mSCLC
with lentiviruses. As a result, these experiments are not yet complete.
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Other studies have determined that tumors are dependent on the continued
expression of oncogenes (Chin et al. 1999; Fisher et al. 2001; Shachaf and Felsher
2005; Evan 2006; Podsypanina et al. 2008; Whittle et al. 2009). In a similar fashion, we
would like to address the role of Nfib during mSCLC progression and whether mSCLC
tumors are dependent on Nfib (and/or L-myc) expression. Construction of a transgenic
mouse with a regulatable allele of Nfib, such as a lung neuroendocrine-specific
doxycycline-regulatable allele (CGRP-LSL-rtTA), and a transgene expressing the
tetracycline responsive element (TRE) preceding Nfib cDNA (TRE-Nfib), would allow
Nfib expression to be turned on and off. These alleles can be combined with the
conditional inactivation alleles of p53 and Rb (p53"Iof";Rbfo"X/";CGRP-LSL-rtTA;TRE-
Nfib). Following the inactivation of p53 and Rb specifically in the lung, Nfib would be
activated by feeding the mice doxycycline-containing food from the time of tumor
initiation or at various timepoints during tumor progression. Nfib expression could then
be turned off at a later timepoint by removing the doxycycline-containing food to address
whether the tumors have become reliant on Nfib expression. Such a regulatable allele
can address the role of Nfib, or other candidate genes, during tumorigenesis.
In addition, the mouse model of SCLC can address whether loss of function of
p53 and Rb are required for mSCLC maintenance. Although both alleles of Rb are
required to be inactivated in mSCLC, it is unknown whether continued inactivation is
required for tumor maintenance (Jain et al. 2002). Other studies have restored
expression of tumor suppressors, such as p53, and found that depending on the
context, the tumors apoptose or senesce (Pelengaris et al. 2002; Meuwissen et al.
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2003; Ventura et al. 2007; Xue et al. 2007). Combining a restorable allele of p53,
p53 LSULSL, with a conditional deletion allele of Rb inactivated by Flp recombinase
(Rb'"") would allow for the restoration of p53 at different times in mSCLC development
(Christophorou et al. 2006; Martins et al. 2006). Additionally, whether the response
depends on the status of L-myc and/or Nfib amplification can also be addressed.
C. Nfib and L-myc Cooperation
Although in vitro functional experiments identified that Nfib and L-myc cooperate
in SCLC, the genes and pathways that these two oncogenes regulate are still unknown.
While one study has elucidated the role of cooperation between Myc and Ras in mouse
mammary tumors (Ventura et al. 2007), another study highlighted specific genes that
are the direct result of cooperation between Ras activation and p53 inactivation in colon
cancer (Vooijs et al. 1998). While our gene expression studies identified specific cancer
pathways that are up-regulated and cell adhesion pathways that are down-regulated in
response to expression of both Nfib and L-myc, it is necessary to perform a more
complete analysis of the altered genes and pathways. Functional validation, as well as
the identification of genes with Nfib binding sites, will aid in this analysis.
Additionally, Nfib and L-myc amplifications have been detected in other tumor
types. More specifically, both oncogenes were amplified in a mouse model of prostate
cancer utilizing the same conditional inactivation alleles of p53 and Rb as the mSCLC
model, but with expression of a prostate-specific Cre (Podsypanina et al. 2008). Similar
to SCLC, the carcinomas that arise in this model of prostate cancer express
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neuroendocrine markers. It is yet to be determined whether L-myc and Nfib
amplifications are specific to neuroendocrine tumors.
II. INJURY AND SCLC INITIATION
Chapter 3 investigated the effect of injury on the neuroendocrine cells in the lung.
Given that SCLC tumors express neuroendocrine markers and are likely to be of
neuroendocrine origin, we examined the effect of injury on tumorigenesis in the mouse
model of SCLC. We determined that naphthalene injury prior to tumor initiation
increased mSCLC formation. Thus, the mouse model of SCLC provides a relevant
platform on which we can address whether the neuroendocrine cell is the cell of origin of
SCLC.
The data presented in Chapter 3 highlight the role of injury in mSCLC formation.
Although we had hypothesized that naphthalene injury one week prior to tumor initiation
would increase the number of cells in which SCLC could arise, we did not observe an
increase in the number or type of mSCLC lesions. Instead, we only observed an
increase in tumor progression when naphthalene was administered five weeks prior to
tumor initiation. These data bring into question the cell of origin of SCLC.
The mouse model provides an excellent tool to examine the cell of origin of
SCLC. While we were unable to directly test the cell of origin of mSCLC, our injury data
are consistent with previous claims of a neuroendocrine cell of origin due to the
observed expansion of neuroendocrine cells at short timepoints following tumor
initiation. To directly address whether neuroendocrine cells are susceptible to
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transformation, a genetic approach can be utilized to delete p53 and Rb specifically in
lung neuroendocrine cells. A knock-in allele could be constructed in which a
neuroendocrine-specific promoter, such as CGRP, drives expression of Cre
recombinase. In addition, a transcriptional and translational "stop" cassette flanked by frt
sites can be placed before the Cre recombinase (CGRP-frt-stop-frt-Cre) to limit deletion
of p53 and Rb to lung neuroendocrine cells. The combination of this allele with the
p53 "*X""O;Rb"/f" alleles would allow one to examine whether p53 and Rb inactivation in
a pulmonary neuroendocrine cell is sufficient to drive tumorigenesis. Following
inhalation of a virus containing FIp recombinase, the stop cassette would be excised,
Cre recombinase expressed, and p53 and Rb inactivated specifically in lung
neuroendocrine cells. At various timepoints following tumor initiation, mice can then be
examined for mSCLC.
Alternatively, specific ablation of lung neuroendocrine cells prior to tumor
initiation would directly address whether neuroendocrine cells are necessary for tumor
initiation. Instead of utilizing naphthalene, which ablates the Clara cells in the lung, the
neuroendocrine cells can be specifically ablated prior to tumor initiation. Since there is
no known chemical mutagen that specifically ablates neuroendocrine cells in the lung,
genetic tools need to be developed to ablate the lung neuroendocrine cells. For
example, diphtheria toxin can ablate specific populations of cells (Zhou et al. 2006;
McMurray et al. 2008). In our case, a mouse model can be engineered to express the
diphtheria toxin receptor in lung neuroendocrine cells and following diphtheria toxin
administration, lung neuroendocrine cells will be ablated. While this mouse can be
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utilized to examine the effects of neuroendocrine cell injury in normal lung, it can also be
bred to p5 3 4""";Rb""/f" mice to examine whether neuroendocrine cells are necessary
for mSCLC initiation.
The future studies addressed in this chapter can provide insight into the
mechanisms of SCLC tumor progression. SCLC is a particularly aggressive form of
cancer and due to the late stage by the time of diagnosis, very little is known about the
initiation and progression of this disease. In addition, a lack of primary tumor samples,
particularly early stage tumors, hinders these studies in humans. In contrast, the mouse
model of SCLC provides a plethora of tumor and metastasis samples at various stages
of tumor progression. Furthermore, in vivo functional studies utilizing genetically-
engineered mice can assess the role of candidate genes in tumorigenesis. Lastly, the
identification of genes and pathways altered in SCLC can provide new potential
therapeutic targets for SCLC. In conclusion, the mouse model of SCLC will enhance our
understanding of the initiation, progression, metastasis, and treatment of this disease.
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ABSTRACT
The development of animal models of lung cancer is critical to our understanding
and treatment of the human disease. Conditional mouse models provide new
opportunities for testing novel chemopreventatives, therapeutics and screening methods
that are not possible with cultured cell lines or xenograft models. This protocol describes
how to initiate tumor formation in two conditional genetic models of human non-small
cell lung cancer (NSCLC) utilizing the activation of oncogenic K-ras and the loss of
function of p53. We discuss methods for sporadic expression of Cre in the lungs via
engineered adenovirus or lentivirus and provide a detailed protocol for the
administration of the virus by intranasal inhalation or intratracheal intubation. The
protocol requires 1-5 minutes per mouse with an additional 30-45 minutes to set-up and
allow for the recovery of mice from anesthesia. Mice may be analyzed for tumor
formation and progression starting 2-3 weeks after infection.
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INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide with non-small cell
lung cancer (NSCLC) being the most prevalent form of lung cancer (Sun et al. 2007;
Jemal et al. 2008; Herbst et al. 2009). Progress within the last decade has led to the
sophisticated engineering and application of advanced preclinical models of human
cancer in the mouse (Van Dyke and Jacks 2002; Frese and Tuveson 2007). These
models are critical to our understanding of the human disease because they shed light
on events and processes that cannot be easily studied using transplantable or
chemically-induced cancer models (Meuwissen and Berns 2005; Shaw et al. 2005;
Frese and Tuveson 2007). Several laboratories have constructed genetically-
engineered mouse models of NSCLC that mimic the genetic and histopathological
features of the human disease (Fisher et al. 2001; Jackson et al. 2001; Johnson et al.
2001; Meuwissen et al. 2001; Meuwissen and Berns 2005; Ji et al. 2006; Dankort et al.
2007). The development of Cre recombinase-controlled (Cre/LoxP) tumor models has
allowed for the generation of autochthonous tumors derived from a limited number of
somatic cells that become transformed in their natural location, surrounded by a normal
tissue microenvironment (Frese and Tuveson 2007). By engineering LoxP DNA
elements into the mouse genome that either surround ('flox') exons critical to a tumor
suppressor gene's function or surround a synthetic 'stop' element ('LSL') inserted in
front of an oncogene, investigators can 'turn-off' tumor suppressors or 'turn-on'
oncogenes with delivery of Cre recombinase to the appropriate cell types
(Supplementary Figure 1 and see Frese and Tuveson 2007 for a review of Cre/LoxP-
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controlled genetically engineered mouse models of cancer). With this technology,
investigators can not only recapitulate the genetic alterations found in the human
disease, but also the timing of onset and potentially the cellular origin of the disease.
Common mutations in human NSCLC are activating mutations in K-RAS (10-
30%) and loss of function point mutations in p53 (50-70%) (Herbst et al. 2009). Our
laboratory has modeled an oncogenic mutation in K-ras by changing a glycine to
aspartic acid at codon 12 in the gene's endogenous locus. To control the expression of
K-raSG12D, a lox-stop-lox (LSL) cassette was engineered into the first intron of the K-ras
gene. The LSL cassette consists of transcriptional and translational stop elements
flanked by LoxP sites that prevents the expression of the mutant allele until the stop
elements are removed by the activity of Cre recombinase (Jackson et al. 2001; Tuveson
et al. 2004). The LSL cassette thus creates a null version of the gene. It is important to
note that K-ras null mice are embryonic lethal (Johnson et al. 1997); therefore, mice can
only be heterozygous for the K-rasLSL-G12D allele. To mimic the loss of p53 function in our
K-rasLSL-G12D-driven tumor model, we have utilized a conditional p53 allele from the
laboratory of Anton Berns. This 'floxed' p53 allele (p53") has LoxP sites flanking exons
two through ten of p53 that are deleted after Cre-mediated recombination, abolishing
p53 function (Jonkers et al. 2001) (Supplementary Figure 1). Prior to Cre-mediated
recombination, the p53 locus is maintained in its wildtype state and p53 activity is
normal. To more accurately recapitulate the p53 loss of function mutations commonly
observed in human NSCLC, our laboratory has generated two conditional point mutant
(mt) versions of p53 (R172H, R270H) that are engineered into the endogenous p53
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locus, but silenced by a LSL cassette in the absence of Cre (Olive et al. 2004). We use
mice that are p5#SL-mtnor p5S3 Lm" to specifically express mutant p53 alone or with
wildtype p53 (respectively) in tumors upon Cre-mediated recombination (Olive et al.
2004; Jackson et al. 2005). Importantly, as with the K-rasLSL-G12D allele, the LSL cassette
in p53LSL-mt alleles blocks p53 expression in the absence of Cre, effectively creating a
p53 null allele. Therefore, p53SL-mt/fIor p53LSL-m+ mice are heterozygous for wildtype
p53 and phenocopy p53*' mice. To specifically express either of these mutant p53
alleles sporadically in cells of the lung, mice inhale viruses engineered to express Cre
either by intranasal instillation or intratracheal intubation.
Additional Cre Recombinase Controlled Animal Models of Lung Cancer
In addition to the models of NSCLC utilized in this protocol, other conditional lung
cancer models have been described which may be initiated with inhalation of viruses
expressing Cre. The activation of oncogenic K-ras along with loss of p1 6Ink4a or
Ink4a/Arf tumor suppressors, which are mutated in 20-50% of human cases, have been
described (Fisher et al. 2001; Ji et al. 2007). In another mouse model, two other
subtypes of NSCLC, squamous cell and large cell carcinoma, develop following the
combined activation of oncogenic K-ras and loss of the LKB1 tumor suppressor, which
is mutant in 10-30% of human cases (Ji et al. 2007). NSCLC models driven by
conditionally activated mutations in Braf or EGFR, mutated in 3% or 10-40%
(respectively) of human lung cancers, have also been generated (Ji et al. 2006; Dankort
et al. 2007) (and unpublished, K. Lane). A model of small cell lung cancer (SCLC) has
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been created in which tumors arise following the loss of both the p53 and Rb tumor
suppressors (Meuwissen et al. 2003).
Limitations of Viral Delivery of Cre Recombinase
Although these Cre/LoxP models provide the most sophisticated means to
sporadically control genetic events at their endogenous loci, they are also limited by the
difficult requirement to introduce Cre into an initiating cancer cell. In this protocol,
investigators cannot restrict the genetic events exclusively to initiating cells of the
disease because of the inherently non-specific nature of the viruses used to deliver Cre
to cells of the lung. However, this has in fact been beneficial in our laboratory because it
does not require that investigators identify and target Cre specifically to the cell of origin
of the disease. Perhaps the best system to deliver Cre specifically to the cells that give
rise to the disease are next generation regulatable Cre alleles, such as the tamoxifen-
inducible Cre-estrogen receptor (CreERT) fusion protein (Frese and Tuveson 2007). By
expressing a Cre ERT transgene under the control of a cell type-specific promoter,
investigators can induce Cre activity specifically in the cells of a given tissue by injecting
animals with tamoxifen. With proper dosing of tamoxifen, investigators can in theory
control the penetrance of Cre activity and therefore the multiplicity of the disease.
However, various promoter-driven CreERT alleles are not yet available and CreERT
models succumb to problems encountered with many transgenic models in that the
expression and activity of these alleles are often leaky and do not provide tight control of
tumor initiation in the organ of interest (Frese and Tuveson 2007). Therefore, despite
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the drawback of using potentially hazardous viruses, this technique is the most effective
means to sporadically deliver Cre to cells of the lung to initiate lung tumor formation.
Alternative Animal Models of Lung Cancer
There are several alternative lung cancer models to those described here that do
not require viral delivery of Cre to the lungs to generate tumors (see Meuwissen and
Berns 2005 for a comprehensive review of mouse models of NSCLC). Transgenic
models have been created that utilize lung tissue specific promoters to drive expression
of viral oncoproteins, such as E6/E7 and large T antigen, or cellular oncogenes, such as
c-myc, c-Raf-1 and v-H-ras (Meuwissen and Berns 2005). However, these models are
limited in recapitulating the human disease because the oncogenic transgene is
expressed in all of the cells of a targeted organ beginning early in the organ's
development. To overcome this limitation, our laboratory has engineered a latent
oncogenic allele of K-ras that is expressed spontaneously in only a limited number of
cells in the lung to initiate lung tumor formation (Johnson et al. 2001). However, the
stochastic nature of this allele does not allow investigators to control tumor onset or
multiplicity. Double transgenic models that rely on doxycycline-regulated transcriptional
transactivators have allowed for the induction of oncogene expression in adult animals,
making it possible to control tumor initiation (Meuwissen and Berns 2005). However,
these models still fail to provide sporadic oncogene expression at physiological levels
due to the use of doxycyline-regulated transcription factors. Furthermore, these
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transgenic systems make it difficult to control tumor multiplicity and require continuous
doxycycline dosing to maintain oncogene expression.
Applications of Intranasal and Intratracheal Delivery Methods
The intranasal and intratracheal infection techniques described in this protocol
are not restricted to tumor-initiating studies. Investigators may theoretically probe the
role of any Cre/LoxP-controlled genes in various cells of the lung using this protocol to
deliver Cre. Alternatively, the intranasal or intratracheal delivery methods can be used in
applications other than the viral delivery of Cre recombinase. The viral delivery systems
may be adapted to express cDNAs or shRNAs in cells of the lung by infection with
lentiviruses (Marumoto et al. 2009). Viruses, such as the influenza virus, can be
delivered for pathological studies (Shen et al. 2008). siRNAs can be delivered as
therapeutic agents for disease (Ge et al. 2004). While either the intranasal or
intratracheal techniques can be utilized for the aforementioned studies, only
intratracheal intubation is recommended for the orthotopic transplantation of lung tumor
cells or lung tumor cell lines to the alveolar space of the lungs (unpublished, C. Kim and
T. Jacks). Certain chemical injurants, such as bleomycin, can be delivered
intratracheally to study repair mechanisms in the lung and the effect of injury on tumor
development (Daly et al. 1997). Therefore, there are a number of uses of this technique
for a variety of studies involving the mouse lung. Here we describe the use of the
intranasal and intratracheal delivery methods to introduce viruses expressing Cre to
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initiate the K-rasLSL-G12D/+ (K) and the K-rasLSL-G12D/+;p53f1f1 (KP) conditional mouse
models of NSCLC (Supplementary Figure 1).
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EXPERIMENTAL DESIGN
After deciding to utilize autochthonous tumor models, investigators must consider
the genetic tumor model, the viral system to express Cre recombinase, and the viral
delivery method when initiating an experiment. Each option has certain advantages and
limitations that are highlighted in the text and the Tables.
Genetic Model
Although both the K-rasLSL-Gl 2D/+ (K) and the K-rasLSL-G12D/+,p534/4 (KP) NSCLC
models induce tumors that resemble the human disease histopathologically, they have
distinct features that make them more suitable for different applications (Table 1). In our
laboratory's mouse models of NSCLC, the activation of an oncogenic allele of K-ras is
sufficient to initiate the tumorigenesis process, while the additional deletion or point
mutation of p53 significantly enhances tumor progression, leading to a more rapid
development of adenocarcinomas that have features of a more advanced disease. K-
ras and p53 mutant tumors exhibit a greater incidence of cellular and nuclear
pleomorphism, desmoplasia, and a high frequency of metastases to the mediastinal
lymph nodes and the pleural spaces of the thoracic cavity, and less frequently to the
liver and kidneys.
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Table 1: Choosing a tumor model
K-rasLSL-G 2 D/+ (K) K-rasLSL-G12D+ ;p53"'" (KP)
Limited tumor progression Rapid tumor progression
(modifier screens)
No metastases Metastatic disease
Local: draining lymph node, pleural cavity
Distant: liver, kidney
Long survival Short survival
Single allele Multiple alleles
(easy to breed)
Small tumors Large tumors
(limited tumor tissue) (more tumor tissue for DNA, RNA, protein)
(easier to track with live imaging, microCT)
Cre System
To generate tumors sporadically in the lungs of K-rasLSL-G12D/+ mice, our
laboratory initially used replication-deficient adenoviruses expressing Cre (Ad-Cre) to
deliver transient Cre expression to infected cells of the lung (Jackson et al. 2001;
Meuwissen et al. 2001). Prior to administration, Ad-Cre is precipitated with calcium
phosphate (see procedure) to improve the delivery of Cre by increasing the efficiency of
viral infection of the lung epithelium (Fasbender et al. 1998). Recently, we have used
lentiviruses to deliver Cre to the lung (Lenti-Cre) (Kumar et al. 2008). Lentiviruses are
beneficial because they integrate into the genome of infected cells (Naldini et al. 1996),
allowing for further modification of the tumors by simultaneously introducing Cre
recombinase and stable expression of cDNAs to overexpress, or short-hairpin RNAs to
silence, genes of interest (Table 2).
In order to control for the number of tumors generated, viruses are titered prior to
use in experiments. Ad-Cre is titered at the University of Iowa, while Lenti-Cre is titered
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in our laboratory by assaying for Cre activity after infection of the 3TZ reporter cell line,
a mouse fibroblast cell line modified to express p-galactosidase after Cre-mediated
recombination (Psarras et al. 2004). We infect mice with 2.5x1 07 infectious particles of
Ad-Cre (titered at Univ. Iowa) or approximately 1 04-1 05 infectious particles of Lenti-Cre
(3TZ titered in-house). It is important to note that Ad-Cre and Lenti-Cre are titered
differently, and as a result, the titers cannot be directly compared.
Table 2: Choosing the Cre system
Adenovirus Cre (Ad-Cre) Lentivirus Cre (Lenti-Cre)
High, reproducible titer Variable titer
(typically produces a greater number of
tumors, shorter survival)
Titered virus is commercially available In-house production may be required
Cannot introduce cDNAs or shRNAs Potential to modify tumors by introduction of
with Cre recombinase cDNAs or shRNAs in lentivirus(gain-of-function or loss-of-function
experiments)
Viral Administration Method
While we initially delivered Cre to the lungs of anesthetized mice using intranasal
(IN) instillation of the virus, we now prefer to deliver the virus to the lungs by
intratracheal (IT) intubation. IT delivery provides the most direct and consistent method
for the virus to reach the lungs. Reproducible delivery of the virus is critical because it
directly affects the number of tumors generated in the mice. However, intratracheal
intubation requires additional equipment and practice to perform it correctly and in a
timely manner (Table 3). Therefore, it may be easier to begin with the IN delivery
method to assess the tumor model and practice the IT method while continuing to breed
animals for future experiments.
187
Table 3: Choosing the viral administration method
Intranasal (IN) Intratracheal (IT)
No training required Technique requires practice
(can implement rapidly) for proficiency
No additional equipment necessary Requires catheters, light
source, platform
Indirect and variable delivery of virus to lungs Direct delivery of virus to
e virus displaced in nasal passage, mouth or lungs
esophagus/stomach
- low penetrance sinonasal adenocarcinomas in KP
infected mice (Jackson et al. 2005)
Anesthesia
We recommend using avertin (2-2-2 Tribromoethanol) to anesthetize the mice.
The amount of avertin administered to the mice is crucial to the success of the
procedure. Mice administered too much avertin are more likely to stop breathing during
the infection procedure, and recover poorly from the anesthesia. Conversely, mice
administered too little avertin may struggle to inhale the virus and should be given more
avertin before continuing. Therefore, we recommend using the smallest volume of
avertin required to keep mice anesthetized during the procedure. Following the
procedure, mice will recover better if they are kept warm to maintain their normal body
temperature after anesthesia.
Age of Mice
Our laboratory has utilized mice between 6 and 12 weeks of age for tumor
initiation by IN or IT delivery of viruses expressing Cre. Mice of this age are old enough
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to recover from the anesthetic, the volume of virus administered to the lung, and the
intubation of the trachea with the catheter.
Volume of Virus
Mice can be infected with a volume ranging from 50-125 pl per mouse, but we
recommend using a total volume of 75 pl per mouse. Although a volume of 125 pl can
be administered, it is not recommended for very young mice (6 weeks of age or
younger). If 125 pl is administered, then the mice should receive two doses of 62.5 pl
each, with a 1-5 minute break in between the doses, to allow the mice to recover a
normal breathing pattern before receiving the second dose.
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MATERIALS
REAGENTS
CRITICAL The following list of reagents represents our laboratory's preference. All
reagents, with the exception of Ad-Cre, can be modified according to investigator
preference.
- Mice: LSL-KrasG12D (Mouse Models of Human Cancers Consortium (MMHCC)
Strain 01XJ6, Jackson Laboratory #008179 (B6), #008180 (129)); p53f'(MMHCC
Strain 01XC2, Jackson Laboratory #008462 (B6)); p53 LSL-R270H (MMHCC Strain
01XM3, Jackson Laboratory #008651 (129svj)); p53 LSL-R172H (MMHCC Strain
01 XM2, Jackson Laboratory # 008652 (129svj)). Researchers in industry can
obtain these mice by contacting the MIT Technology Licensing Office
(http://web.mit.edu/tlo/www/industry/).
CAUTION All experiments should be done in accordance with protocols
approved by the Institutional Animal Care and Use Committee.
- K-rasLSL-G1 2D (LSL K-ras G12D) and p53 mutant genomic targeting vectors are
available from Addgene
(http://www.addgene.org/pgvecl ?f=c&cmd=showcol&colid=1 71). Koch Institute
Core Facilities can perform chemotherapeutic testing and small animal imaging
(http://web.mit.edu/ki/facilities/core.html)
CAUTION Mice should be kept under specific pathogen-free conditions during
experiments.
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Protocols to genotype the mouse strains listed above can be found on the Jacks
Lab website (http://web.mit.edufjacks-lab/protocols table.html)
- Protocols to determine the recombination efficiency of the KrasLSL-G12 D and p53
alleles can be found on the Jacks Lab website (http://web.mit.edujacks-
lab/protocols table.html)
- 2-2-2 Tribromoethanol (Avertin, Sigma Aldrich T48402)
- 2-methyl-2-butanol (Tert-amyl alcohol, Sigma Aldrich 152463)
- Phosphate Buffered Saline (PBS)
- Minimal Essential Media (MEM, Sigma, M4655)
- CaC12 (Mallinckrodt, Catalog #4160)
- Bleach
- Adenovirus-Cre (University of Iowa, Gene Transfer Vector Core,
http://www.uiowa.edu/~gene/; Jacks Lab website http://web.mit.edufjacks-
lab/protocols/AdenovirusCre.html)
CAUTION Preparation and administration of viruses should occur in a biosafety
hood and follow all guidelines for biosafety level 2 research.
- Lentivirus-Cre (Three plasmid transfection system of CMV-VSV-G (Addgene
plasmid 8454), A8.2 (gag/pol) (Addgene plasmid 8455), and transfer vector
expressing Cre (modified from Addgene plasmid 17408)) (Naldini et al. 1996;
Pfeifer et al. 2001; Lois et al. 2002; Stewart et al. 2003; Tiscornia et al. 2006;
Kumar et al. 2008)
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CAUTION Preparation and administration of viruses should occur in a biosafety
hood and follow all guidelines for biosafety level 2 research. Research with
lentiviruses pseudotyped with VSV-G containing known or putative oncogenes or
short hairpin RNAs to silence tumor suppressor genes should abide with all
institute safety practices.
EQUIPMENT
- Bottle top vacuum filter (.22 pM, 150 ml, Corning, cat. no. 430624)
- Scale (Ohaus, cat. no. HH120D)
- Needles (30 gauge, inch, Becton Dickinson, cat. no. 305106)
- Syringes (1 ml, Becton Dickinson, cat. no. 309602)
- Flat forceps (Roboz, cat. no. RS-8260)
- Exel Safelet IV catheters (22 gauge, 1 inch, Fisher, cat. no. 14-841-20)
- Intubation platform (Steve Boukedes, labinventions@gmail.com)
- Fiber-Lite Illuminator (Dolan-Jenner Industries, Inc., Model 3100-1)
* Heat lamp (or latex gloves filled with warm water)
REAGENT SETUP
Avertin Stock (1.6 g ml') Add 15.5 ml tert-amyl alcohol to 25 g of avertin. Stir
overnight to dissolve. Stable at room temperature (18-25 *C) for approximately 1 year.
CRITICAL Seal bottle tightly and protect from light. Discard the solution if it yellows.
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Avertin Working Solution (20 mg ml1) Dilute avertin stock in PBS, stir overnight, and
protect from light. Sterilize by passing solution through a 0.22 pm filter. Aliquots may be
safely stored at 4 0C in the dark for approximately 4 months.
2 M CaCl 2 Dissolve in distilled water and store at 4 *C for up to 5 years.
Virus Ad-Cre should be prepared fresh each time and used within one hour of
preparation. For extended storage times, Lenti-Cre should be stored at -80 0C or
alternatively, at 4 0C for periods of a few days. Keep viruses on ice prior to infection.
EQUIPMENT SET-UP
Biosafety hood To set-up for either IN or IT administrations, arrange the virus, a heat
lamp (or gloves filled with warm water), and a beaker filled with 50% bleach (to disinfect
catheters and pipette tips that have contacted the virus) in a biosafety hood.
Intubation platform and light source For IT administration, set up the platform and
light source on a flat surface near the biosafety hood (Figure 1 a). Insert the catheter into
the trachea outside of the hood, and then move the mouse into the biosafety hood to
inhale the virus. A sharps waste container is also required for the proper disposal of the
needles from the Exel Safelet IV Catheter.
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PROCEDURE
Virus Preparation TIMING 30 min
1 For infection with Lenti-Cre, proceed to step 5. For Ad-Cre, prepare the adenovirus-
precipitate mixture. Determine the number of mice that you will infect and pipette the
appropriate volume of MEM into a tube. Refer to the Experimental Design Section to
determine the volume of virus to administer per mouse.
CAUTION Preparation and administration of viruses should occur in a biosafety hood
and follow all guidelines for biosafety level 2 research. Research with lentiviruses
pseudotyped with VSV-G containing known or putative oncogenes or short hairpin
RNAs to silence tumor suppressor genes should abide with all institute safety practices.
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
CRITICAL STEP The adenovirus-precipitate mixture should be used within one hour of
preparation. If many mice will be infected, precipitates should be prepared sequentially.
2 After the adenovirus thaws on ice, pipette the adenovirus directly into the MEM to
obtain a final titer of 2.5x10 7 PFU per mouse. Flick the tube to mix.
CRITICAL STEP Do not freeze/thaw the adenovirus as this reduces the titer of the virus
10 fold with each thaw.
3 Add 2M CaCI2 into the MEM mix to obtain a final CaCl2 concentration of 10 mM. Flick
the tube to mix.
4 Incubate at room temperature for 20 min to allow for the formation of calcium
phosphate precipitates.
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Delivery of Ad-Cre or Lenti-Cre using the intratracheal or intranasal infection method
5 Avertin Administration TIMING 5 min per mouse
Anesthetize mice via intra-peritoneal injection of room temperature 20 mg mr1 avertin
(use 0.4 mg g1 body weight for females and 0.45 mg 1 body weight for males). Confirm
the mice are fully anesthetized by ensuring that they lack a toe reflex.
CRITICAL STEP Administering the correct amount of avertin is crucial to successfully
delivering the virus.
TROUBLESHOOTING
6 Delivery of Ad-Cre or Lenti-Cre can be carried out using Option A the intratracheal
infection method or Option B the intranasal infection method
A. Intratracheal infection method TIMING 1-5 min per mouse
i. Place mouse on the platform so that it is hanging from its top front
teeth on the bar (Figure 1 b, c).
ii. Push the mouse towards the bar so that the chest is vertical
underneath the bar (perpendicular to the platform) (Figure 1 b).
iii. Direct the Fiber-Lite Illuminator to shine on the mouse's chest, in
between the front legs (Figure 1c).
iv. Prepare the Exel Safelet IV catheter for the infection procedure. To
ensure that the needle does not become exposed and impale the
mouse, hold the square part of the needle with one's thumb and index
finger, and using one's middle finger, push the catheter over the end of
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the needle completely and continue to hold the catheter in place during
the infection protocol (Supplementary Figure 2a, b).
TROUBLESHOOTING
v. Using the Exel Safelet IV catheter, open the mouth and gently pull out
the tongue with the flat forceps (Figure 1d).
vi. Locate the opening of the trachea by peering into the mouth and
looking for the white light emitted from the trachea (Figure 1 e).
TROUBLESHOOTING
vii. While holding the Exel Safelet IV catheter vertically, position the
catheter over the white light emitted from the opening of the trachea,
and allow the catheter to slide into the trachea until the top of the
catheter reaches the mouse's front teeth (Figure 1f). There should be
no resistance while inserting the catheter into the trachea.
viii.While stabilizing the Exel Safelet IV catheter with one hand, remove
the needle from the mouth (Figure 1g).
CRITICAL STEP Prior to removing the needle, the mouse cannot
breathe through the catheter. Once the Exel Safelet IV catheter has
been inserted into the trachea, promptly remove the needle to allow the
mouse to breathe through the catheter.
ix. The proper placement of the catheter in the trachea can be confirmed
by visualizing the white light shining through the opening of the
catheter in the mouth (Figure 1 h).
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x. Move the platform, mouse, and catheter into the biosafety hood.
xi. Pipette the virus directly into the opening of the catheter to ensure the
entire volume is inhaled (Figure 1i).
xii. If the catheter is correctly inserted into the trachea, the mouse will
begin inhaling the virus immediately. Once the virus is no longer visible
in the opening of the catheter, wait a few seconds for the entire volume
to travel down the catheter before removing the catheter from the
trachea and disposing of it in 50% bleach.
TROUBLESHOOTING
B. Delivery of Ad-Cre or Lenti-Cre using the intranasal delivery method TIMING
2-5 min per mouse
i. In the biosafety hood, lay the mouse in your hand, ventral side up. Tilt
the mouse so that the head is positioned above its feet (Figure 2a).
CRITICAL STEP Do not grasp the mouse tightly as this will inhibit the
mouse's breathing
ii. Hold the end of a pipet tip over the opening of one nostril and dispense
the virus dropwise until the entire volume of virus has been inhaled
(Figure 2b, c).
CRITICAL STEP Do not attempt to insert the pipet tip into the nostril.
TROUBLESHOOTING
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Animal Recovery TIMING 10-15 min
7 Place the mouse under a heat lamp (Supplementary Figure 3a) or on a latex glove
filled with warm water (Supplementary Figure 3b) to recover in the biosafety hood.
TROUBLESHOOTING
TIMING
Steps 1-4 Virus Preparation (Ad-Cre only): 30 min
Step 5 Avertin Administration: 5 min per mouse
Step 6A Intratracheal Infection: 1-5 min per mouse after an initial training phase
Step 6B Intranasal Delivery: 2-5 min per mouse
Step 7 Animal Recovery: 10-15 min
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TROUBLESHOOTING
Troubleshooting advice can be found in Table 4.
Table 4: Troubleshooting advice_
Step Problem Possible Reason Solution
Number
Not enough Administer more avertin, 50-100 piMouse is not falling avertin at a time
asleep administered
. Too much avertin Wait until breathing becomes5 Mouse is over- amnsee
anesthetized and administered more regular but ensure thebreahingverymouse still lacks a reflex responsebreathing before attempting to infect the
slowlymouse
Catheter has Make sure that the catheter is held
ABlood appears in slipped and in p ace to cover the needle
mouth exposedathe correctly (Supplementary Figure
needle 2a, b)
Light is not in the Re-direct the light on the upper
correct position chest
Not looking at the Lean further over the mouth and
ventral surface of push the tongue with the catheter
6Avi Caodt alize i the throat towards the ventral surface of the
6Alv muth exposethroat
Saliva is covering Gently probe at the back of the
the opening of the throat with the Exel Safelet IV
trachea catheter to expose the trachea
Catheter inserted Pipette the virus out of theMouse does not into esophagus catheter for reuse, dispose of the
6Axi inhale the virus catheter in 50% bleach, and begin
t(viruss the procedure again at step 6Aiv
catheter)with a new catheter
Too much virus Let coughing subside before
placed on nostril continuing. Pipette the virusMouse is coughing before being resting on nostril for reuse
6B and sputtering inhaled
virus Virus dispensed Only dispense virus into one
into both nostrils nostril
Mouse does not Mouse is too cold Mouse should be kept warm until it
recover well starts to wake uprecolovwell Mouse is too hot Turn off heat lamp temporarily or
followingunehatlm
anesthesia under heat lamp let mouse recover on a glove filledII_ with warm water
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ANTICIPATED RESULTS
We have reported that recombination of K-rasLSL-G12D and p53fl alleles in tumors
can be examined by PCR for the presence of a "1 lox", or recombined, product (see
Reagents in Materials section for the protocols) (Jackson et al. 2001). Although it is
possible to perform PCR on DNA isolated from whole lung after infection to assess
infection efficiency, this is not recommended. Typically very few cells in the lung have
undergone recombination of these alleles, making it difficult to detect recombination.
Instead, it is more informative to examine Cre expression after infection by using
conditional reporter strains such as Rosa2 6LSL-LacZ or Rosa2 6 LSL-eGFP and examining
reporter expression by immunohistochemistry, immunofluorescence, or fluorescent
activated cell sorting (Soriano 1999). Polyclonal antibodies that can specifically detect
the oncogenic K-raSG12D protein are no longer available; however, increased Ras-GTP
levels in tumors or cells can be assessed using a Raf-GST pulldown assay (Tuveson et
al. 2004).
The time to tumor development and progression will vary depending upon the
model chosen (K v. KP), while survival time will also depend on the amount and type of
virus administered to the mice. The survival of mice is reduced approximately twofold in
KP mice compared to K mice (median survival with Ad-Cre: K, 185 days; KP, 76 days,
with Lenti-Cre: K, 266 days; KP, 170 days) (Figure 3a, b). Decreased survival is due to
a greater growth rate of tumors lacking p53, leading to the more rapid development of a
tumor burden that disrupts the normal function of the lungs. Reduced survival after p53
loss is not due to an increased number of tumors or metastatic disease. Survival of mice
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is also reduced after infection with Ad-Cre as compared to Lenti-Cre (Figure 3a, b). This
is due to the higher titer of virus typically administered to mice with Ad-Cre but may also
reflect the viral tropism or the efficiency of the virus to infect the cell of origin of the
disease. Mice infected with 2.5x1 07 infectious particles of Ad-Cre (Univ. Iowa, Gene
Transfer Vector Core) can generate greater than 200 tumors per mouse, whereas mice
infected with roughly 104 -105 infectious particles of Lenti-Cre (3TZ titered) can generate
10-100 tumors per mouse. Our laboratory has had success titrating the viruses to lower
levels (Ad-Cre: 5x1 06 infectious particles/mouse, Lenti-Cre: 5x1 03 infectious
particles/mouse) which reduce the number of primary tumors and increase the survival
time of mice, allowing for a greater frequency of metastatic disease in the KP model.
Monitoring tumor development and progression histologically is an important,
though difficult, way to follow the disease, and it is especially useful in experiments
where genetic events or modifications in addition to K-ras activation and/or p53 loss
may be expected to impact tumor progression. We stress that the NSCLC model
generates a multi-focal disease and therefore, investigators should expect some tumor
heterogeneity; tumors do not always progress in exactly the same way or at the same
time. To follow these changes objectively, we have employed a 4-stage grading system
for tumor progression in our NSCLC models (adapted from Jackson et al. 2005). The
earliest lesions, designated as grade 1, are atypical adenomatous hyperpasias (AAH) or
small adenomas that feature uniform nuclei and can appear as early as 2-3 weeks post-
infection (Figure 4a). These earliest lesions can only be identified through careful
histological analysis. To see visible lesions on the surface of the lung, investigators
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should wait until 6-8 weeks after tumor initiation or later. Grade 2 tumors are larger
adenomas that have slightly enlarged nuclei with prominent nucleoli and are observed
6-8 weeks post-infection (Figure 4b, c). Adenocarcinomas are classified as grade 3;
they have a great degree of cellular pleomorphism and nuclear atypia and can develop
as early as 16 weeks post-infection (Figure 4d, e). Grade 4 tumors are invasive
adenocarcinomas (Figure 4f) that harbor all the cellular characteristics of Grade 3
tumors but with a higher mitotic index - including irregular mitoses, a distinctive highly
invasive stromal reaction (desmoplasia) (Figure 4g), and invasive edges bordering
lymphatic vessels, blood vessels, or the pleura (Figure 4h). Grade 4 tumors may
develop as early as 18 weeks post-infection in KP animals, but are not observed in K
animals. Finally, locally metastatic disease to the mediastinal lymph nodes (Figure 4i) or
the pleural cavity develops in approximately 50% of KP mice as early as 18-20 weeks
post-infection. In some mice, distant metastases can be found seeding the liver or the
kidneys as early as 20 weeks post-infection (Figure 4j). Although the time to progression
in K and KP mice is described here to be similar up to Grade 3 lesions, mice with p53
deficient tumors often harbor cells that exhibit nuclear atypia at very early time points
after tumor initiation. In addition, a greater proportion of tumors that lack p53 progress to
higher grades during tumor development (Jackson et al. 2005). For example, at 6 weeks
after infection the distribution of tumor grades in the K model is ~90% grade 1 and ~10
grade 2, whereas in the KP model it is -40% grade 1, ~40% grade 2 and -20% grade 3
(Jackson et al. 2005). At 19 weeks after infection in the KP model, the tumor distribution
is -5% grade 1, -20% grade 2, ~70% grade 3 and --5% grade 4 (Jackson et al. 2005).
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At 26 weeks after infection in the K model, ~30% of tumors are grade 1, ~40% are
grade 2 and ~30% are grade 3 (Jackson et al. 2005). However, as with most
autochthonous mouse tumor models, there is some variation in the results, such as
tumor number and approximate time to progression, depending on the strain/
background of mice as well as other factors that vary between institutions.
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Figure 1. Intratracheal infection technique. Anesthetized mice are placed on the
platform by their front teeth so that their chest hangs vertically beneath them (a, b). The
light is directed on the mouse's upper chest (a, c), on the spot marked by the 'X' (c). The
mouth is opened using the Exel Safelet IV catheter (d), and the tongue is gently pulled
out using the flat forceps. After locating the white light emitted from the trachea (e), the
Exel Safelet IV catheter is slid into the trachea (f), and the needle is removed (g). The
mouse with the inserted catheter (h) on the platform is moved into a biosafety hood,
where the virus is dispensed into the opening of the catheter (i).
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
204
.................................... .
Figure 2. Intranasal infection technique. The anesthetized mouse lies gently in the hand
of the investigator (a), and the virus is administered dropwise (b) into one nostril until the
virus is completely inhaled (b, c).
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
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Figure 3. Survival is reduced in KP model compared to K model. Kaplan-Meier plot of
KP mice (median survival 76 days) and K mice (median survival 185 days) infected with
2.5x1 07 PFU of Ad-Cre per mouse (provided by T. Oliver) (a). Kaplan-Meier plot of KP
mice (median survival 170 days) and K mice (median survival 266 days) infected with
105 Lenti-Cre viruses per mouse (provided by P. Sandy and M. DuPage) (b).
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
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Figure 4. Tumor progression and histopathological phenotype in KP model.
Haematoxylin and eosin stained (H&E) tumors from KP mice at various times after
infection with Lenti-Cre: (a) Grade 1 lesion of an AAH progressing to a small adenoma.
(b) Grade 2 adenoma. (c) Uniform nuclei in a grade 2 adenoma. (d) Pleomorphic nuclei
in a Grade 3 adenocarcinoma. (e) Grade 3 adenocarcinoma displaying mixed cellular
phenotypes. (f) Grade 4 invasive adenocarcinoma. (g) Grade 4 adenocarcinoma with
glandular/acinar architecture and desmoplasia. (h) Adenocarcinoma from the lung (L)
invading across the mesothelium into the pleural cavity (P). (i) Local lung tumor
metastasis (T) to mediastinal lymph node (LN). (j) Distant lung tumor metastasis (T) to
the kidney (K). Panels a, b, e, f, i and j are at 1OOX magnification. Panels c, d, g and h
are at 400X magnification. Scale bar = 100 lim.
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
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Supplementary Figure 1. Genetically controlled events in a mouse model of lung
cancer. Engineering of LoxP elements and a stop element allow for the controlled
expression of oncogenic K-ras and the loss of p53 function after Cre expression.
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Supplementary Figure 2. Preparation of the Exel Safelet IV catheter for intratracheal
infection. Upon opening the Exel Safelet IV catheter, the needle is exposed (a). Slide
the catheter over the end of the needle to completely cover the tip (b) and the Exel
Safelet IV catheter is now ready to use.
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Supplementary Figure 3. Recovery following intranasal or intratracheal infection. Mice
can be placed under a heat lamp (a) or on a glove filled with warm water (b) to recover
following anesthesia in the biosafety hood.
CAUTION All experiments should be done in accordance with protocols approved by
the Institutional Animal Care and Use Committee.
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ABSTRACT
Lung cancer is the leading cause of cancer deaths worldwide each year and has
an overall five-year survival rate of less than 15% (ACS 2010). The poor prognosis is
due to the typically advanced stage of the disease at the time of diagnosis and the
development of tumors refractory to chemotherapeutics (Worden and Kalemkerian
2000; Simon and Wagner 2003; Cooper and Spiro 2006). Small cell lung cancer, which
comprises 18% of lung cancer cases, is particularly devastating with a five-year survival
rate of less than 5% (Wistuba et al. 2001; Cooper and Spiro 2006). To enhance our
understanding of the mechanisms of therapeutic resistance, we utilized a mouse model
of SCLC (mSCLC) in which two tumor suppressor genes, Trp53 and Rbl, are
specifically inactivated in the lung (Jonkers et al. 2001; Vooijs et al. 2002; Meuwissen et
al. 2003; Sage et al. 2003). Following transplantation of mSCLC cell lines into immune-
compromised recipient mice, we demonstrated that tumors respond best to combination
therapy with both cisplatin and etoposide. Furthermore, mice administered both
treatments had extended survival compared to control-treated mice.
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INTRODUCTION
Small cell lung cancer (SCLC) is a devastating disease marked by the presence
of distant metastases at the time of diagnosis (Worden and Kalemkerian 2000). As a
result, the five-year survival rate for SCLC is less than 5% (Worden and Kalemkerian
2000; Cooper and Spiro 2006). Less than 6% of patients present with one localized
tumor, making surgery not a treatment option (Cooper and Spiro 2006). Current
standard of care for this aggressive disease is combination chemotherapy and radiation
(Simon and Wagner 2003). Combination chemotherapy usually consists of cisplatin and
etoposide or, if toxicity is a concern, carboplatin and etoposide (Simon and Wagner
2003). While cisplatin and carboplatin are both platinum-based drugs that lead to the
formation of platinum-DNA adducts, etoposide is a topoisomerase 11 inhibitor (Wang and
Lippard 2005). Although tumors respond well to therapy at first, most SCLC patients will
suffer relapse (Simon and Wagner 2003).
Previous studies have highlighted the importance of mouse models in testing
chemotherapeutics used in the clinic. Tumors arising in a mouse model of non-small cell
lung cancer (NSCLC) were treated with cisplatin and found to elicit the DNA damage
response (Oliver et al. 2010). While DNA damage occurred in both chemotherapy-
sensitive and -resistant tumors, resistant tumors were able to repair the DNA damage
more efficiently (Oliver et al. 2010). Thus, genetically-engineered mouse models enable
the direct examination of the efficacy of treatments at different stages of disease.
A mouse model of SCLC (mSCLC) has been previously described, which utilizes
conditional inactivation alleles of two tumor suppressor genes, p53 (Trp53) and Rb
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(Rb 1) (p53/'";Rbf/f), commonly mutated in SCLC (Jonkers et al. 2001; Vooijs et al. 2002;
Meuwissen et al. 2003; Sage et al. 2003; Meuwissen and Berns 2005). Following
inhalation of a virus that contains Cre recombinase, p53 and Rb are inactivated, and
tumors develop that closely recapitulate human SCLC histopathologically with a median
latency of 210 days (Meuwissen et al. 2003).
Although the mechanism of small cell lung tumor resistance is poorly understood,
previous studies have correlated L-MYC amplification with poor prognosis (Forgacs et
al. 2001). L-MYC is an oncogene amplified in approximately 20-30% of SCLC
(Meuwissen and Berns 2005) and amplifications of this gene occur more frequently in
patients with relapsed tumors (Forgacs et al. 2001). The identification of other
alterations in resistant tumors would promote the development of novel therapeutics
capable of circumnavigating resistance.
The strong initial response to treatment provides hope that, with the appropriate
therapeutics, SCLC will one day be a treatable disease. The mouse model of SCLC
provides the perfect platform on which to test current and novel therapeutics and gain
information on resistance mechanisms. We now demonstrate that the mouse model of
SCLC responds to the current standard of care in a similar manner to human SCLC.
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RESULTS
In order to assess whether current standard of care is effective in the mouse
model of SCLC (mSCLC), we first developed a transplantation model of mSCLC.
Although the surrounding environment is not the same as autochthonous tumors,
transplantation of cell lines into recipient mice produces tumors that are all genetically
similar in the different treatment groups. Thus, the tumors' response to the treatment
itself can be determined. In addition, tumors form in recipient mice much more quickly
than autochthonous tumors, which makes cell line transplantation easier to work with for
initial drug studies. To generate a transplantation model, we first derived nearly forty cell
lines from primary tumors and metastases, from sites such as the lymph nodes and
liver. Although orthotopic, subcutaneous, and intra-venous (IV) methods of
transplantation were tested, the formation of tumors in recipient mice was the most
reproducible in cell lines transplanted intra-venously (data not shown). In addition,
immune-compromised recipient animals (Rag2i) were utilized because tumors did not
develop in immune-competent recipient mice due to the mixed background of the
parental mice.
Tumors arising in the recipient mice histopathologically resembled the parental
tumor (Figure 1). Surprisingly, the cell line utilized in these experiments homed to the
liver in recipient mice despite having arisen from a lymph node metastasis. Since micro-
computed tomography relies on detection of density differences, this imaging modality
cannot resolve tumor and normal liver boundaries. To follow the growth of the tumors
and response to treatments, we engineered the cell line to express luciferase by
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infecting the cells with a retrovirus expressing both green fluorescent protein (GFP) and
luciferase (Figure 2a). Following infection and collection of infected GFP* cells using
flow cytometry, luciferase-expressing cells were transplanted into recipient mice (Figure
2b).
In order to examine whether combination chemotherapy would be effective in
treating mSCLC tumors, recipient Rag2" mice were divided into four treatment groups:
control, cisplatin, etoposide, and both cisplatin and etoposide. Mice were treated once a
week for two weeks, and then were given a two-week respite to recover from the toxicity
associated with the drug treatments (Figure 3) (Oliver et al. 2010). Mice were first
imaged ten days following transplantation, which was also the first day of treatments,
and then were imaged weekly starting at day 23 to monitor tumor response to
treatments (Figure 3). Ten days following transplantation, we were able to detect
luciferase-expressing tumor cells in the livers of all the mice involved in the study
(Figure 4a).
Tumor growth was monitored over time in recipient mice utilizing luciferase
imaging. As expected, tumors in control-treated mice continued to grow rapidly, and the
mice succumbed to the tumor burden (Figure 4b, Figure 5). Interestingly, mice receiving
etoposide alone also continued to have rapid tumor growth (Figure 4b). These data
suggest that the timing of etoposide treatments may need to be altered in order to
obtain maximal response or, alternatively, that mSCLC may not respond well to
etoposide treatments alone. In contrast, mice receiving cisplatin alone did have a
decrease in tumor growth following treatments, as monitored by luciferase imaging
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(Figure 4b). Similar to human SCLC patients, mice treated with both cisplatin and
etoposide had the smallest increase in tumor growth between drug treatments (Figure
4b).
Additionally, the overall effect on survival was monitored. As expected from the
imaging regimen, we observed that mice treated with cisplatin and etoposide
demonstrated increased survival (Figure 5). Although palpation of the abdomen
revealed the smallest tumor burden in mice treated with both cisplatin and etoposide,
mice in this treatment group had severe weight loss and as a result, the mice were
sacrificed due to drug toxicity, not tumor burden. Thus, these data demonstrated that
the mSCLC tumors, much like human SCLC, responded to combination chemotherapy
involving both cisplatin and etoposide, as observed with decreased tumor burden and
increased survival.
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Figure 1. Tumors in recipient mice resemble the parental tumor following
transplantation. (a) Lymph node metastasis from which a cell line was derived. (b) High
magnification view of the region in the black box of the lymph node metastasis shown in
(a). (c) Hematoxylin and eosin stain (H&E) staining of a tumor in the recipient mouse.
This cell line, following transplantation, produced tumors in the livers of recipient mice.
(d) High magnification view of the region in the black box of the liver metastasis shown
in (c). (a-d) Hematoxylin and eosin stain.
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Figure 2. Production of cell lines expressing both GFP and luciferase. (a) Schematic of
the MSCV plasmid utilized to infect mSCLC cell lines. Infected cells express both GFP
and luciferase. (b) Representative flow cytometry plot demonstrating the presence of
live (7AAD~), GFP* cells.
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Figure 3. Schematic of the treatment and imaging schedule. (a) Timeline illustrating the
treatment and imaging schedule following transplantation, which was performed on day
0. Red arrows: treatments, green arrows: imaging.
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Figure 4. Luciferase imaging can be utilized to monitor tumor growth over time. (a)
Luciferase-expressing tumors can be detected ten days following transplantation using
luciferase imaging in the livers of all recipient mice. The scale bar ranges from 3.29x10 4
to 2.06x1 06 radiance (p/sec/cm2/sr) (b) Luciferase signal, as monitored with total flux,
over time. Control and etoposide only groups succumbed to their tumor burden early.
Mice treated with both etoposide and cisplatin had the smallest increase in tumor
burden over time. Total flux is averaged for each treatment group and normalized to day
23. Cells were transplanted on day 0.
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Figure 5. Treatment with cisplatin and etoposide extended survival. (a) Kaplan-Meier
plot indicates survival of mice treated with either control, cisplatin, etoposide or cisplatin
and etoposide. The data demonstrate increased survival of mice following treatment
with both cisplatin and etoposide compared to control-treated mice (p value: 0.008).
Cells were transplanted on day 0.
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DISCUSSION
These experiments highlight the effectiveness of combination chemotherapy in
treating mSCLC. Tumors in recipient mice had a decrease in growth when treated with
both etoposide and cisplatin, as determined with luciferase imaging. These studies need
to be extended to analyze the effectiveness of different drug doses and treatment
schedules. We utilized a cisplatin dose of 10 pg / g body weight, but this dose may need
to be decreased, especially when used in combination with etoposide. Mice receiving
both cisplatin and etoposide had significant weight loss and they had to be sacrificed
due to toxicity concerns after several treatments. These data indicated the effectiveness
of combination chemotherapy, as well as the benefits of this model in testing additional
therapies.
While we demonstrated that treatment with both cisplatin and etoposide was
effective in the mouse model of SCLC, we have yet to examine the response of the
tumors histologically. For example, an examination of the proliferative and apoptotic
response of the tumors to cisplatin and etoposide would prove beneficial (Oliver et al.
2010). In addition, the presence of the platinum-DNA adducts and DNA damage
markers, such as yH2AX, Chkl, and Chk2, in the tumors should be monitored over time
(Oliver et al. 2010). Such studies would enable us to examine the response of the
tumors to the drug treatments and to determine when tumor resistance is initiated.
Although the transplantation model provides the benefit of genetically similar
tumors arising in all of the treatment groups, combination chemotherapy studies should
be extended to the in vivo model. To perform these studies, luciferase imaging can
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monitor primary tumor, and potentially metastatic, response in p53 4'";Rbf"';Rosa26LSL-
Luciferase/LSL-Luciferase mice. In contrast, lung tumors arising in p53 1 ;Rbflfl mice can be
monitored using micro-computed tomography imaging. Understanding how
autochthonous tumors respond to drugs would enhance human treatment studies.
While we determined that mice responded to combination chemotherapy
treatments with decreased tumor burden and increased survival, we were unable to
determine whether resistant tumors develop. Transplanting fewer cells or starting
treatments earlier would aid in the production of resistant tumors. Once resistant tumors
are obtained, the mechanism of resistance can be examined. First, copy number
profiles can be obtained for both chemotherapy resistant and sensitive tumors and
analyzed for loci only altered in resistant tumors, which would highlight candidate genes
involved in resistance. As documented in Chapter 2, copy number profiles have already
been obtained for several cell lines and these particular cell lines can be utilized for
chemotherapy resistance studies. Second, cell lines derived from resistant tumors, or
the resistant tumors themselves, can be profiled for gene expression changes using
techniques such as gene expression arrays or high throughput transcript sequencing
(RNAseq). Candidate resistance genes can then be functionally validated utilizing cell
lines in in vitro experiments. The development of resistant tumors, as well as an
understanding of the underlying mechanisms, would aid in providing more effective
treatments for human SCLC patients.
Although human SCLC tumors respond well at first, SCLC has a very poor overall
response, and as a result, is a particularly devastating disease. These studies
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demonstrated the ability to utilize the mouse model of SCLC for testing therapeutics and
can be extended to both in vitro and in vivo analyses of current treatment options. In
addition, novel therapeutics can be tested for their effectiveness in both mSCLC cell
lines and autochthonous tumors. The identification of novel drugs, as well as an
enhanced understanding of the resistance mechanisms, will aid the treatment of this
devastating disease.
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METHODS
Mice. p53";Rbf"/" mice have been previously described (Meuwissen et al. 2003). They
were infected intranasally or intratracheally with 2.5x1 07 or 108 PFU of adenovirus, as
previously described (DuPage et al. 2009). Rag2i mice were obtained from the Koch
Institute ES cell and transgenic core facility and were utilized in the transplantation
experiments. Mouse research was approved by the Committee for Animal Care, and
conducted in compliance with the Animal Welfare Act Regulations and other Federal
statutes relating to animals and experiments involving animals, and adheres to the
principles set forth in the Guide for the Care and Use of Laboratory Animals, National
Research Council, 1996 (Institutional animal welfare assurance no. A-3125-01).
Production of mSCLC cell lines. Part of each tumor was kept for histology and cell
line preparation. To dissociate tumors for cell lines, minced tumors were digested in
HBSS (without calcium and magnesium), 1 mg/mL Collagenase IV (Worthington
Biochemicals), and 0.025% trypsin-EDTA (Gibco) at 37'C for thirty minutes. Following
dissociation, samples were quenched in PBS with 10% FBS, incubated in 25 pg/mL
DNase I (Sigma), centrifuged, filtered and plated in standard tissue culture media (DME,
10% FBS, 1 % L-glutamine and 50 units/mL Penicillin, 50 pg/mL Streptomycin).
Infection with luciferase/GFP virus. Retroviruses were made by transfecting (Mirus or
Fugene) 293 cells with equal amounts of the luciferase/GFP and pCL-Eco plasmids.
Two days after transfection, the virus was collected, filtered and used to infect the
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mSCLC cell line. Two days following infection, cells were trypsinized and incubated in
7AAD (1:300, Molecular Probes) prior to flow cytometry. Live (7AAD~), GFP* cells were
sorted and collected, and allowed to recover prior to transplantation.
Transplantation. 100,000 cells were transplanted into the tail vein of Rag2' mice.
Chemotherapy treatments. Cisplatin treatments were performed as previously
described (Oliver et al. 2010), except that mice were given a dose of 10 pg / g body
weight intra-peritoneally. Etoposide (Sigma) was dissolved in DMSO and stock aliquots
of 50 mM were kept at -20oC. Etoposide was freshly diluted to 0.5 mM in 0.9% NaCl and
5% dextrose prior to injection and was injected intra-peritoneally (l.P.) at a concentration
of 12 pg / g body weight. Four mice each were in the control, cisplatin, and etoposide
treatment groups, and five mice were treated with both cisplatin and etoposide.
Treatments were given once a week for two weeks, and then for toxicity reasons, the
mice were allowed to recover for two weeks before the next treatment (Oliver et al.
2010).
Luciferase Imaging. Bioluminescence imaging was performed according to
manufacturer's instructions (Xenogen).
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SUPPLEMENTARY TABLE 1
ProbelD Gene Symbol logFCCL adjP_CL1 IlogFCCL2|adjPCL2
Genes upregulated by L-myc
1448147 at Tnf rsf19 1.83 0.01 1.26 0
1427342 at Fastkd1 1.13 0.01 1.86 0
1439263 at LOC14210 1.83 0.05 1.15 0.02
1418178 at LOC100047943 1.49 0 1.34 0
1417890 at Pdxp 1.12 0.04 1.53 0
1422709 a at Wdr46 1.01 0.04 1.57 0.01
1424223 at 1700020C11Rik 1.12 0.01 1.46 0
1428485 at Carl2 1.53 0.01 1.04 0.03
1435783 at Fam169a 1.25 0.01 1.31 0
1448531 at Lmnb2 1.01 0.03 1.51 0
1426118 a at Tomm40 1.17 0.03 1.33 0
1416798 a at Nme4 1.14 0.01 1.31 0
1426630 at Exosc2 1.02 0.02 1.4 0
1431782_s_at Ypel1 1.11 0.04 1.3 0.05
1451119 a at FbInl 1.36 0 1.04 0.01
1428069 at Cdca7 1.15 0.01 1.14 0.02
1457964 at 1810044D09Rik 1 0.03 1.21 0.01
1451278 a at Mettl11a 1.11 0.01 1.11 0
1418335 a-at Dphl, Ovca2 1.07 0.01 1.03 0
1420510 at LOC636713, Srfbpl 1.02 0.01 1.02 0.01
Genes downregulated by L-myc
1460344_at 2310033F14Rik, -1.11 0.03 -1.34 0
LOC1 00046056, Pbxipl
1455581 x at 9530028C05 -1.3 0.01 -1 0.02
1421840 at Abcal -1.29 0.05 -1.4 0.01
1418838 at Abcd1 -1.01 0.02 -1 0.02
1417527 at Ap3m2 -1.11 0 -1.01 0.01
1418025 at Bhlhe40 -1.05 0.01 -1.08 0
1417009 at Cir -1.17 0.03 -2.31 0
1456437_x_at Clr, Clrb -1.17 0.05 -2.75 0
1424041 s at C1s, LOC100044326 -2.33 0.02 -3.35 0
1423954 at C3 -1.94 0.02 -1.4 0
1419483 at C3arl -2.38 0.01 -1.58 0.04
1449556_at C920025E04Rik, H2- -1.1 0.02 -1.55 0
T23
1449265_at Casp1 -1.89 0.02 -1.2 0
1421228 at CcI7 -2.13 0 -1.26 0.03
1423551 at Cdhl3 -1.22 0 -1.05 0.03
1418456 a at Cxcl14 -1.95 0.01 -2.05 0
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1449368 at Dcn -2.19 0 -2.59 0
1448390_a_at Dhrs3 -1.52 0.01 -2.1 0
1448613 at Ecm1 -1.34 0.01 -2.91 0
1424680 at Fam26e -1 0.02 -1.25 0
1416164 at FbIn5 -1.58 0 -1.18 0
1417876 at Fcgrl -2.42 0 -1.12 0
1449875_s_at H2-T1O, H2-T17, H2- -1.16 0.01 -1.09 0
T22, H2-T9
1426278 at Ifi2712a -3.16 0.02 -1.77 0
1451798 at ilrn -1.9 0.01 -2.72 0
1417793_at Irgm2 -1.05 0.04 -1.41 0
1424885 at Klhdc8a -1.09 0.04 -1.33 0
1426127 x at Klral8 -1 0.03 -1.09 0
1424807 at Lama4 -1.34 0.03 -1.86 0
1452436 at Lox12 -1.07 0.01 -1.88 0
1415904_at Lpl -3 0.01 -1.34 0.02
1421899 a at Mr1 -1.16 0 -1.03 0.01
1419663_at Ogn -1.88 0 -2.45 0
1416441_at Pgcp -1.1 0.03 -1.63 0
1460194_at Phyh -1.24 0 -1.05 0
1424906_at Pqlc3 -1.04 0.02 -1.33 0
1450122_at Ptprg -1.2 0.01 -1.46 0
1419668_at Sgcb -1.1 0.02 -1.21 0
1418933 at Slcla6 -1.24 0.03 -2.03 0
1452445 at Slc4la2 -1.12 0.01 -1.76 0
1420913 at Slco2al -1.66 0.02 -1.52 0
1418651 at Spata6 -1.11 0.03 -1.14 0.01
1448200 at Tcn2 -1.57 0.01 -2.18 0
1422782 s at Tlr3 -1.36 0.01 -1.08 0
1426093 at Trim34 -1.58 0.01 -1.66 0
1426260_a_at Ugtlal, Ugtlal0, -1.43 0.05 -2.15 0
Ugtl a2, Ugtl a5,
Ugtla6a, Ugtla6b,
Ugtl a7c, Ugtl a9
1426221 at Vwa5a -1.45 0.01 -1.8 0
1448818 at Wnt5a -2.13 0.01 -1.2 0.01
Supplementary Table 1. Genes significantly up- and down-regulated only by L-myc. To
be considered significantly upregulated or downregulated, the log2 of the fold change
was greater than or equal to 1 or less than or equal to 1, respectively, and the adjusted
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p-value was less than or equal to 0.05. The log2 of the fold change (logFC) and adjusted
p-value (adjP) are shown for each cell line (CL1 and CL2) for cells expressing L-myc
compared to control.
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SUPPLEMENTARY TABLE 2
ProbelD |Gene Symbol logFCCL1 adjP_CL1|logFCCL2 adjPCL2
Genes upregulated by Nfib
1417633 at Sod3 4.93 0 2.44 0
1416322 at Prelp 4.26 0 4.18 0
1423555 a at Ifi44 4.14 0 3.43 0
1418580 at Rtp4 4.06 0 2.42 0
1421404 at Cxcl15 3.91 0 2.46 0
1419015 at Wisp2 3.89 0 4.51 0
1451860 a at Trim30 3.74 0 4.06 0
1449169 at Has2 3.43 0 1.88 0
1426640 s at Trib2 3.27 0.01 1.62 0
1450783 at Ifit1 3.23 0 4.48 0
1438953 at Figf, LOC1 00047108 3.22 0 4.5 0
1438954 x at Figf 3.09 0 4.23 0
1451054 at Orm1 3.08 0 4.25 0
1424518_at Apol9a, Apol9b 3 0 1.41 0
1431569 a at Lypdl 2.99 0 3.81 0
1418191 at LOC100048346, Uspl8 2.94 0 3.6 0
1453196 a at OasI2 2.85 0 2.57 0
1419209 at Cxci1 2.81 0 3.25 0
1431591_s_at Gm9706, Isg15 2.77 0 2.58 0
1435370 a-at Ces3 2.68 0 2.28 0
1434380_at Gbp6 2.63 0 1.92 0
1419603 at Ifi204 2.63 0.01 2.38 0
1450297 at 116 2.59 0.03 3.02 0.02
1433691 at Ppplr3c 2.55 0.02 4.37 0
1424775 at Oasla 2.54 0.01 2.64 0
1418445 at SIcl6a2 2.47 0 1.92 0
1423954 at C3 2.46 0.01 4.67 0
1448550 at Lbp 2.38 0 1.4 0
1427038 at Penk 2.37 0.02 2.19 0
1452349_x_at Ifi205, Mnda 2.36 0 1.05 0
1426278 at Ifi2712a 2.34 0.05 1.36 0
1424451 at Acaalb 2.31 0 1.58 0
1437062 s-at Phyhipl 2.3 0.01 1.24 0
1449522 at Unc5c 2.22 0 1.32 0
1419728 at Cxci5 2.19 0.05 5.15 0
1418186 at Gsttl 2.17 0.01 2.28 0
1425894 at Mrgprf 2.07 0 1.37 0
1438676 at Mpa21 2.04 0 2.14 0
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1424921 at Bst2 2 0 1.48 0
1418753_at Gfpt2 1.99 0 2.36 0
1427747 a at Lcn2 1.98 0 2.29 0
1450637_a_at Aebpl 1.93 0 1.76 0
1424807 at Lama4 1.91 0 2.06 0
1417793 at Irgm2 1.9 0 2.53 0
1418392 a-at Gbp3 1.86 0.02 1.68 0.01
1418061 at Ltbp2 1.82 0 2.19 0
1449368 at Dcn 1.78 0 4.29 0
1456494_a at A1451617, Trim30 1.75 0 1.03 0.01
1448380 at Lgals3bp 1.72 0 1.52 0
1429076_a_at Gdpd2 1.71 0 3.1 0
1452231 x at Ifi203 1.7 0.01 2.4 0
1451564_at Parpl4 1.68 0 1.74 0
1448649 at Enpep 1.63 0.02 1.26 0.03
1421278_s_at Spnal 1.6 0.01 1.98 0
1449025 at Ifit3 1.58 0.01 2.39 0
1434776 at Sema5a 1.58 0.01 1.62 0
1417244 a at Irf7 1.53 0 1.6 0
1450826 a-at Saa3 1.5 0 3.53 0
1417141_at Igtp 1.49 0.04 2.46 0
1424524 at Dram1 1.49 0.04 1.37 0
1448590 at Col6al 1.49 0.01 1.02 0
1418021 at C4b 1.48 0 1.79 0
1451644_a_at 0610037M15Rik, H2- 1.46 0.03 1.53 0.02
.__ _gsl0
1418240 at Gbp2 1.41 0.01 1.33 0
1418259 a at Entpd2 1.41 0 1.29 0
1423878 at Gypc 1.38 0 1.08 0
1427522 at Arhgap20 1.38 0 1.6 0
1423252 at Hdgfrp3 1.38 0.01 1.12 0
1448250 at 9030425E11Rik 1.37 0.01 2.29 0
1424277_at Haus7, LOC100044098 1.37 0.01 1.18 0.01
1422648 at SIc7a2 1.36 0.01 1.1 0
1419417 at Vegfc 1.35 0.01 1.21 0
1425405 a at Adar 1.33 0 1.08 0.01
1421007 at Col4a6 1.28 0 1.37 0.03
1417311 at Crip2 1.28 0 1.67 0
1426093 at Trim34 1.26 0.01 1.01 0.01
1449350 at Osr1 1.26 0.01 1.98 0
1421295 at Chrdl1 1.25 0 2.22 0
1425336 x at H2-K1 1.24 0.01 1.03 0
1426869 at Boc 1.24 0.02 3.59 0
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1450468_at Myoc 1.22 0.04 3.15 0
1449396 at Aoc3 1.22 0.04 2.3 0
1418304 at Pcdh2l 1.19 0.01 1.57 0
1421034 a at Il4ra 1.19 0.03 1.68 0
1417395 at Klf4 1.17 0.01 1.64 0
1415856 at Emb 1.14 0.03 1.16 0
1418090 at Plvap 1.13 0.01 2.68 0
1448154 at Ndrg2 1.12 0.05 1.02 0.01
1423171 at Gpr88 1.12 0.02 7.24 0
1418946 at St3gal1 1.11 0.03 3.52 0
1448755 at Col15al 1.1 0.01 3.47 0
1451660 a at Hoxb6 1.07 0.01 1.39 0.01
1425620_at Tgfbr3 1.07 0.05 2.09 0
1449591 at Casp4 1.06 0.01 2.49 0
1424659 at Slit2 1.06 0.01 2.89 0
1450611 at Orm3 1.06 0.01 1.39 0
1425511 at Mark1 1.05 0.01 1.86 0
1451809 s at Rwdd3 1.04 0.04 1.33 0
1418858 at Aox3 1.03 0.02 1.85 0
1423523 at Aass 1.03 0.02 1.9 0
1417399 at Gas6 1 0.02 3.72 0
Genes downregulated by Nfib
1420450_at Mmpl0 -1.78 0.02 -3.87 0
1435697 a-at Cytip -2.29 0.01 -2.75 0
1448595 a at Bex1 -3.57 0 -2.41 0
1422632 at Ctsw -1.51 0 -2.3 0
1450414 at Pdgfb -1.53 0.01 -2.12 0
1417588 at Galnt3 -1.39 0.01 -1.97 0
1426926 at Plcg2 -1.5 0 -1.85 0
1452257 at Bdhl -1.29 0 -1.8 0
1436448 a at Ptgsl -1.44 0.03 -1.79 0
1420994 at B3gnt5 -1.62 0 -1.6 0
1442554 s at Kalrn -1.21 0.02 -1.4 0
1420361 at SIcl1al -2.16 0.02 -1.39 0
1422803 at Fst13 -1.37 0.02 -1.33 0
1450728_at Fjxl -1.46 0 -1.31 0.01
1449036 at Rnfl28 -1.79 0.02 -1.24 0.01
1420699 at Clec7a -3.67 0 -1.23 0.01
1451161 a at Emrl -1.29 0.05 -1.15 0
1428018 a-at AF251705 -1.93 0 -1.09 0
1418842 at HcIsl -1.87 0.01 -1.06 0
1448561 at Ncf2 -1.86 0 -1.06 0
1422010 at TIr7 -1.66 0.01 -1.03 0
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1426112 a at Cd72 -1.5 0.01 -1.01 0.01
1417346_at Pycard -1.44 0.01 -1.01 0.04
1452583_s_at Galm -1.03 0.01 -1.01 0
Supplementary Table 2. Genes significantly up- and down-regulated only by Nfib. To
be considered significantly upregulated or downregulated, the log2 of the fold change
was greater than or equal to 1 or less than or equal to 1, respectively, and the adjusted
p-value was less than or equal to 0.05. The log2 of the fold change (logFC) and adjusted
p-value (adjP) are shown for each cell line (CL1 and CL2) for cells expressing Nfib
compared to control.
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SUPPLEMENTARY TABLE 3
ProbelD Gene Symbol logFCCL1|adjP_CL1 logFC CL2 adjPCL2
Genes upregulated by L-myc & Nfib
1418920 at Cldn15 13 0 2.87 0
1421317 x_at Myb 3.11 0 2.4 0
1448676 at Camk2b 1.77 0 2.21 0
1418649 at EgIn3 1.14 0.01 2.08 0
1450188 s-at Lipg 1.05 0 2.08 0
1431893 a at Pdssl 1.05 0.02 2.07 0
1448740 at Rangrf 1 0.02 2.07 0
1423601 s at Tcof1 1.53 0.01 1.99 0
1449945 at Ppargclb 1.25 0.01 1.95 0
1426286 at Noc31 1.06 0.03 1.91 0
1424282 at Pet1121 1.41 0 1.87 0
1452606 at Mndl 1.5 0 1.81 0
1435896 at Sfxn2 1.07 0.01 1.79 0
1416363 at Fkbp4, LOC100048743 1.29 0.03 1.74 0
1418337_at Rpia 1.25 0 1.74 0
1418869 a at Pus1 1.22 0.01 1.74 0
1448365 at Exosc7 1.03 0.02 1.74 0
1425178 s at Shmtl 1.57 0 1.67 0
1448181 at Klf15 1.77 0 1.66 0
1418158_at Trp63 1.14 0.01 1.66 0
1417511_at Lyar 1.14 0.02 1.65 0
1424396 a at Asrgl1 1.05 0.02 1.64 0
1418026 at Exol 1.08 0 1.62 0
1418511 at Dpt 2.93 0 1.6 0
1417976 at Ada 1.14 0.03 1.58 0
1420389 at Pax3 1.42 0.01 1.57 0
1416730 at RcIl 1 0 1.56 0
1449744 at SIc19al 1.23 0.03 1.52 0
1448506_at Serpina6 2.7 0 1.51 0
1426063 a at Gem 2.66 0.02 1.5 0
1417146 at Mril 1.23 0.01 1.5 0
1424792 at Rpp40 1.1 0 1.47 0
1420925 at Tub 3.82 0 1.46 0
1416940_at Ppif 1.49 0 1.45 0
1416203 at Agpl 1.41 0 1.45 0
1421205 at Atm 1.06 0.01 1.44 0
1449390 at Gpatch4 1.23 0.01 1.4 0
1425271 at Psmc3ip 1.21 0.01 1.4 0
1426462 at Gphn 1.15 0.01 1.4 0
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1454737 at Dusp9 1.28 0.02 1.39 0
1460370_at Toplmt 1.38 0.01 1.38 0
1422824 s_at Eps8 1.71 0.02 1.36 0
1419122 at Mettl1 1.14 0.03 1.35 0
1417323 at Psrcl 1.66 0 1.34 0
1426048_s_at Tcfap2a 1.35 0.05 1.34 0
1417404 at Elov16 1.63 0 1.33 0
1448681 at Il15ra 1.69 0 1.32 0
1428635 at Comtdl 1.07 0.01 1.31 0
1451308 at Elov14 2.38 0 1.3 0
1417972 s at Pop5 1.23 0 1.28 0
1426046 a at Rabggta 1.01 0.04 1.28 0
1448926 at Hoxa5 1.78 0 1.27 0
1435231 at Coq4 1.29 0 1.27 0
1426939 at Tsr2 1.11 0 1.27 0
1452416 at Il6ra 1.62 0 1.26 0
1423815 at Ddx56 1.02 0.01 1.26 0
1421498 a at 2010204K13Rik 1.28 0 1.25 0
1449118 at Dbt 1.48 0 1.22 0
1424810 at Tasp1 1.1 0.02 1.2 0
1418184_at Cenpm 1.06 0.02 1.16 0
1422823_at Eps8, LOC632638 2.13 0.02 1.14 0
1420146 at Tiam2 1.04 0.01 1.14 0
1435193 at A23005OP2ORik 1.65 0 1.12 0
1422645 at Hfe 1.18 0 1.12 0
1423761 at Mettl13 1.16 0.01 1.12 0
1450132 at Hivep3 1.21 0 1.1 0
1419077 at Mpp3 1.92 0 1.09 0.03
1431784 a at Bxdc5 1 0.01 1.08 0
1425118 at Spire2 2.19 0 1.06 0
1427445 a at Ttn 1.01 0.01 1.06 0.01
1439516 at 2610201A13Rik 1.19 0 1.05 0
1416553 at Stral3 1 0.01 1.04 0.01
1416629 at Sicla5 2.02 0 1.03 0.01
1449098 a at Poll 1.13 0.02 1.03 0
1427441 a-at SucIg2 1.4 0 1 0
Genes downregulated by L-myc & Nfib
1452106_at Npnt -1.58 0 -4.34 0
1422643 at Moxdl -2.3 0 -4.18 0
1451484_a_at Syn1 -1.72 0 -3.83 0
1419435 at Aoxl -1.22 0.03 -3.67 0
1418945_at Mmp3 -2.37 0 -3.43 0
1426615 s-at Ndrg4 -1.5 0.03 -3.32 0
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1426858 at Inhbb, LOC100046802 -1.45 0 -3.03 0
1421227 at Gzmd, Gzme -1.95 0 -2.74 0
1417700 at Rab38 -1.84 0 -2.71 0
1448428 at NbIl -2.28 0 -2.7 0
1444052 at FIt4 -4.11 0 -2.54 0
1450171 x at Gzme -1.7 0 -2.54 0
1421385 a at Myo7a -1.65 0 -2.52 0
1448665 at Dmd -1.9 0.01 -2.43 0
1450027 at Sdc3 -1.63 0 -2.43 0
1418471 at Pgf -1.18 0 -2.4 0
1430522_a_at Vamp5 -1.31 0.02 -2.38 0
1426873 s at Jup -1.66 0 -2.36 0
1427485 at Lmodl -2.32 0 -2.33 0
1418136 at Tgfblil -1.59 0 -2.28 0
1425913 a-at Spats2l -2.74 0 -2.22 0
1418752 at Aldh3al -1.07 0.01 -2.2 0
1422837 at Scel -2.03 0 -2.19 0
1455642 a-at Tspanl7 -1.05 0.04 -2.17 0
1417109 at Tinagll -1.65 0 -2.16 0
1419070 at Cys1 -2.29 0 -2.15 0
1416968 a at Hsd3b7 -1.32 0 -2.13 0
1424097 at Elovl7 -1.5 0.01 -2.11 0
1418569 at Fbliml -1.63 0 -2.08 0
1419358 at Sorcs2 -1.93 0 -2.07 0
1456603 at FamlOb -1.2 0.03 -2.06 0
1421217 a at Lgals9 -1.16 0 -2.06 0
1452657 at Apls2 -1.46 0.02 -2.02 0
1418497 at Fgf13 -1.79 0 -1.96 0
1418778 at Ccdcl09b -1.44 0 -1.96 0
1423363 at Sort1 -1.02 0.03 -1.95 0
1416468 at Aldhial -2.11 0 -1.94 0
1448300 at Mgst3 -2.99 0 -1.92 0
1422852 at Cib2 -1.47 0 -1.91 0
1417061 at SIc40al -1.2 0.01 -1.9 0
1451486 at Sic46a3 -1.07 0.02 -1.9 0
1420417 at Gm2521, Sema3a -1.46 0.01 -1.88 0
1422053 at Inhba -1.11 0.02 -1.87 0
1424560_at Pstpipl -1.35 0.01 -1.81 0
1420382_at Apob48r -1.29 0.02 -1.81 0
1424463 at Mfsd6 -1.75 0 -1.78 0
1426576 at Sgmsl -1.33 0.04 -1.78 0
1449670_x_at Gprl37b, -1.34 0.01 -1.76 0
LOC1 00044979 _ 1 1
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1439422 a at Fam132a -1.03 0 -1.76 0
1418486 at Vnnl -1.88 0.01 -1.75 0
1425503 at Gcnt2 -1.37 0 -1.74 0
1450731 s at Tnfrsf2l -1.69 0.01 -1.72 0
1424763_at Rsph9 -1.21 0.01 -1.7 0
1460210 at Pkdl -1.47 0 -1.68 0
1448468 a at Kcnabl -2.12 0 -1.67 0
1424694 at 201001112ORik -1.31 0.01 -1.66 0
1423915 at OlfmI2b -1.88 0 -1.64 0
1436050 x at Hes6 -1.21 0 -1.61 0
1423331_a_at LOC100047693, PvrI3 -1.55 0 -1.6 0
1448656 at Cacnb3 -1.97 0 -1.56 0
1426541 a at Endod1 -1.61 0 -1.56 0
1420125 at Tcta -1.19 0.01 -1.56 0
1460204 at Tec -1.06 0.02 -1.55 0
1427633_a_at Pappa -1.51 0 -1.54 0
1420641_a_at Sqrdl -1.28 0 -1.54 0
1451611 at Pla2g16 -1.63 0 -1.53 0
1433485 x at Gpr56 -3.35 0 -1.52 0
1429173 at Dnase11 -1.64 0 -1.52 0
1418509 at Cbr2 -1.07 0 -1.52 0
1450567 a at Col2al -4.19 0 -1.51 0
1422550 a at Mtap6 -2.07 0 -1.51 0
1437405_a_at lgfbp4 -1.92 0.02 -1.49 0
1416689 at Tuft1 -1.61 0 -1.49 0
1416537 at Creld1 -1.09 0 -1.49 0
1417932 at 1118 -3.35 0 -1.48 0
1416935 at Trpv2 -1.82 0 -1.47 0
1460341 at Plekhb2 -1.05 0 -1.47 0
1427149 at Plekha6 -1.88 0 -1.46 0
1416236 a-at Mpzl2 -1.39 0.02 -1.45 0
1418162 at TIr4 -1.35 0 -1.43 0.01
1417801 a-at Ppfibp2 -2.89 0 -1.42 0
1436790 a at Soxl1 -2.44 0.04 -1.42 0
1431394 a at Lrrk2 -1.09 0.01 -1.42 0
1423284 at Mansc1 -1.81 0.02 -1.41 0
1450036 at Sgk3 -1.64 0 -1.39 0
1451339 at Suox -1.64 0 -1.39 0
1419455 at IllOrb -1.12 0.02 -1.38 0
1417985_at Nrarp -1.05 0.02 -1.38 0
1449583 at Pcdhb20 -1.63 0 -1.36 0
1452320 at Lrp2 -3.48 0 -1.35 0
1460674 at Paqr7 -1.73 0 -1.35 0
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1417644_at Sspn -1.65 0 -1.31 0
1434151 at Mettl7al -1.12 0.05 -1.31 0
1449559 at Msx2 -2.02 0 -1.28 0
1439368 a at SIc9a3r2 - -1.35 0.01 -1.28 0.02
1460359 at Armcx3 -1.68 0.01 -1.27 0
1453004 at Slc22a23 -1.48 0.02 -1.26 0
1426743_at App12 -2.18 0 -1.23 0
1454897 at 6330509M05Rik -1.56 0.01 -1.23 0.01
1448411 at Wfsl -1.23 0 -1.23 0
1416313 at Mlltl1 -1.04 0 -1.23 0
1418285 at Efnbl -1.15 0 -1.2 0
1455741 a at Ecel -1 0 -1.19 0
1417214 at Rab27b -2.29 0 -1.18 0
1418448 at Rras -1.56 0 -1.18 0
1438968 x-at Spint2 -1.56 0.04 -1.18 0.02
1418941 at Pcdhb22 -1.04 0.05 -1.18 0.02
1424356 a at Metrnl -1.2 0.02 -1.17 0.01
1424404 at 0610040JOlRik -1.51 0 -1.16 0.01
1417220 at Fah -1.39 0.01 -1.16 0
1422428 at Acsbgl -1 0.02 -1.16 0
1417732 at Anxa8 -2.71 0 -1.15 0
1448031 at Gnaol -1.93 0 -1.15 0
1448320 at Stim1 -1.37 0 -1.14 0
1418355 at Nucb2 -1.35 0.01 -1.14 0
1418578 at Dgka -1.26 0 -1.14 0
1426791 at Rusc2 -2.09 0 -1.13 0
1419458 at Rgnef -1.92 0 -1.13 0.01
1433741 at Cd38 -1.4 0.02 -1.12 0.03
1434642 at Hsdl7bll -1.31 0.03 -1.12 0.01
1423584 at lgfbp7 -1.22 0 -1.12 0
1420416 at Sema3a -1.11 0.02 -1.12 0
1420928_at St6gal1 -1.07 0 -1.12 0
1417917 at Cnn1 -3 0 -1.11 0.01
1448477 at Chstl2 -1.51 0 -1.11 0
1427853_a_at Hsp25-psl -1.64 0 -1.1 0
1437874 s at Hexb -1.32 0.01 -1.1 0
1450107_a_at Renbp -1.28 0.01 -1.1 0
1416357 a-at Mcam -1.76 0 -1.09 0
1426571 at Anol -1.78 0 -1.07 0
1416457 at Ddah2 -1.29 0 -1.07 0.01
1427009 at Lama5 -1.34 0.02 -1.06 0
1428122 s-at Fam125b -1.33 0 -1.06 0
1453281 at Pik3cd -1.3 0 -1.06 0.01
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1420502 at Sat1 -1.32 0 -1.05 0
1450029_s_at Itga9 -1.03 0.01 -1.05 0
1448233_at Prnp -1.02 0.01 -1.05 0
1420653 at Tgfb1 -1.26 0 -1.04 0.05
1430889_a_at Tpmt -1.06 0 -1.04 0
1449887 at Chmp4c -1.46 0 -1.03 0.01
1416635_at Smpdl3a -2.06 0 -1.02 0
1433504_at Pygb -1.97 0 -1.02 0
1448269 a at Klhl13 -1.64 0 -1.02 0
1420443 at Pcdhb19 -1.14 0.01 -1.02 0.01
1418302 at Ppt2 -1.01 0.01 -1.02 0.01
1452844 at Pou6f1 -1.68 0 -1.01 0.01
1419108_at Ophnl -1.53 0 -1 0.01
Supplementary Table 3. Genes significantly up- and down-regulated only by cells
expressing L-myc & Nfib. To be considered significantly upregulated or downregulated,
the log2 of the fold change was greater than or equal to 1 or less than or equal to 1,
respectively, and the adjusted p-value was less than or equal to 0.05. The log2 of the
fold change (logFC) and adjusted p-value (adjP) are shown for each cell line (CL1 and
CL2) for cells expressing L-myc & Nfib compared to control.
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SUPPLEMENTARY TABLE 4
ProbelD Gene Symbol Lmyc Lmyc Lmyc Lmyc Nfib Nfib Nfib Nfib
logFC adjP logFC adjP logFC adjP logFC adjP
CL1 CL1 CL2 CL2 CL1 CL1 CL2 CL2
Genes downregulated by L-myc and Nfib
1422903 at 1Ly86 -3.46 0 -1.41 0.01 -3.5 0 -1.17 0.03
1448123_s-at Tgfbi -1.77 0.02 -1.56 0 -2.58 0 -2.72 0
Supplementary Table 4. Genes significantly down-regulated in cells expressing L-myc
alone and Nfib alone. To be considered significantly downregulated, the log2 of the fold
change was less than or equal to 1 and the adjusted p-value was less than or equal to
0.05. The log2 of the fold change (logFC) and adjusted p-value (adjP) are shown for
each cell line (CL1 and CL2) for cells expressing L-myc compared to control and Nfib
compared to control.
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SUPPLEMENTARY TABLE 5
ProbelD Gene L-myc L-myc L-myc L-myc L-myc L-myc L-myc L-myc
Symbol IogFC adjP IogFC adjP &Nfib &Nfib &Nfib &Nfib
CL1 CL1 CL2 CL2 IogFC adjP IogFC adjP
CL1 CL1 CL2 CL2
Genes upregulated by L-myc and L -myc & Nfib
1422087 MycIl 8.04 0 7.39 0 8.22 0 7.89 0
at _
1417585 Nup2l0 2.09 0.01 3.32 0 2.73 0 3.22 0
at
1450630 Qtrt1 1.6 0.01 1.91 0 1.68 0 2.26 0
at
1451016 Ifrd2 1.37 0.01 1.99 0 1.51 0 2.28 0
at
1435572 231001 1.5 0.05 1.71 0.01 1.3 0.04 1.8 0.01
at 4L17Rik
1430128 Reep6 1.23 0.02 1.87 0 1.28 0.01 2.36 0
a at
1424731 Nel 1.24 0.02 1.85 0.01 1.35 0 2 0
at
1429270 Syce2 1.19 0 1.82 0 1.27 0 1.18 0
a at
1417212 953005 1.02 0.02 1.87 0 1.33 0 1.9 0
at 8B02Rik
1417233 Chchd4 1.26 0.02 1.61 0 1.14 0.01 1.65 0
at
1421682 Gm341 1.02 0.05 1.73 0.01 1.35 0.01 1.63 0
a-at 7,
Gm344
8, Tcte3
1416126 PoIrib 1.16 0.01 1.48 0 1.15 0 1.28 0
at
1421544 Dnahcl 1.26 0.02 1.31 0 1.31 0.01 1.34 0
at 1
1416806 Fdxr 1.14 0.01 1.35 0 1.56 0 1.32 0
at
1415977 Isynal 1.46 0 1.04 0 1.17 0 1.19 0
at
1417302 Rcor2 1.12 0.01 1.2 0.01 1.67 0 1.15 0
at
1428069 Cdca7 1.15 0.01 1.14 0.02 1.09 0 1.01 0.03
at
1450718 Sh2b2 1.2 0.04 1.07 0.01 1.36 0.01 1.23 0
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at
1449019 Akap1 1.09 0.03 1.02 0 1.02 0.01 1.06 0
at
1416622 Wbscrl 1 0.01 1.08 0.03 1.1 0 1.37 0.01
at 6
1452830 Cad 1.03 0.05 1.04 0.01 1.23 0.01 1.16 0
s at
Genes dovmregulatd by Lmyc and L-mycNfib
1425519 Cd74 -8.07 0 -3.49 0 -7.86 0 -2.79 0
a at
1448617 Cd53 -6.49 0 -3.91 0 -5.68 0 -2.97 0
at
1452016 Alox5ap -5 0 -2.22 0 -4.9 0 -2.36 0
at
1418037 C4bp -2.11 0.01 -1.5 0 -3.88 0 -2.47 0
at
1448748 Plek -3.37 0 -1.35 0 -3.28 0 -1.44 0
at
1421471 Npylr -1.62 0 -1.18 0 -3.23 0 -1.78 0
at
1424214 913021 -2.29 0.01 -1.59 0 -2.9 0 -3.54 0
at 3BO5Rik
1416326 Crip1 -2.28 0 -1.45 0.01 -2.73 0 -3.24 0
at
1448933 Pcdhbl -2.25 0 -1.65 0 -2.62 0 -2.15 0
at 7
1435857 Aplp1 -1.9 0 -1.92 0 -2.47 0 -1.83 0
s at
1434059 B23031 -1.51 0 -1.21 0 -2.4 0 -2.22 0
at 2A22Rik
1418671 Capn5 -1.39 0.01 -1.12 0.02 -2.38 0 -1.98 0
at
1449259 Rab3d -1.52 0 -1.62 0 -2.34 0 -1.75 0
at
1424308 Sic24a3 -1.63 0.01 -1.61 0 -2.2 0 -1.61 0
at
1449419 Dock8 -1.61 0 -1.11 0 -2.05 0 -1.12 0
at
1450224 Col4a3 -2.01 0.02 -1.91 0 -2.02 0.01 -3.35 0
at
1418638 H2- -2.23 0.01 -1.72 0 -1.92 0 -1.9 0
at DMb1,
H2-
DMb2
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1450241 Evi2a -1.61 0 -1.85 0 -1.83 0 -1.87 0
a-at
1449429 Fkbplb -1.11 0.02 -1.17 0.01 -1.79 0 -1.84 0
at
1452067 Naaa -1.71 0 -1.44 0 -1.76 0 -1.61 0
at
1452646 Trp53in -1.53 0.01 -1.31 0 -1.76 0 -1.95 0
at p2
1417237 PId2 -1.47 0.02 -1.31 0 -1.76 0 -1.64 0
at
1418345 Tnfsf12, -1.31 0.04 -1.37 0 -1.73 0 -1.8 0
at Tnfsf 12-
tnfsf 13,
Tnfsf 13
1450967 Ptplad2 -1.63 0 -1.54 0 -1.67 0 -1.83 0
at
1423086 Npcl -1.04 0.03 -1.34 0 -1.63 0 -1.59 0
at
1417741 PygI -1.74 0.01 -1.52 0 -1.62 0 -1.24 0
at
1423136 Fgf1 -1.3 0.01 -1.7 0 -1.58 0 -3.1 0
at
1449154 Coll1al -2.27 0.01 -1.58 0 -1.4 0.03 -2.31 0
at
1425214 P2ry6 -1.12 0.02 -1.24 0 -1.37 0 -1.18 0
at
1416289 Plod1 -1.18 0.01 -1.43 0 -1.34 0 -2 0
at
1431302 Nudt7 -2 0 -1.53 0 -1.3 0 -1.39 0
a-at
1419328 Sema4f -1.12 0.01 -1.55 0 -1.28 0 -2.26 0
at
1460273 Naip2 -1.41 0.01 -1.07 0 -1.28 0 -1.09 0
a at
1424761 Fam115 -1.49 0 -1.04 0.04 -1.25 0 -1.3 0.01
at c
1416619 463242 -1.59 0.01 -1.13 0 -1.22 0.01 -1.23 0
at 8N05Ri
k
1419705 Car5b -1.38 0.01 -1.15 0.01 -1.14 0.01 -1.52 0
at
1422425 Sprr2k -1.44 0.01 -1.39 0 -1.11 0.01 -1.26 0
at
1418888 Sepxl -1 0.04 -1.14 0.01 -1.08 0.01 -1.75 0
252
a at
1450626 Manba -1.74 0.01 -1.02 0.01 -1.01 0.03 -1.54 0
at
Supplementary Table 5. Genes significantly up- and down-regulated by cells
expressing L-myc and L-myc & Nfib. To be considered significantly upregulated or
downregulated, the log2 of the fold change was greater than or equal to 1 or less than or
equal to 1, respectively, and the adjusted p-value was less than or equal to 0.05. The
log2 of the fold change (logFC) and adjusted p-value (adjP) are shown for each cell line
(CL1 and CL2) for cells expressing L-myc compared to control and L-myc & Nfib
compared to control.
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SUPPLEMENTARY TABLE 6
ProbelD Gene Nfib Nfib Nfib Nfib L-myc L-myc L-myc L-myc
Symbol logFC adjP logFC adjP &Nfib &Nfib &Nfib &Nfib
CL1 CL1 CL2 CL2 logFC adjP logFC adjP
CL1 CL1 CL2 CL2
Genes upregulated by Nfib and L-m c & Nfib
1420855 at Eln 3.71 0 6.68 0 4.35 0 2.11 0
1448377 at SIpi 2.08 0 8.05 0 1.65 0 4.98 0
1423719_at LOC632 2.59 0 6.56 0 2.81 0 2.35 0
073,
U46068
1439423 x at U46068 1.55 0.01 7.31 0 1.87 0 2.5 0
1424968_at 221002 1.8 0.05 6.96 0 3.97 0 2.77 0
3GO5Ri
k
1428662 a-at Hopx 3.37 0 5.12 0 2.53 0 2.39 0
1419182 at Svepl 3.36 0 3.89 0 4.42 0 2.07 0
1416855 at Gas1 4.59 0 2.58 0 6.29 0 1.21 0
1451756 at FIt1 3.03 0 4.03 0 2.84 0 2.73 0
1448326 a at Crabp1 3.89 0 3.1 0 5.16 0 1.46 0
1426915 at Dapkl 1.92 0.01 4.59 0 2.31 0 1.44 0
1425528 at Prrx1 2.45 0 4.03 0 3.06 0 3.24 0
1418603 at Avprla 2.38 0 3.97 0 1.61 0 2.13 0
1449827 at Acan 1.7 0.02 4.28 0 2.66 0 3.13 0
1419724 at Edar 2.55 0 3.09 0 2.44 0 1.86 0
1460732 a at PpI 2.39 0 3.1 0 1.04 0.01 1.96 0
1452250 a at Col6a2 3.19 0 2.21 0 3.1 0 1.14 0.01
1450699_at Selenbp 2.22 0 3.16 0 1.6 0.01 1.36 0
1
1422243 at Fgf7 2.2 0 3.15 0 3.4 0 1.34 0
1426013 s at Plekha4 1.71 0.01 3.31 0 2.34 0 1.01 0.01
1451038 at Apin 1.6 0 2.8 0 2.35 0 1.43 0
1434889 at Plekha7 1.52 0 2.6 0 1.3 0 2.03 0
1448194 a at H19 2.73 0 1.27 0 4.1 0 2.19 0
1449484 at Stc2 1.04 0.01 2.92 0 2.35 0 2.3 0
1417169_at Usp2 1.48 0.01 2.38 0 2.6 0 1.71 0
1417300_at Smpdl3 1.72 0 1.7 0 1.91 0 1.16 0
b
1425658 at Cd109 1.52 0 1.61 0 2.24 0 1.55 0
1448201_at Sfrp2 1.45 0 1.24 0 1.34 0 1.36 0
Genes downregulated by Nfib and L-myc & Nfib
1417266_at Cc16 -6.19 0 -1.49 0 -6.09 0 -1.12 0
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1417256 at Mmpl3 -2.84 0 -3.88 0 -2.91 0 -4.61 0
1427482 a at Car8 -2 0.05 -4.68 0 -3.59 0 -3.55 0
1452284 at Ptprzl -2.04 0 -3.99 0 -2.63 0 -3.83 0
1451287 s at Aifl1 -2.03 0 -4.01 0 -1.1 0.01 -2.34 0
1416246 a-at Coro1a -3.47 0 -1.77 0 -3.28 0 -1.94 0
1450791 at Nppb -3.99 0 -1.09 0.01 -4.72 0 -1.22 0
1418203 at Pmaipl -1.75 0.01 -3.06 0 -1.7 0 -2.29 0
1448710 at Cxcr4 -2.02 0 -2.74 0 -3.21 0 -1.9 0
1418252 at Padi2 -1.86 0 -2.82 0 -2.57 0 -3.11 0
1422592_at Ctnnd2, -1.67 0 -2.8 0 -3.32 0 -2.14 0.01
LOC100
045979
1417937 at Dact1 -1.16 0.01 -3.29 0 -1.32 0 -2.58 0
1435493 at Dsp -1.07 0.01 -3.29 0 -1.24 0 -3.32 0
1448612_at Gm527 -3.17 0 -1.11 0 -4.38 0 -1.01 0
9'
Gm785
0, Sfn
1420753 at Tll1 -2.19 0.01 -2.02 0 -1.94 0 -2.07 0
1451440 at Chodl -1.97 0 -2.15 0 -1.73 0 -1.34 0
1426113_x at A13008 -1.82 0 -2.08 0 -1.42 0 -1.71 0
2M07Ri
k, Tcra
1424649 a-at Tspan8 -1.18 0.01 -2.64 0 -3.17 0 -2.83 0
1426454 at Arhgdib -2.43 0.02 -1.37 0 -2.35 0.01 -2.03 0
1416053 at Lrrn1 -2.2 0 -1.44 0 -2.37 0 -1.04 0.01
1420362 a at Bik -1.4 0.05 -2.17 0 -2.71 0 -2.24 0
1422668_at Serpinb -2.1 0.01 -1.44 0 -3.57 0 -2.05 0
9b
1424443 at Tm6sf1 -2.16 0 -1.32 0 -2.25 0 -1.03 0.01
1423221 at Tubb4 -2.34 0 -1 0 -4.07 0 -1.41 0
1416295 a-at Il2rg -1.48 0 -1.87 0 -1.5 0 -2.24 0
1424568 at Tspan2 -1.34 0.02 -1.91 0 -2.43 0 -2.23 0
1452352 at Ctla2b -1.87 0.04 -1.41 0 -1.71 0.03 -1.29 0
1455180 at Gcoml -1.5 0 -1.71 0 -2.15 0 -1.44 0
1460188 at Ptpn6 -2.02 0 -1.1 0 -2.06 0 -1.33 0
1435950 at Hr -1 0.01 -1.85 0 -1.46 0 -1.77 0
1421594 a-at Syt12 -1.29 0 -1.56 0 -4.29 0 -1.82 0
1417860 a at Spon2 -1.62 0.01 -1.17 0 -4.14 0 -1.21 0
1460343 at Neurlla -1.11 0.03 -1.66 0 -2.65 0 -2.03 0
1450389 s-at Pip5klb -1.13 0.02 -1.63 0 -2.17 0 -2.14 0
1451407_at Igsf5, -1.28 0.01 -1.44 0 -1.79 0 -1.63 0
Pcp4 I I I I
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1422644_at Sh3bgr -1.6 0.01 -1.07 0.01 -2.08 0 -1.01 0.01
1436613 at Coro6 -1.23 0.01 -1.34 0 -2.53 0 -1.63 0
1426968 aat Rdh1O -1.18 0 -1.29 0 -1.15 0 -1.36 0
1450199_a at Stab1 -1.18 0.02 -1.21 0 -1.36 0 -1.38 0
Supplementary Table 6. Genes significantly up- and down-regulated in cells
expressing Nfib and L-myc & Nfib. To be considered significantly upregulated or
downregulated, the log2 of the fold change was greater than or equal to 1 or less than or
equal to 1, respectively, and the adjusted p-value was less than or equal to 0.05. The
log2 of the fold change (logFC) and adjusted p-value (adjP) are shown for each cell line
(CL1 and CL2) for cells expressing Nfib compared to control and L-myc & Nfib
compared to control.
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SUPPLEMENTARY TABLE 7
ProbelD Gene L-myc L- L-myc L- Nfib Nfib Nfib Nfib L- L- L- L-
Symbol logFC myc logFC myc logFC adjP logF adjP myc myc myc myc
CL1 adjP CL2 adjP CL1 CL1 C CL2 & & & &
CLI CL2 CL2 Nfib Nfib Nfib Nfib
logF adjP logF adjP
C CL1 C CL2
CL1 CL2
Genes upregulated by all three groups
1425923_at Mycn 10.64 0 10.05 0 10.58 0 10.0 0 10.51 0 10.69 0
6
Genes downregulated by all t ree g roups
1436996_x_ Lyz1 -9.28 0 -4.89 0 -8.68 0 - 0 -9.49 0 -9.49 0
at 7.81
1437726_x_ Clqb -8.64 0 -6.2 0 -9.06 0 -7.2 0 -8.79 0 -6.99 0
at I I
1423547_at Lyz2 -8.23 0 -5.5 0 -8.24 0 - 0 -8.75 0 -7.93 0
7.01
1420394_s_ Gp49a, -7.72 0 -4.84 0 -7.86 0 - 0 -7.88 0 -5.1 0
at LiIrb4 5.53
1448591_at Ctss -6.66 0 -5.14 0 -6.59 0 - 0 -6.76 0 -5.14 0
5.57,
1436905_x_ Laptm5 -6.44 0 -5.03 0 -6.83 0 - 0 -7.13 0 -5.33 0
at 5.16
1419004_s_ Bcl2ala, -7.07 0 -3.57 0 -7.31 0 - 0 -7.2 0 -3.3 0
at Bcl2alb, 3.97
Bcl2al d
1450792_at Tyrobp -6.31 0 -3.67 0 -6.45 0 - 0 -6.39 0 -4.23 0
4.51
1415983_at Lcpl -4.91 0 -3.43 0 -5.86 0 - 0 -5.45 0 -3.94 0
4.54
1420804_s Clec4d -6.85 0 -2.7 0 -7.04 0 - 0 -7.14 0 -2.89 0
at 3.28
1427076_at Mpegl -6.38 0 -3.21 0 -6.13 0 - 0 -6.29 0 -3.42 0
3.44
1418340_at Fcerlg -5.57 0 -3.5 0 -5.71 0 - 0 -5.64 0 -3.91 0
3.64
1417426_at Srgn -5.42 0 -3.78 0 -5.26 0 - 0 -5.43 0 -3.29 0
3.82
1449153_at Mmp12 -5.99 0 -2.43 0 -5.85 0 - 0 -6 0 -3.03 0
3.06
1460218_at Cd52 -5.16 0 -3.31 0 -5.19 0 -3.6 0 -5.21 0 -3.56 0
1419549_at Arg1 -6.19 0 -1.51 0 -6.37 0 - 0 -6.14 0 -1.9 0
_______ ______1.99 _ _
1448061 at Msrl -5.37 0 -2.62 0 -5.5 0 -2.7 0 -5.49 0 -2.53 0
1419872_at Csf1r -5.08 0 -3.29 0 -5.35 0 - 0 -5.48 0 -3.17 0
2.21
1452431_s H2-Aa -4.8 0 -2.04 0 -4.94 0 - 0 -4.84 0 -2.3 0
at 2.25 _ _
1419599_s Ms4a6d -4.21 0 -2.54 0 -4.6 0 - 0 -4.92 0 -2.58 0
at 2.43
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1450678_at ltgb2 -5.15 0 -2.01 0 -5.42 0 -1.6 0 -4.95 0 -1.97 0
1417025_at H2-Ebl -4.66 0 -2.19 0 -4.78 0 - 0 -4.8 0 -2.21 0
2.19
1448620_at Fcgr3 -4.38 0 -2.24 0 -4.58 0 - 0 -4.44 0 -1.97 0
2.11
1449401 _at Ciqc -4.12 0 -1.9 0 -4.27 0 - 0 -4.08 0 -1.73 0
1.98
1424727 at Ccr5 -4.47 0 -1.62 0 -4.35 0 -1.9 0 -4.39 0 -1.41 0
1419315_at Slamf9 -2.54 0 -1.16 0 -4.16 0 - 0 -4.97 0 -1.89 0
1.96
1419627_s Clec4n -4.43 0 -1.28 0 -4.55 0 - 0 -4.47 0 -1.24 0
at 1 1 1.42
1427327_at Pilra -3.36 0 -1.39 0 -3.85 0 - 0 -3.64 0 -1.5 0
1.52
1422124_a_ Ptprc -3.51 0 -1.67 0 -3.49 0 - 0 -3.75 0 -2 0
at 1 1.84
1417381_at Ciqa -3.53 0 -1.61 0 -3.53 0 - 0 -3.49 0 -1.83 0
1.79
1419186_a St8sia4 -2.91 0 -2.02 0 -3.36 0 - 0 -3 0 -1.56 0.01
at 1.92
1437661 at AU0210 -1.91 0.01 -1.82 0 -3.02 0 - 0 -4.14 0 -3.5 0
92 2.25
1448598_at Mmpl7 -1.57 0.03 -1.2 0.01 -3.08 0 - 0 -5.62 0 -2.25 0
1.89
1420330_at Clec4e -3.18 0 -1.44 0 -3.25 0 - 0 -3.2 0 -1.72 0
1.57
1449453_at Bstl -1.77 0.01 -1.1 0 -3.44 0 - 0 -4.62 0 -1.4 0
1 1.29
1455332_x_ Fcgr2b -2.87 0.01 -1.65 0 -3.06 0.01 - 0 -3.04 0 -1.5 0
at 1.57
1417601_at Rgsl -2.83 0 -1.37 0.02 -3.06 0 - 0.01 -2.83 0 -1.69 0
1___ _1.58 1 1
1449164_at Cd68 -2.55 0.01 -1.19 0 -3.12 0 - 0 -2.99 0 -1.55 0
1.34
1449455_at Hck -2.87 0 -1.46 0 -2.74 0 - 0 -4.55 0 -3.01 0
1.69
1425407_s_ Clec4a2, -2.62 0.01 -2.03 0 -2.51 0.01 - 0 -2.53 0 -1.41 0
at Clec4bl 1.83
1423570_at Abcgl -3.17 0 -1.39 0.02 -2.82 0 - 0.02 -2.7 0 -1.52 0.01
1.46
1450648_s H2-Abl -2.48 0.01 -1.49 0 -2.46 0 - 0 -1.51 0.01 -1.84 0
at 1.73
1433678_at Pld4 -2.42 0 -1.7 0 -2.28 0 - 0 -2.33 0 -1.86 0
1.74
1417936_at Cc19 -2.68 0 -1.75 0 -1.79 0 - 0 -2.12 0 -3.7 0
2.04
1421366_at Clec5a -2.03 0.01 -1.56 0 -1.89 0 - 0 -1.88 0 -1.54 0
1.76
1424793_a_ Pbp2 -1.58 0.01 -1.47 0.01 -1.63 0.01 - 0 -2.04 0 -2.22 0
at 1.96
1421989_s_ Papss2 -2.58 0 -2.56 0 -1.36 0 - 0 -3.2 0 -3.64 0
at 1.72
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Supplementary Table 7. Genes significantly up- and down-regulated in cells
expressing Nfib, L-myc, and L-myc & Nfib. To be considered significantly upregulated or
downregulated, the log2 of the fold change was greater than or equal to 1 or less than or
equal to 1, respectively, and the adjusted p-value was less than or equal to 0.05. The
log2 of the fold change (logFC) and adjusted p-value (adjP) are shown for each cell line
(CL1 and CL2) for cells expressing L-myc compared to control, Nfib compared to
control, and L-myc & Nfib compared to control.
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SUPPLEMENTARY TABLE 8
L-myc Nfib L-myc &
Nfib
GeneGo Pathway Maps
Cell adhesion ECM remodeling 0.00006441 0.0001618 0.00006441
Development VEGF-family signaling 0.0001357 0.0004475 0.0001357
Immune responsePIP3 signaling in B 0.0005568 --- 0.0005568
lymphocytes
Cell adhesionPlasmin signaling 0.0005626 --- 0.0005626
Immune responseFc gamma R-mediated 0.0007691 0.002745 0.0007691
phagocytosis in macrophages
ChemotaxisLeukocyte chemotaxis 0.001336 0.001187 0.001336
Immune response-IL-15 signaling 0.001559 0.001559
Immune response_BCR pathway 0.001771 0.001771
Cytokine production by Th17 cells in CF (Mouse 0.002648 0.002648
model)
DevelopmentTranscription regulation of 0.003401 0.0007547 0.003401
granulocyte development
Immune responseClassical complement ---- 9.72E-10 --
pathway
Immune responseLectin induced complement ---- 1.074E-08 --
pathway
Immune responseAlternative complement ---- 0.00001008 --
pathway
Immune responseAntiviral actions of ---- 0.0000548 --
Interferons
Immune response_lFN alpha/beta signaling ---- 0.003621 --
pathway
GeneGo Process Networks
Cell adhesion Cell-matrix interactions 5.491 E-1 2 1.855E-06 1.361 E-06
Immune responsePhagocytosis 3.801E-08 6.252E-07 0.00003618
Cell adhesion Platelet aggregation 2.41 E-07 -- --
Chemotaxis 0.00000115 -- --
Cell adhesionPlatelet-endothelium-leucocyte 6.888E-06 0.00006865 2.641 E-06
interactions
Cell adhesion Leucocyte chemotaxis 0.00001508 ---- 0.0007539
ApoptosisAnti-Apoptosis mediated by external 0.00001965 0.000531 --
signals via P13K/AKT
InflammationComplement system 0.00002121 2.683E-07 --
Cell adhesionGlycoconjugates 0.0000462 0.00003266 -
ProteolysisConnective tissue degradation 0.0002005 ---- --
Immune responsePhagosome in antigen -- 3.557E-06 0.0004895
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Immune responsePhagosome in antigen -- 3.557E-06 0.0004895
presentation
ProteolysisECM remodeling ---- 0.0002015 0.0001219
InflammationjIL-4 signaling --- 0.0006379 --
ProliferationPositive regulation cell proliferation --- 0.0006885 0.0003652
Cell adhesionIntegrin-mediated cell-matrix ---- ---- 0.00002574
adhesion
Cell adhesionIntegrin priming ---- ---- 0.0001855
ProliferationNegative regulation of cell ---- ---- 0.0008984
proliferation
GeneGo Diseases (by Biomarker)
Inflammation 1.54E-14 -- --
Vascular Diseases 3.876E-14 -- --
Pathologic Processes 5.723E-14 1.663E-18 4.033E-14
Cardiovascular Diseases 5.052E-12 --
Hemostatic Disorders 1.96E-11 -- --
Hemic and Lymphatic Diseases 4.092E-1 1 ----
Nephritis 9.1E-11 ---- ---
Connective Tissue Diseases 1.188E-10 4.881 E-15 ----
Wounds and Injuries 1.425E-10 ---- _----
AIDS-Related Opportunistic Infections 1.46E-1 0 --- ---
Lupus Erythematosus, Systemic ---- 7.526E-1 7 ---
Arthritis ---- 3.576E-16 2.406E-13
Joint Diseases ---- 4.437E-16 3.61E-13
Arthritis, Rheumatoid ---- 6.472E-16 ---
Cicatrix ---- 1.96E-15 2.013E-11
Rheumatic Diseases ---- 3.507E-15 ---
Dry Eye Syndromes ---- 6.366E-15 ---
Lacrimal Apparatus Diseases ---- 6.366E-15 ---
Periodontal Diseases ---- ---- 3.892E-13
Purpura ---- ---- 5.902E-13
Skin Manifestations ---- ---- 1.575E-12
Pathological Conditions, Signs and Symptoms ---- ---- 6.65E-1 2
Periodontitis ---- ---- 1.069E-11
Urologic Diseases ---- ---- 2.038E-11
GeneGo Metabolic Networks
N-acyl-sphingosine phosphate pathway 3.595E-06
GalNAcbetal -3Gal pathway 0.0003291 ---- --
2-arachidonoyl-glycerol_3-phosphocholine 0.0007715 ---- --
pathway
Glucosylceramide pathways and transport 0.0008182 ---- --
Ceramide pathway 0.001195 ---- --
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Glucose pathway 0.003648 -- --
Sphingomyelin pathway 0.004188 0.00002001 0.00001793
1-al kyl-glycerol_3-phosphoethanolamine 0.004238 -- --
pathway
1 -oleoyl-sn-glycero-3-phosphocholine pathway 0.006116 -- --
Phosphatidylinositol-3,4,5-triphosphate pathway ---- 0.000218 0.0008996
Vitamin, mediator and cofactor ---- 0.002679 ---
metabolismNitric oxide biosynthesis and
transport
(L)-lysine pathways and transport ---- 0.009499 --
Lipid metabolismPhosphatidylinositol ---- 0.01194 0.003096
metabolism
(L)-proline pathways and transport ---- 0.02289 --
[O-hexadecanoyl-(L)-carnitine pathway ---- 0.02487 ---
L-ornithine pathways and transport ---- 0.03511 --
Aminoacid metabolismLysine metabolism and ---- 0.04337 --
transport
N-acetyl-D-galactosamine pathway ---- ---- 0.01224
Vitamin, mediator and cofactor metabolismCoA ---- ---- 0.01756
biosynthesis and transport
1,2-dioleoyl-sn-glycerol3-phosphate pathway ---- ---- 0.02348
(L)-alanine pathways and transport ---- ---- 0.04307
(L)-threonine pathways and transport ---- ---- 0.04452
GO Processes
immune system process 2.434E-36 9.537E-35 1.958E-24
immune response 1.025E-34 9.793E-35 7.89E-24
response to stimulus 8.989E-25 6.202E-23 7.477E-18
response to external stimulus 5.821 E-24 1.145E-17 ---
response to wounding 3.004E-23 ---- ---
positive regulation of immune system process 1.328E-19 2.583E-19 7.125E-16
defense response 2.378E-1 9 1.297E-23 2.694E-1 6
inflammatory response 8.401E-19 -- --
regulation of immune system process 1.02E-18 5.142E-18 ---
response to stress 5.643E-18 --- --
antigen processing and presentation of ---- 3.57E-18 4.202E-15
exogenous peptide antigen
system development ---- 2.858E-17 7.913E-17
anatomical structure development ---- 4.51 E-1 7 2.819E-1 7
developmental process ---- ---- 1.566E-16
multicellular organismal development I-- -- 2.527E-16
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Supplementary Table 8. GeneGo Analysis on mSCLC cells expressing L-myc, Nfib or
L-myc & Nfib. Gene Ontology terms from the GeneGo Analysis highlight several
pathways of importance in cells expressing Nfib and/or L-myc. Each column contains
the p-values.
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